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 While the cardioprotective effect of statins are undeniable, experimental and observational 
research has suggested the potential for increased type 2 diabetes (T2D) risk. However, few studies have 
directly compared statin-associated benefits and harms or examined heterogeneity by population 
subgroups or assumed treatment effect. Thus, we aimed to project the benefits and harms of statin 
treatment in primary prevention adult populations newly eligible for statin treatment using four proposed 
statin treatment recommendations. First, we conducted a meta-analysis of statin-associated T2D risk 
among randomized controlled trials (RCTSs) and observational studies (OBSs), excluding studies 
conducted among secondary prevention populations. We identified 23 studies (35% RCTs) of 
n=4,012,555 participants. There was little evidence for publication bias (P>0.1); however, evidence of 
heterogeneity was observed overall and among OBSs and RCTs (PCochran=<0.05).  
 Findings from the meta-analysis provided us with statin-associated T2D risks to be used to 
project the benefits and harms of statin treatment. A series of simulations were constructed using Markov 
models and contemporary data from biracial (African American and Caucasian), adult (aged 40-75) 
national population-based surveys and published meta-analyses. Statin treatment eligibility for each of 
four recommendations was determined by 10-year atherosclerosis cardiovascular disease (ASCVD) risk 
and, for one recommendation, age. This simulation framework was used to project statin-associated 
absolute benefit, quantified as the number needed to treat (NNT) to prevent one ASCVD event, absolute 
harm, quantified as number needed to harm (NNH) to incur one incident T2D, and relative benefit, 
quantified as the likelihood to be helped or harmed (LHH, NNH/NNT). Overall, the number of ASCVD 
events prevented was at least twice as large as the number of incident T2D incurred (LHH range: 2.10-
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2.90). However, the relative benefit of statin treatment decreased when higher statin-associated T2D RRs 
were assumed. Findings highlight the higher relative burden of T2D occurred among female and younger 
adult populations, with disparities widening as statin-associated T2D RR increased, underscoring the need 
for more research quantifying statin-associated benefits and harms. 
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CHAPTER 1. OVERVIEW 
 Hmg CoA reductase inhibitors, commonly known as statins, are the most widely prescribed class 
of medication used to prevent atherosclerotic cardiovascular disease (ASCVD).1, 2 Numerous meta-
analyses have demonstrated that statins decrease ASCVD incidence by approximately 20% for every 38 
mg/dL reduction in low-density lipoprotein cholesterol (LDL-C), with protective effects that extend to 
populations at low ASCVD risk.3, 4 In 2013, American College of Cardiology/American Heart 
Association (ACC/AHA) cholesterol treatment recommendations changed the threshold to initiate statin 
treatment for primary prevention from 10% 10-year coronary heart disease (CHD) risk to 7.5% 10-year 
ASCVD (CHD and stroke) risk. As a result, the number of adults newly eligible for statin treatment for 
the primary prevention of ASCVD increased by an estimated 10.4 million, with 80% of the increase 
occurring in populations between the ages of 60-75.5 Changes in statin eligibility also increased the 
proportion of females eligible for statins from 21.2% to 53.6%.6 In 2018, the ACC/AHA continued to 
recommend the 7.5% 10-year ASCVD risk threshold; however, other recommendations suggest even 
more aggressive treatment recommendations, for example a 5% 10-year ASCVD risk threshold or 
initiating statin treatment in populations ≥55 years of age regardless of risk factor profile.7 In contrast, 
recommendations calling for more conservative recommendations such as increasing the 10-year ASCVD 
risk threshold to 10%,5, 8, 9 also have been proposed.  
 While the cardioprotective effect of statins are well established4, 10, experimental and 
observational research has suggested the potential for adverse drug effects, including type 2 diabetes 
(T2D).11-15 Yet, few studies have performed a direct comparison of the number of statin-associated 
ASCVD events prevented in comparison to the number of statin-associated T2D incurred across proposed 
statin recommendations. In theory, traditional epidemiologic studies could help address this research gap 
if such studies (1) were contemporary, (2) spanned ages specified by current recommendations, (3) 
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included high quality statin adherence measures, and (4) precisely and validly measured ASCVD and 
T2D incidence within generalizable male and female multi-ethnic populations with adequate follow-up; 
but very few studies can meet all of these criteria. Additional challenges include estimating valid statin-
associated ASCVD and T2D risk in observational settings.16 As an alternative, simulation tools can help 
extend the reach of traditional epidemiological studies examining intended and unintended consequences 
of statin treatment through synthesis of high quality observational, experimental, and meta-analysis data. 
However, most meta-analyses have restricted analyses to either randomized controlled trials (RCTs) or 
observational studies (OBSs) and have combined primary and secondary prevention populations to 
examine statin associated T2D risk. Yet, meta-analyses that incorporate summary data from both study 
designs may take advantage of the internal validity of RCTs and the external validity of OBSs17, 18 and the 
risk of T2D may differ when used for primary vs. secondary prevention.19 Therefore, this dissertation will 
first estimate the effect of statins on T2D among populations most affected by changes to statin use 
recommendations. Second, we will use a simulation framework to combine evidence from meta-analyses, 
observational studies, and population surveys to estimate statin-associated benefits and harms.5, 6, 8, 20 
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CHAPTER 2. SPECIFIC AIMS 
 This work will use a simulation framework to combine evidence from meta-analyses of statin-
associated ASCVD and T2D risk, observational studies measuring ASCVD and T2D incidence, and 
population surveys informing ASCVD risk factor distributions and demographics to estimate the number 
of ASCVD events prevented and incident T2D incurred in primary prevention populations across four 
proposed 10-year ASCVD risk statin treatment recommendations.5, 6, 8, 20 
We therefore will: 
1. Estimate the effect of statins on T2D incidence among primary prevention populations.  
a. Conduct a meta-analysis of all available published data from large primary prevention 
RCTs and observational studies. 
b. Investigate publication bias, heterogeneity, and the extent to which both RCTs and 
observational studies are inherently combinable. 
2. Project ASCVD risk reduction and increase in T2D from statin treatment in primary prevention 
adult populations newly eligible for statin treatment using four proposed statin treatment 
recommendations. 
a. Build series of Markov models by assembling contemporary and validated data from 
NHANES (statin eligibility and probability of statin use), REGARDS (T2D and ASCVD 
incidence and prevalence), published RCT meta-analyses3, 12(statin associated RRs), and 
results from aim 1 (statin associated RRs) using decision analyses software TreeAge Pro.   
b. Using Markov models from Aim 2A, estimate the number of ASCVD events prevented 
and incident T2D incurred across four proposed statin treatment recommendations: 
• 10-year ASCVD risk threshold ≥10%21  
• 10-year ASCVD risk threshold ≥7.5%22 
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• 10-year ASCVD risk threshold ≥5%5 
• 10-year ASCVD risk threshold ≥7.5% and including all populations ≥ 55 
years of age23  
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CHAPTER 3. BACKGROUND 
A. Low-Density Lipoprotein Cholesterol 
 Cholesterol is a fat like substance found in cell membranes and was first isolated as a hard, fatty 
material from gallstones in 1769 by Poulletiere de la Salle.24, 25 However, it was not until 1910 that a 
possible association between cholesterol and atherosclerosis, a major risk factor for cardiovascular 
disease (CVD), was made, when Adolf Windaus reported that aortas with atherosclerosis contained up to 
20 times the cholesterol found in normal arterial walls.26 As more evidence accumulated in support of the 
association between cholesterol and atherosclerosis, studies revealed a majority of the cholesterol content 
in the body was transported by low-density lipoproteins.27 Cholesterol carried by low-density lipoprotein 
is referred to as low-density lipoprotein cholesterol (LDL-C) and elevated levels of LDL-C have been 
associated with atherosclerosis and downstream CVD manifestations.28 To prevent LDL-C-associated 
CVD, particularly myocardial infarction/coronary heart disease (MI/CHD [refers to MI incidence and 
CHD mortality, unless otherwise noted]) and ischemic stroke, reducing excessive levels of LDL-C has 
focused on pharmacological therapy, specifically statins.6 While existing evidence has demonstrated the 
reduction of LDL-C levels and risk of MI/CHD from statins, research has suggested that statins may also 
increase the risk of adverse events, including diabetes mellitus (T2D).12 Many questions on the 
association between statins and T2D still remain, particularly, projecting changes in T2D and MI/CHD 
incidence and prevalence associated with various statin recommendations from cholesterol treatment 
recommendations.  
 The purpose of the following sections are to provide an overview of LDL-C and its role in 
atherosclerosis, starting with a brief description of cholesterol and the underlying biochemistry and 
pathophysiology of low-density lipoprotein metabolism. Second, I will summarize evidence from the 
scientific literature for the role of LDL-C in the atherosclerotic process. Third, I will report the 
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epidemiology of LDL-C and the various treatments that have been recommended to target elevated LDL-
C levels. Fourth, I will describe the epidemiology of statins, the primary cholesterol medication used 
today, and report evidence from the scientific literature for the efficacy of statins in reducing LDL-C 
levels. Fifth, I will present evidence for potential side effects of statins, with a focus on T2D, including 
potential mechanisms. Sixth I will summarize the epidemiology of health outcomes associated with 
elevated LDL-C levels. Seventh, I will describe the development of cholesterol treatment 
recommendations starting from the first recommendations created until the most recent recommendations 
released. Finally, I will provide information on the impact of statin therapy on public health.  
A.1. Cholesterol 
 Low-density lipoprotein transports cholesterol to cells throughout the body to enable hormone 
synthesis, cell membrane formation, and to aid in functions of the central nervous system. Cholesterol 
serves as a precursor of the bile acids formed in the liver and of steroid hormones.29 Cholesterol also 
impacts cell membrane stability, permeability, and fluidity by changing the order of fatty acyl chains and 
determining the functional properties of membrane-resident proteins like ion channels and transmitter 
receptors.30 For example, several studies have demonstrated that an increase in cholesterol content in 
plasma membranes leads to increased intake of Ca2+ in plasma membranes, thereby altering membrane 
fluidity. In addition, neurons use cholesterol to establish and maintain synaptic connections, essential for 
the brain to transmit and process information.31 
A.2. The Role and Formation of Low-Density Lipoprotein  
 As mentioned previously, cholesterol plays a major role in all cells for growth and maintenance; 
however, because of the polarity of cholesterol, it requires plasma lipoproteins to transport it through 
circulation. Plasma lipoproteins transport hydrophobic cholesterol through the use of hydrophilic 
phospholipids that surround the cholesterol, preventing it from interacting with an aqueous environments 
(i.e. blood). A major plasma lipoprotein in the transport of cholesterol is low-density lipoprotein, which 
carries more than 60% of the total cholesterol (TC) content in blood.32 Before transport of cholesterol can 
occur, however, low-density lipoprotein must be produced through the endogenous lipoprotein pathway 
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(Figure 1). Briefly, in the endogenous lipoprotein pathway, the liver secretes very low-density 
lipoproteins (VLDL), formed from adipose-derived or de novo synthesis of fatty acids, into circulation 
(Figure 1).32, 33  
 During the fasting state, when dietary 
fat is not available, the primary source of 
fatty acids for VLDL synthesis is the 
adipocyte.34 As insulin levels fall, 
triglycerides (i.e. a type of lipid) attached to 
adipocytes are hydrolyzed (i.e. broken down 
with the use of H20), resulting in the release 
of fatty acids. The fatty acids are transported 
to the liver by proteins such as albumin, 
where they are taken up by hepatocytes for VLDL production. In contrast to the fasting state where the 
adipocyte is the main source of fatty acids, during the feeding state, VLDLs are synthesized through de 
novo lipogenesis whereby dietary carbohydrates are converted to fatty acids in the liver.35 Once fatty 
acids have been produced or reach the liver, they are esterified (i.e. turned into an ester by replacing the 
hydrogen with a hydrocarbon group36) to form triglycerides. In addition to forming triglycerides, the liver 
also synthesizes cholesterol from acetyl CoA (see section E.2. Statin Therapy) and loads both 
triglycerides and cholesterol on an apolipoprotein B-100 (apoB100) through the microsomal triglyceride 
transfer protein complex to form VLDL particles.32 VLDL particles are then secreted from the liver into 
circulation, where they are hydrolyzed and release their fatty acids. The loss of fatty acids results in the 
formation of intermediate-density lipoproteins (IDL) particles containing apoB100, cholesterol, and 
triglycerides (Figure 1). Half of the IDL particles bind to hepatic low-density lipoprotein receptors 
(LDLR) and are removed from circulation, while the remaining IDL particles are converted to low-
density lipoprotein.32 To form LDL, triglycerides from IDL particles are hydrolyzed and substituted by 
cholesterol esters and all apolipoproteins except apoB100 are removed. .This results in LDL particles 
Figure 1. Endogenous lipoprotein pathway 
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containing mostly apoB100 and cholesterol. Low-density lipoprotein particles can then deliver the 
cholesterol in the form of LDL-C to extrahepatic cells and to the liver by binding to LDLRs.37  
 LDL particles are important for the transport of cholesterol from the liver to cells throughout the 
body; however, additional plasma lipoproteins play vital roles in helping to maintain body cholesterol 
homeostasis. For instance, high-density lipoproteins (HDL) deliver free cholesterol and excess cholesterol 
that cannot be metabolized back to the liver in a process known as reverse cholesterol transport.38 In depth 
discussions of HDL and additional plasma lipoproteins, however, are beyond the scope of this 
dissertation.  
A.3. LDL-C and Atherosclerosis 
 LDL-C is an important mediator 
between food intake and the narrowing 
and hardening of the arteries during 
atherosclerosis. The “lipid hypothesis” 
states that high levels of LDL-C are a 
major risk factor and can be a sufficient 
cause of atherosclerosis and MI/CHD (see 
section D.1. Myocardial 
Infarction/Coronary Heart Disease) and 
stroke (see section D.2. Stroke).28  
 LDL-C is hypothesized to increase 
the risk of MI/CHD by contributing to the 
development of atherosclerotic lesions in the artery wall (Figure 2).28, 39 Briefly, lifestyle (see section 
C.4.Lifestyle Modification) and genetic risk factors (see section B.2. Genetic Evidence for the Role of 
LDL-C in Atherosclerosis),40-42 can result in elevated LDL-C in circulation.43, 44 Elevated circulating 
LDL-C can lead to LDL-C retention at atherosclerosis-prone sites in arteries. Factors responsible for focal 
retention, however, are not clear.45  
Figure 2. Atherosclerotic thickening of the arterial wall 
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 Accumulation of LDL-C particles in the arteries results in fatty streaks and generation of foam 
cells. Once beneath the endothelium, LDL-C particles undergo oxidation to result in highly toxic and 
chemoattractant oxidized LDL-C (ox-LDL-C) particles.46 The formation of ox-LDL-C attracts 
macrophages and smooth muscle cells, which ingest ox-LDL-C. Macrophages contain receptors for both 
ox-LDL-C (scavenger receptors) and native LDL-C (LDLR); however downregulation of LDL-C 
ingestion is only present in LDLR.47 When downregulation is absent, uptake of ox-LDL-C by scavenger 
receptors occurs more rapidly than uptake of native LDL-C by LDLR. Accumulation of ox-LDL-C in 
macrophages and smooth muscle cells generates foam cells underneath the endothelium, with continued 
buildup resulting in fatty streaks, early indicators of atherosclerosis (Figure 3).48  
 The accumulation of 
macrophages and smooth 
muscle cells underneath the 
endothelium can lead to release 
of toxic ox-LDL-C, resulting in 
endothelial injury and 
eventually in the formation of 
advanced atherosclerotic 
lesions. Although macrophage 
ingestion of ox-LDL-C temporarily protects the endothelium from damage by trapping highly toxic ox-
LDL-C, once macrophages are heavily loaded, they can become nonfunctional or die, releasing ox-LDL-
C and resulting in damage to the endothelium. As this process continues, the sustained damage of the 
endothelium can lead to an inflammatory response to further damage the walls of the artery and accelerate 
the development of fatty-streaks (Figure 3).48, 49 Disruption of the endothelial barrier then can lead to 
platelets and smooth-muscle cells migrating to the site of the injury and proliferating. This results in the 
formation of intermediate lesions containing inflammatory response cells and LDL-C, contributing to the 
Figure 3. Hypothesized linkage between LDL-C, endothelial 
injury, and atherosclerosis 
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thickening of the artery wall over time.39 As the process continues, these events can result in the 
formation of advanced lesions and narrowing of the artery (Figure 3). 50 
B. Evidence for the Role of LDL-C in Atherosclerosis and Clinical Events from Human and 
Animal Studies 
 The relationship between LDL-C, and in early studies, TC, with atherosclerosis and downstream 
clinical events has been examined in numerous observational and experimental studies in both human and 
animal populations. This section provides a summary of this relationship from the scientific literature that 
spans findings from the earliest animal studies to results from cholesterol-lowering drug trials. 
B.1. Evidence of the Association between TC and Atherosclerosis in Animal Studies 
 Animal studies have provided evidence of elevated TC levels increasing risk of atherosclerosis 
since the early 20th century. Anitschkow et al. observed that rabbits fed high levels of cholesterol had 
elevated TC levels and developed atherosclerosis.51 Following Anitschkow’s work, scientists confirmed 
his findings in additional rabbit strains and eventually other animals.52, 53 For instance, Rowsell et al. 
compared pigs fed egg yolk (mimicking a high cholesterol diet) to those maintaining usual diets and 
observed increases in both TC levels and the burden of atherosclerosis.54 Research examining potential 
long-term effects of high cholesterol diets in rhesus monkeys also found that maintaining elevated levels 
of TC over 40 months resulted in an increased incidence of  MI/CHD.55, 56 Investigators also examined the 
impact diets low in cholesterol had on rhesus monkeys with atherosclerosis and found that after a 40-
month period, both TC levels and aortic plaque decreased.57  Together, these and other studies suggested 
that elevated TC levels increased risk of atherosclerosis and downstream MI/CHD events in animals; 
however, it was unclear whether these associations generalized to humans. 
B.2. Genetic Evidence for the Role of LDL-C in Atherosclerosis 
 The relationship between LDL-C and MI/CHD has been most clearly shown in studies examining 
populations with genetic forms of hypercholesterolemia.58 Familial hypercholesterolemia (FH) is one of 
five types of familial dyslipidemia and was first identified in 1964.59 FH is an autosomal dominant 
disorder that impacts the LDLR gene, resulting in reduced function of the LDLR and subsequent elevation 
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in LDL-C levels.60 While the prevalence of heterozygous and homozygous FH is low (0.2% and <0.01% 
respectively), populations with FH have six to ten-fold elevations in LDL-C levels and higher risks of 
developing MI/CHD compared to populations without the mutation, with homozygous FH patients found 
to develop MI/CHD by the second decade of life.59, 61  
 In parallel to the discovery of LDLR, Yosio Watanabe studied Watanabe Heritable-
Hyperlipidemic (WHHL) rabbits, characterized by abnormally high levels of LDL-C, to better understand 
mutations in the LDLR and its impact on LDL-C.62-64  Briefly, Watanabe compared LDL-C levels from 
normal rabbits and WHHL-rabbits and found accumulation of LDL-C, reduced rate of clearance of LDL-
C from blood, and that rabbits subsequently developed atherosclerosis early in life. Watanabe observed a 
delay in the disappearance of LDL-C from blood and the absence of LDL binding to LDLR in rabbit skin 
fibroblasts, thereby hypothesizing that mutations in LDLR gave rise to extremely high LDL-C levels. In 
1985, Drs. Michael Brown and Joseph Goldstein suggested FH was associated with defects in the LDLR 
in humans, similar to defects found among WHHL rabbits.  
 Current genetic evidence on the association of LDL-C and atherosclerosis is contributed by large-
scale genetic association studies that identified numerous genetic variants associated with LDL-C, some 
of which also increased MI/CHD risk. For example, single nucleotide polymorphisms (SNPs) associated 
with LDL-C and mapping to the  LDL-C, APOB (apolipoprotein B)65, PCSK9 (proprotein convertase 
subtilisin/kexin type 9)66, and LDLR67 genes also increase MI/CHD incidence.68 Mendelian 
Randomization studies, which avoid temporal ambiguity and confounding given “random assignment” of 
alleles at birth, also support a direct role of LDL-C on MI/CHD.65-68 
B.3. Observational Evidence of the Association between LDL-C and Atherosclerosis 
 Results from early observational studies in human populations were consistent with those from 
animal studies and early family-based studies of Mendelian lipid traits and suggested that elevated TC, 
the cholesterol metric available at that time, also was associated with atherosclerosis and risk of 
MI/CHD.69-72 Observations on the relationship between diet, TC, and atherosclerosis were made as early 
as 1916, when Dr. Cornelius De Langen compared TC levels of various populations and found that 
 
12 
cholesterol-rich diets and atherosclerosis were associated with elevated levels of TC.73 For example, after 
comparing MI/CHD prevalence and incidence among Javanese, Dutch, French, and Germans, De Langen 
observed that Javanese had the fewest events of both. To understand the differences in MI/CHD disease 
burden, De Langen observed characteristics of each population, including TC. Comparing average TC 
levels, De Langen found that Dutch, French, and Germans had similar (high) TC levels, while the 
Javanese had much lower TC levels; these differences attributed to the low cholesterol and lipid content 
in the Javanese diet. In addition, he found that Javanese stewards on the Dutch transport liners, who 
adopted a Dutch diet rich in meat and eggs, had TC levels that were more similar to the Europeans than to 
other native Javanese, further suggesting a cholesterol-rich diet impacted TC levels.73  
 As work on diet and TC levels continued to be done in the early 20th century74, 75, the National 
Heart Institute reported that, by 1948, 44% of deaths in the U.S. could be attributed to MI/CHD, an 
absolute increase of 20% from 1940.76 The causes of MI/CHD, however, were poorly understood. In 
response, the U.S. Public Health Service launched what would become the Framingham Heart Study 
(FHS), to study prospectively MI/CHD and its risk factors among 5,209 participants with no history of 
MI/CHD.77 After 18 years of follow-up, Shurleff et al. reported the incidence rate of MI/CHD was higher 
among participants with TC levels >220 mg/dl compared to those with TC levels <220 mg/dl (incidence 
rate difference [IRD] = 8.86 cases/1000 person-years; 95% confidence interval [CI]: 5.57-11.9) among 
Caucasian men aged 45-64.72, 78 Consistent with results done in the U.S., studies performed in other 
countries also suggested direct associations between rising TC levels and incident MI/CHD.79, 80 For 
instance, Johnson et al. examined a Japanese population sample of men and women in Hiroshima with 
mean TC levels (mean TC = 157 mg/dl) lower than those in the US (mean TC=222 mg/dl) between 1958-
1964. Using autopsy reports, ECG evidence, and medical history to classify MI/CHD, Johnson et al. 
found that men with TC values ≥220 mg/dl (95th percentile) had a higher rate of developing incident 
MI/CHD compared to the rate of those with TC values ≤220 mg/dl (incidence rate difference [IRD] =9.8 
events/1000 person-years [95: CI: -02.2-21.7]). No association, however, was found among women (IRD 
=-0.4/1000 person-years [95% CI: -3.0-2.2]).80, 81 Johnson et al. also found that as the category of TC 
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values increased, the rate of incident MI/CHD increased among men; however this relationship was not 
assessed with TC as a continuous variable.  
 Until the 1960s, population studies were limited to measuring TC and TGs in blood; however, the 
introduction of ultracentrifugation made it possible to separate and examine specific components of TC 
such as LDL-C and VLDL-C. One of the earliest studies to examine multiple cholesterol components was 
the Honolulu Heart Study in 1970.82 The Honolulu Heart Study aimed to investigate MI/CHD risk in men 
of Japanese ancestry born in the years 1990-1919 and living on the island of Oahu in 1967.83 Using ultra-
centrifugation to separate TC components, Rhoads et al. conducted a case-control study and demonstrated 
that LDL-C was correlated with TC (correlation coefficient =0.78) and that the risk of MI/CHD was 
higher among populations in the upper (≥ 168 mg/dl) versus lower (≤ 119 mg/dl) quartiles of LDL-C 
(relative risk [RR] = 1.8).32 To examine the relationship between LDL-C and MI/CHD prospectively, 
Medalie et al. studied 10,000 Israeli male government employees over five years and found the risk for 
incident MI/CHD was associated with increasing LDL-C levels.84 For instance, the five-year risk of 
incident MI/CHD among the group with the highest decile (220-460 mg/dl) of LDL-C was 2.5 percentage 
points higher than the risk of incident MI/CHD among the lowest decile (40-119 mg/dl) (risk difference 
[RD] = 2.5%). Additional prospective studies found similar associations between LDL-C levels and risk 
of CHD and MI/CHD; however, studies were largely restricted to employed, Caucasian men.84-86  
To examine whether the 
relationship between TC and CHD 
mortality was continuous, the Multiple 
Risk Factor Intervention Trial (MRFIT) 
recruited 356,222 Caucasian men aged 
35-57 years and followed participants up 
to six years.87 Using International 
Classification of Diseases (ICD) 9 codes 
to define CHD mortality, MRFIT 
Table 1. Deciles of serum cholesterol and six-year CHD 
mortality in the MRFIT 
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investigators found that the risk of CHD mortality increased as TC concentration increased, with larger 
increases in CHD mortality occurring above 180 mg/dl (Table 1). Together, these and other observational 
studies suggested that the risk of MI/CHD increased as TC or LDL-C levels increased, further motivating 
studying evaluating the causal relationship between LDL-C and MI/CHD.  
B.4. Early Intervention Studies  
Observational epidemiologic studies as well as animal experiments and pathologic observations 
suggested that the higher the LDL-C or TC, the greater the risk of MI/CHD. However, before concluding 
that TC and LDL-C played a causal role in the pathogenesis of MI/CHD, conclusive evidence from 
randomized controlled trials (RCTs) was required. To examine the impact of cholesterol-lowering 
through medication on MI/CHD incidence, the National Heart, Lung, and Blood Institute (NHLBI) 
commissioned the Lipid Research Clinics Coronary Primary Prevention Trial (LRC CPPT) in 1973.88 
LRC CPPT investigators recruited 3,806 men aged 35-59 years with TC levels ≥265 mg/dl to a trial of 
either a cholesterol-lowering diet or cholesterol-lowering diet plus cholestyramine resin (bile acid 
sequestrant [BAS] binds to bile, preventing it from entering the intestine to be used in the formation of 
plasma lipoproteins as mentioned in section A.2. The Role and Formation of Low-Density Lipoprotein). 
After seven years, compared to the diet-only group, the diet and medication group had lower LDL-C 
levels (12.6% lower [p <0.01]) and incidence rate of MI/CHD (19% relative difference [p <0.05]). Thus, 
the LRC CPPT showed that among Caucasian men with high levels of TC, reductions in LDL-C levels 
were associated with reductions in incident MI/CHD through medication in a clinical trial setting. 
 In addition to clinical trials that showed associations between cholesterol-lowering medication 
and reductions in subsequent MI/CHD events, RCTs also demonstrated benefits of cholesterol-lowering 
medication on reducing atherosclerotic lesions. The NHLBI Type II Coronary Intervention Study was 
designed to examine the impact of lowering LDL-C levels through medications and diet on 
atherosclerotic lesions.89 The study assigned participants to receive either a low-cholesterol, low-fat diet 
and cholestyramine treatment or the same diet and placebo. Investigators found after five-years, LDL-C 
levels were reduced by 5% among the placebo group as compared to 26% among the treated group. Using 
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coronary angiography to measure changes in lesion size (lesions were identified by analyzing multiple 
arterial tree segments), results also showed that lesions progressed in 49% of the placebo-treated patients 
versus 32% of the cholestyramine-treated patients (p <0.05). Thus, the NHLBI Type II Coronary 
Intervention Study provided further evidence of the impact medications had on coronary angiographic 
defined atherosclerosis and clinical events; albeit in a limited sample (N =116) of mostly Caucasian men.  
 Clinical trials providing evidence of LDL-C reduction and its impact on atherosclerosis and 
clinical events motivated further interventions targeting elevated LDL-C throughout the 1980s. While 
interventions during this period mostly focused on pharmacotherapy and lifestyle changes, the first statin, 
the subject of this dissertation and described in detail in section C.3. Statin Therapy, was not approved by 
the Food and Drug Administration (FDA) until 1987 and, at this time, was decades away from being 
recommended as the first line cholesterol-lowering medication.  
C. Epidemiology and Treatment of LDL-C 
C.1. Epidemiology of LDL-C 
Since the 1970s when LDL-C levels were first measured in large U.S. population-based surveys, 
mean levels of LDL-C have decreased among both men and women.90 Age-adjusted results from national 
surveys of noninstitutionalized populations found the mean LDL-C levels for adults (≥20 years old) not 
taking cholesterol-lowering medication declined from 128 mg/dl in 1988-1994 to 124 mg/dl in 1999-
2002, and to 119 mg/dl during 2007-2010, with mean LDL-C levels decreasing for both men and 
women.90 Similar reductions were found in the prevalence of high LDL-C levels (defined as ≥160mg/dl), 
decreasing from 59% in 1976-1980 to 42% in 1988-1994, and to 33% in 2001-2004, reaching 27% in 
2007-2010 with similar reductions observed among both Caucasian and African American men and 
women.90 Changes in diet have been hypothesized as the primary driver in the reduction of LDL-C levels 
in part due to decreases in consumption of trans-fatty acids.91 
Decreases in mean LDL-C levels have occurred in parallel to increases in awareness, treatment, 
and control of elevated levels of LDL-C. For example, among populations with high LDL-C (≥160mg/dl), 
the percentage of the population aware of their elevated LDL-C increased from 39.2% in 1988-1994 to 
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63% in 1999-2004.92 Using the National Health and Nutrition Examination Survey (NHANES), Carroll et 
al found that from 1988 to 2010, there was an increasing trend in the age-adjusted percentage of adults 
(≥20 years old) treated for high LDL-C increased from 3.4% in 1988-1994 to 15.5% in 2007-2010, with 
the largest increases among adults ≥50 year old. To estimate LDL-C control, Hyre et al. examined the 
percentage of the treated adults ≥20 years old with LDL-C levels lower than goal, as defined by 
cholesterol treatment recommendations at the time (see section E.3.NCEP-ATP III). Hyre et al. reported 
that LDL-C control increased from 34.7% in 1988-1994 to 60.7% in 1999-2004. LDL-C control was 
highest among older adults (ages ≥65 years), women, and Caucasians.92 As awareness and control of 
LDL-C levels have increased, however, Kuklina et al. found 51.9% of the NHANES population eligible 
for medication (based on LDL-C levels or 10-year CHD risk [see section E.3.NCEP-ATP III] ) was still 
untreated93, consistent with results found in the Multi-Ethnic Study of Atherosclerosis (MESA) where 
46% of the medication eligible population was untreated in the middle to late aged cohort (ages 45-80 
years old at study baseline in 2000-2002).94 
LDL-C and TC levels have also been shown to change across the life-course. Cross-sectional and 
prospective studies suggest that TC increases with age in young and middle-aged adults until peaking 
around the ages of mid-life, where TC levels then begin to decline with age.95 Additionally, hormonal 
changes contribute to LDL-C changes observed among women. For instance, before the ages of 
menopause, women tend to have lower LDL-C levels than men of the same age; however, afterwards the 
differences by sex become less apparent and LDL-C levels in women may surpass those of men of the 
same age due to a decline in estrogen production resulting in changes in lipid metabolism.96, 97 
C.2. Pharmacologic Treatments 
 Pharmacologic treatments to lower LDL-C have been available since the 1960s; however, 
limitations in efficacy and side effects prevented the earliest available treatments from becoming widely 
used first-line medication for LDL-C reduction. Niacin was the first medication used in the clinical 
treatment of high LDL-C level, operating by inhibiting triglyceride synthesis and thus decreased secretion 
of VLDL and LDL particles (see section A.2. The Role and Formation of Low-Density Lipoprotein). 
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Although niacin reduced TC and LDL-C levels by 12-14% and 15-18%, respectively in randomized 
trials98  and has been shown to reduce inflammation and oxidative stress99, it is often underused in clinical 
settings due to findings from large secondary prevention RCTs (N>3000), that found niacin had no effect 
on MI/CHD incidence.100, 101 In addition, in combination with statins, niacin has also shown an increase in 
T2D incidence, has been reported to increase hepatic toxicity, peptic ulcers, and deficiencies of clotting 
factor synthesis,101 and does not decrease the risk for MI/CHD.  Fibrates have been studied since 1962, 
decreasing LDL-C by stimulating reverse cholesterol transport (see section A.2. Role and Formation of 
Low-Density Lipoprotein) and increasing LDL-C clearance. Although once viewed as important in LDL-
C lowering, RCTs have shown mixed results when using fibrates to reduce MI/CHD incidence.102 In 
addition, increased risk of rhabdomyolysis, a syndrome resulting from the breakdown of skeletal muscle 
with release of muscle cell contents into the blood103, when combined with statins has been reported, 
limiting the utility of fibrates as cardioprotective agent.104 BAS have been proven to reduce LDL-C levels 
by 15-30% in monotherapy105 as described in B.4. Early Intervention Studies. In addition to monotherapy, 
BAS have also have been tested in combination with statins to reduce LDL-C levels by 40-60%106 and the 
National Lipid Association has recommended the use of BAS in combination with statins when statin 
monotherapy is inadequate in lowering LDL-C levels.107 
 Recent clinical trials have evaluated PCSK9 target agents as potential LDL-C lowering therapies. 
PCSK9 binds to the LDLR and escorts it to the lysosome for degradation; however, blocking the PCSK9-
LDLR interaction allows LDLR to continue to clear LDL-C into the liver and reduces LDL-C 
concentration in the blood.108, 109 Clinical trials testing PCSK9 inhibitors with statins have shown 
reduction in LDL-C levels by 61% (95% CI: 59%-63%; P<0.001) for a median absolute reduction of 48 
mg/dl.110 Results have also found MI/CHD incidence to be lower in the PCSK9 inhibitor plus statin group 
compared to statin-only group (hazard ratio [HR] = 0.47; 95% CI: 0.28-0.78) at one year. Despite 
associations with reductions in both LDL-C levels and MI/CHD incidence, PCSK9 inhibitors are 
generally prescribed after treatment with statins plus ezetimibe have failed to reduce LDL-C levels among 
patients at high risk of ASCVD, due to the high cost compared to statins ($14,000/year vs $50/year) and 
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limited data on long-term safety.111, 112  
C.3. Statin Therapy 
Because of their effectiveness at reducing LDL-C and MI/CHD, statins are the most 
recommended cholesterol-lowering agent. 
Mechanism of action. A major factor regulating blood LDL-C levels is the rate LDL-C is cleared 
into the liver via the LDLR, as approximately 70% of circulating LDL-C in blood is cleared by LDLR 
activity.32 Briefly, statins lower the production of LDL-C by targeting the conversion of HMG-CoA to 
mevalonate, the rate-limiting step in lipogenesis to produce cholesterol from acetyl CoA within the liver 
(Figure 4).113 Limiting lipogenesis (see section A.2. The Role and Formation of Low-Density 
Lipoprotein) results in the reduction of LDL-C content within 
the liver and induces LDLR expression on the liver cell 
surface to increase the amount of LDL-C cleared into the 
liver. This results in an increased removal of LDL-C from the 
blood and decreased concentrations of circulating LDL-C by 
approximately 20-63% depending on the dose and specific 
type of statin.32  
Statin Pleiotropic Effects. In addition to LDL-C 
reduction, statins have pleiotropic effects that extend beyond 
LDL-C lowering,114-120for example reduced inflammation.121, 
122 Previous findings have shown that statin therapy lowers high-sensitivity C-reactive protein (hs-CRP), 
an inflammatory marker that has been shown to be associated with increased risk of MI/CHD and stroke. 
For example, the Pravastatin Inflammation/CRP Evaluation trial (PRINCE) evaluated the effect of statins 
on hs-CRP reduction among a primary prevention cohort of 1,702 men and women from the U.S. The 
PRINCE investigators found that compared with placebo, participants randomized to statin had median 
hs-CRP levels that were 16.9% lower (p <0.01) after 24 weeks.123 As mentioned previously, the process 
of atherosclerosis can be characterized by the presence of macrophages and smooth muscle cells 




damaging the endothelial lining of arteries and resulting in the release of inflammatory cytokines (see 
section A.2. The Role of Low-Density Lipoprotein); thus, the anti-inflammatory property of statins has 
been suggested to be one explanation for its beneficial effects on endothelial dysfunction.  
Efficacy. From 1993 to 2000, several primary and secondary prevention trials designed to 
examine the effect of statins on clinical endpoints were conducted (Table 2). Five of the largest 
multicenter trials (N>4,000) are reviewed below.  
Table 2. Randomized trials of statins and MI/CHD prevention (modified from Grundy 2000) 
*Primary Prevention Trials. Trt =treatment. Ctrl =control  
  **Primary endpoint of MI/CHD including unstable angina as well as nonfatal MI and CHD death not shown. 
 
Primary Prevention Trials 
 The West of Scotland Coronary Prevention Study (WOSCOPS) Study examined the effectiveness 
of statin medication in men with elevated LDL-C levels and no history of MI.124 Previous studies like the 
LRC CPPT did not have the power to detect the reduction in CHD death rate from medication use; 
however, WOSCOPS purposefully recruited a large sample size and population of middle-aged men to 
evaluate changes in CHD death rate. Among 6,595 healthy 45-65 year old men with mean follow-up time 
of 4.9 years, statins lowered LDL-C levels and reduced the risk of CHD death (RR = 0.67 [95% CI: .0.47-
.0.97]) and incident MI/CHD (RR= 0.69 [95% CI: 0.57-0.83]) (Table 2) among statin therapy group 
compared to placebo group. Similarly, the Air Force/Texas Coronary Atherosclerosis Prevention Study 















ACAPS* No 919 3.0 19.9 0.13 0.56 
AFCAPS/TexCAPS* No 6605 5.2 19.3 0.73 0.60** 
CAIUS* No 305 3.0 12.4 7.54 1.02 
CARE Yes 4159 5.0 20.0 0.80 0.75 
KAPS* No 447 3.0 21.0 1.00 0.62 
LIPID Yes 9014 6.1 17.9 0.75 0.75 
MAAS Yes 381 4.0 23.0 0.97 1.54 
PLAC I Yes 408 3.0 19.0 0.98 0.50 
PLAC II Yes 151 3.0 21.6 0.52 0.40 
Post CABG Yes 1351 4.5 31.6 1.49 0.87 
4S Yes 4444 5.4 25.0 0.57 0.62 
WOSCOPS* No 6595 4.9 20.0 0.67 0.69 
All statin trials       
89,123 person-years  34779 4.2 20.0 0.71 0.70 
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(AFCAPS/TexCaps) examined primary prevention of MI/CHD (defined as fatal or nonfatal MI, unstable 
angina, or sudden cardiac death) in 5,608 men and 997 women with TC levels between 180-264 mg/dl 
and LDL-C levels between 130-190 mg/dl.125 After a mean follow-up of 5.2 years, the risk of MI/CHD 
was lower among the statin therapy group compared to the control group (RR = 0.63 [95% CI: 0.50- 
0.79]).  
Secondary Prevention Trials 
 Similar to primary prevention trials, secondary prevention trials also found cardioprotective 
benefits of statins. The  Scandinavian Simvastatin Survival Study (4S) followed 4,444 men and women 
aged 35 to 70 years with a history of MI from five Nordic countries for a median of 5.4 years.126 The 
investigators found a 38% reduction in risk of MI/CHD (RR=0.62 [95% CI: 0.28-0.45]) among statin 
users compared to the placebo group. Furthermore, the Cholesterol and Recurrent Events Trial (CARE) 
trial and Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study reported results 
consistent with 4S. CARE examined the effect of statins on MI/CHD after recent MI in patients with TC 
levels (≤240 mg/dl) in the U.S. and Canada. Among 4,159 participants and mean follow up of 5.0 years, 
the statin therapy group had 28% lower LDL-C levels and  lower incidence of MI/CHD than placebo 
group (RR= 0.75 [95% CI: 0..64-0.91]).127 Similar to CARE, the LIPID study examined statin therapy for 
secondary prevention among patients; however, LIPID enrolled patients from Australia and New Zealand 
with a broad range of TC levels (155 to 271 mg/dl).128 Among 9,014 patients with a mean follow-up of 
6.1 years, the group randomized to statins had a 24% reduction in risk of CHD mortality (RR=0.76 [95% 
CI: 0.65-0.88]) and 24% reduction in risk in MI/CHD (RR=0.76 [95% CI: 0.68-0.85]) compared to the 
placebo group. Both primary and secondary prevention trials examining statins demonstrated that the 
largest absolute change in LDL-C corresponded with the most favorable results for MI/CHD risk, albeit 
among primarily European populations. 
 Grundy et al. conducted a meta-analysis including several of the statin RCTs previously discussed 
and summarized that statins consistently reduced MI/CHD incidence by an estimated 30% (Table 2).10 
When stratified by primary and secondary prevention trials, risk of CHD mortality (RR reduction =0.93 
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[p-value <0.05]) and MI/CHD incidence (RR reduction =0.93 [p-value <0.05]) were reduced in primary 
prevention trials, further supporting the use of statins for primary prevention. 
Epidemiology. In 2011-2012, more than one-quarter (27.9%) of adults ≥40 years old (ages 
eligible for treatment under cholesterol recommendations, see section E.3. NCEP-ATP III) had reported 
taking cholesterol-lowering medication in the past month (measured using medication inventory),with 
93% of users classified as using a statin.2 The proportion of adults ≥40 years of age who have reported 
taking statins has increased from 16.3% in 2003-2004 to 23.2% in 2011-2012, with similar increases 
observed among populations taking statins for primary prevention (13.4%  in 2004-2005 to 22.2% in 
2010-2011).2, 129  
While statin use has increased overall within the past decade among both men and women, data 
from the Medical Expenditure Panel Survey found African Americans, Hispanics, and women are less 
likely to have statin prescriptions (measured using prescriptions filled) compared to Caucasian men.129 
Uninsured populations are also less likely to have statin prescriptions compared to populations with 
public insurance; findings consistent with research that emphasize equitable access to healthcare to reduce 
health care disparities.129, 130 Furthermore, in addition to disparities in obtaining statin prescriptions, 
observational studies have also suggested adherence to statins to be an obstacle in practice. Ellis et al. 
examined electronic medical claims databases in the U.S. with approximately 200,000 enrollees.131 
Among 4,802 patients who were ≥18 years of age, non-Medicaid enrollees, and had filled at least two 
statin prescriptions; Ellis et al. found 50% discontinuation rate of statin use after 3.7 years among primary 
prevention patients and 50% discontinuation rate after 3.4 years among secondary prevention patients. To 
examine predictors of non-adherence to statins, Mann et al. conducted a meta-analysis consisting of 22 
cohort studies using pharmacy and insurance database refill rates to measure discontinuation and with 
follow-up times ranging from nine months to 13 years.132 Mann et al found that women, ethnic minorities, 
populations <50 years of age, and populations ≥70 years of age were associated with increased non-
adherence to statins, while increased testing of LDL-C levels and higher income were associated with 
increased adherence to statins. 
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Statin Adverse Events. While numerous studies have emphasized the benefits of statins, evidence 
has suggested that statins use is associated with side effects as well. For example, meta-analyses have 
shown statins to be associated with an increased risk of myopathy (i.e. muscle pain or weakness), 
rhabdomyolysis, and T2D.133  Rhabdomyolysis is defined as having muscle symptoms with increases in 
creatine kinase elevations typically greater than 10 times the upper limit of normal. Although rare, with 
the incidence of rhabdomyolysis per one year of statin therapy approximately 0.0042%, fatal 
consequences can arise from hyperkalaemia, cardiac arrhythmia, and renal failure.134 While 
rhabdomyolysis is rare, statins have been found to be more frequently associated with myopathy.135 
Macedo et al. conducted a meta-analysis among 90 observational studies and reported an increased risk of 
myopathy (odds ratio [OR] =2.63; 95% CI: 1.50-4.61) among statin users compared to non-statin users, 
with the number needed to harm (NNH) for an additional case of moderate or severe myopathy over five 
years of 259 (95% CI: 186-375) for women and 91 (95% CI: 74-112) for men.136 In practice, clinic-based 
studies have reported myopathy to be more common than estimated in clinical trials, with one-third of 
patients on statins reporting myopathy in the Netherlands. Importantly, drug-induced myopathy is 
reversible if identified at early stages.137, 138 While evidence on myopathy has been limited, especially 
among RCTs, the body of evidence from clinical trials has suggested an association between statins and 
elevated risk for T2D, the focus of this dissertation. 
C.3.1. Diabetes Mellitus as a Potential Side Effect of Statins 
 In addition to the established cardioprotective effects of statins, RCTs have reported a 
relationship between statins and elevated T2D risk. T2D is characterized by hyperglycemia resulting from 
defects in insulin secretion, response to insulin action, or both, and can be diagnosed using fasting plasma 
glucose, oral glucose tolerance, or hemoglobin A1C tests to measure blood glucose levels.139 The vast 
majority of cases fall into two types of T2D: type 1 diabetes caused by deficiency of insulin secretion, and 
type 2 diabetes (more prevalent type) caused when insulin’s ability to mediate uptake of glucose is 
impaired, which results in the body becoming resistant to the effect of insulin.140 The incidence of T2D 
has doubled in the past 30 years among adults, with 1.7 million new cases of T2D occurring in 2012. 
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While burden of T2D is already high –affecting 1 in 10 US adults in 2012 –and continues to rise- the 
burden disproportionately affects racial/ethnic minorities. National survey data found 7.1% of Caucasians 
had diabetes compared to 8.4% of Asian Americans, 11.8% of Hispanics, and 12.6% of African 
Americans.141 
In addition to the long-term complications of T2D, which include potential loss of vision, 
nephropathy leading to renal failure, and amputations, T2D also increases the risk of MI/CHD and 
stroke.142 For instance, a recent meta-analysis of 102 prospective studies among 264,353 participants 
(43% women) found participants with T2D had an increased risk of MI/CHD (HR = 2.00 [95% CI: 1.83-
2.19]) and stroke (HR =1.56 [95% CI: 1.19-2.05]) compared to participants without T2D.143 The 
increased cardiovascular morbidity, mortality, and long-term consequences associated with T2D all 
contribute to the rising costs of T2D –in 2012, it was estimated as $245 billion–with $176 billion from 
direct medical costs.144 
C.3.1.1. Statin Use among Populations with T2D 
 As mentioned previously, populations with T2D are at an increased risk of MI/CHD and as a 
result, research has supported the use of statins to reduce the risk of MI/CHD, as well as ASCVD more 
broadly (classification includes MI/CHD and stroke [all types]) among populations with T2D.22, 145 The 
Cholesterol Treatment Trialists’ (CTT) Collaboration conducted a meta-analysis of 14 RCTs consisting of 
18,686 participants with T2D to evaluate the association between statin use and ASCVD.146 With mean 
follow-up time of approximately four years, results showed that ASCVD events were reduced in groups 
randomized to statins compared to control groups (RR =0.79 [95%CI: 0.72-0.86]). As a result of the 
benefits of statins among populations with T2D shown from previous studies and recommendations from 
recommendations, the prevalence of statin use among adults with T2D has increased from 4.2% in 1988-
1994 to 28.8% in 1999-2002, and to 44.1% in 2003-2006, reaching 51.4% in 2007-2010.147   
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C.3.1.2. Incidence of T2D among Statin Users 
Evidence from RCTs 
 While evidence has demonstrated the cardioprotective effect of statins on ASCVD risk4, research 
has also suggested an increased risk of incident T2D among statin users (Table 3). One of the first major 
trials to demonstrate a possible association between statins and incident T2D was the Anglo-Scandinavian 
Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) trial which examined 10,305 moderately 
high-risk (hypertensive, elevated TC levels, and ≥3 other MI/CHD risk factors [i.e. smoking, history of 
MI/CHD, or family history of MI/CHD]) participants.148  
Table 3. Summary of statins and risk of incident T2D by study design (randomized clinical trial or 
observational study) 
HR= hazard ratio, OR = Odds ratio 
*Included in Sattar et al. 2011. **Japanese Participants.  
a P-value <0.05 
b Population with T2D 
cConsistent statin adherence vs low statin adherence 











RCT    
*WOSCOPS149 Primary 55.2 100.0 NA HR= 0.70a 
*HPS150 Primaryb 63.9 75.3 NA OR= 1.1 
*LIPID151 Secondary 62.0 83.0 NA OR= 0.91 
*ASCOT148 Primary 63.1 81.2 94.7 OR= 1.15 
*CORONA152 Secondary 73.0 76.0 NA OR= 1.14 
*JUPITER153 Primary 66.0 61.9 71.2 HR=1.28a 
*PROSPER154 Primary 76.0 48.3 NA OR= 1.30a 
***MEGA155 Primary 58.3 32.0 0.0 OR= 1.05 
*AFCAPSTexCAPS125 Primary 58.0 85.0 89.0 OR= 0.97 
*4S126 Secondary 58.6 82.0 100.0 OR= 1.03 
*ALLHAT-LLT156 Primary 66.4 51.4 40.8 OR= 1.12 
*GISSI HF157 Secondary 67.0 76.2 100.0 OR= 1.05 
*GISSI PREVENZIONE158 Secondary 59.3 86.3 100.0 OR= 0.91 
PROVE-IT159 Secondary 58.3 78.1 90.7 OR= 1.01 
TNT160 Secondary 61.0 81.0 94.1 HR= 1.10 
IDEAL161 Secondary 62.0 80.8 NA HR= 1.19 
SPARCL162 Secondary 63.0 60.0 NA HR= 1.37a 
HOPE-3163 Primary 65.8 53.6 20.0 HR= 1.02 
Observational Studies      
WHI164 Primary 63.2 0.0 83.7 HR= 1.48a 
Tricare Prime/Plus165 Primary 53.0 61.0 NA OR= 1.87a 
METISM166 Primary and Secondary 59.4 100.0 100.0 HR= 1.46a 
Italian Lombardy Region167 Primary and Secondary 62.4 48.6 NA HR = 1.32a, c 
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 In contrast to previous RCTs that showed reduction in incident T2D149, after approximately three 
years of follow-up, the ASCOT-LLA trial noted 3% of participants randomized to statins developed T2D 
compared to 2.6% of participants randomized to placebo (p-value =0.25), however it was not statistically 
significant. Additional evidence was provided by the Justification for Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, which was designed to determine whether hs-
CRP could identify patients with low levels of LDL-C (<130mg/dl) at increased risk for ASCVD. 
JUPITER recruited men (≥50 years of age) and women (≥60 years of age) with no history of MI/CHD 
and hs-CRP levels ≥2 mg/l.153 To investigate the risk of T2D, Ridker et al. conducted a secondary 
analysis of the JUPITER trial and examined 17,802 participants with various T2D risk factors (i.e. 
metabolic syndrome, impaired fasting glucose, body mass index ≥30 kg/m2, or glycosylated hemoglobin 
(HbA1C) >6%) and found that among participants with at least one T2D risk factor (N =11,508), the risk 
of incident T2D was greater among participants randomized to statins compared to placebo (HR =1.28 
[95% CI: 1.07-1.54]).  In addition to the JUPITER trial, several other RCTs collected incident T2D 
information, providing enough data for meta-analyses. For instance, Sattar et al. performed a meta-
analysis of statin-associated T2D in primary and secondary prevention trials and identified 13 RCTs that 
collected data on incident T2D (11 out of 13 RCTs had information on fasting glucose levels to diagnose 
T2D; the remaining two studies relied on physician reports), spanned the years 1994-2009, and totaled 
91,140 participants with mean follow up time approximately four years (Table 4).12 Sattar et al. found that 
statin therapy was associated with a 9% increased risk for incident T2D compared to placebo (OR =1.09 
[95% CI: 1.02-1.17]) over a mean of 4 years of follow-up; the association was stronger in older 
participants at baseline (p-value =0.02). However, baseline BMI and percent change in LDL-C levels 
were not significant sources of heterogeneity.13, 168, 169 Mills et al. also conducted a meta-analysis of the 
RCT statin trial literature to examine associations with T2D among primary and secondary prevention 
RCTs; differences from Mills and Sattar include the former broadening of the eligibility criteria to include 
RCTs regardless of study size and length of follow-up time (Table 4). Among 16 RCTs examining 
incident T2D evaluated by Mills et al., representing three additional studies and 19,863 additional 
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participants from Sattar et al., Mills et al.reported a similarly increased risk of T2D among participants 
randomized to statins compared to those randomized to placebo (OR =1.09 [95% CI: 1.02-1.16]) that was 
slightly more precise.13  
 As described above, several meta-analyses of the association between statins and incident T2D 
combined primary and secondary prevention trials; however, secondary prevention trials include 
survivors of MI/CHD whose risk of  MI/CHD mortality has been estimated to be five to six times higher 
than that of people of the same age who did not experience an MI/CHD.170 Further, the benefits of statins 
may differ when used for primary vs. secondary prevention.19 Thus, research was still needed to 
understand statin-associated T2D among populations free of clinically diagnosed MI/CHD. 
 Interests in estimating statin-associated T2D risk prompted efforts to quantify the association 
between statins and incident T2D among primary prevention RCTs. For example, Taylor et al. conducted 
a meta-analysis among primary prevention trials, excluding studies based on population baseline 
characteristics and time length (Table 4). Among two RCTs examining the association between statins 
and T2D, Taylor et al. estimated that 2.8% of participants randomized to statins developed incident T2D 
(342/12,205) compared to 2.4% of participants randomized to placebo (290/12,202), resulting in an 18% 
increased risk of T2D among the statin group (RR =1.18 [95% CI: 1.01-1.39]).14 To inform the 
development of recommendations on statins for primary prevention of ASCVD in adults ≥40 years of age 
(see section F.1.Recent Recommendations Recommendations), a recent meta-analysis conducted by the 
US Preventive Services Task Force (USPSTF) identified six RCTs; differences from Taylor et al. 
included expanding eligibility criteria based on publication date and availability of previously 
unpublished work. Chou et al. reported that participants randomized to statins had a higher risk of 
developing T2D, although not statistically significant, compared to those randomized to placebo (RR 
=1.05 [95% CI: 0.91-1.20]), however, statistical heterogeneity was present (I2 =52%, statistical 
heterogeneity was defined as I2 >30%; Cochran’s Q not reported) .15 Sensitivity analyses using the profile 




Table 4. Summary of meta-analyses examining statins and incident T2D 
Author (date) Studies included Rationale Summary estimate 




AFCAPS TexCAPS, 4S, 




comparing statins (only 
included placebo-
controlled trials) and 
RCTs assessing statins 
among T2D populations, 
<1,000 participants, and 
mean follow-up time of ≤ 
one year. Also only 
included RCTs published 
between 1994-2009. 
OR =1.09  
(95% CI: 1.02-1.17) 








Pravastatin Multi (16) 
Excluded RCTs evaluating 
different statins as 
comparison groups 
OR =1.09 
 (95% CI: 1.02-1.16) 
Taylor (2013) JUPITER, AFCAPS 
TexCAPS (2) 
Included RCTs comparing 
statins with placebo or 
usual care for at least 12 
months, follow-up time >6 
months, RCTs with ≤10% 
of participants at baseline 
with a history of MI/CHD, 
and RCTs published 
between 1994-2006 
RR =1.18  
(95% CI: 1.01-1.39) 




Excluded studies in which 
≤10% of the participants 
had prior MI/CHD events, 
compared statins to 
placebo or no statin. 
Included RCTs published 
between 1991-2016. 
RR =1.05  
(95% CI: 0.91-1.20) 
Casula* (2017) Jick (2004), Culver 2012), 
Danaei (2012), Wang 
(2012), Chen (2013), Currie 
(2013), Izzo (2013), 
Zaharan (2013), 
Bhattacharya (2014), 
Cederberg (2014), Macedo 
(2014), Lichtenstein (2015), 
Mansi (2015), Radford 
(2015), van de Woestijne 
(2015), Calza (2016), 
Castro (2016), Lin (2016), 
Olotu (2016), Rha (2016) 
(20) 
Included observational 
studies examining statin 
use versus non-use, studies 
with ≥1,000 participants, 
and follow-up ≥ one year 
RR =1.44  
(95% CI: 1.31-1.58)** 
*Conducted on observational studies 
**Geographic area found to be a source of heterogeneity, P <0.001 
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 Even as meta-analyses of RCT evidence has suggested an increased risk in incident T2D (5-18%) 
from statins, several characteristics of RCTs may limit the external validity of findings. RCTs can be 
characterized by exclusive study populations that may only include populations most likely to benefit 
from the therapy under study.171 For instance, many of the primary prevention RCTs enrolled populations 
at increased risk for ASCVD who had LDL-C levels ≥130 mg/dl124, 125, 155, 172, hypertension148, 173, or 
additional ASCVD risk factors (i.e. obesity or current smokers).163 Some studies specified narrow 
inclusion criteria. For example, the JUPTER trial assessed the benefit of stains in populations with 
elevated hs-CRP levels and LDL-C levels ≤130 mg/dl; however, populations with LDL-C levels ≥130 
mg/dl, multiple non-LDL-C risk factors, but normal hs-CRP levels were not included.174 In addition, few 
RCTs have included diverse populations, missing important segments of the population given the known 
race/ethnic and sex-specific differences in ASCVD risk, T2D risk, and LDL-C changes across the life 
course (see sections C.1.Epidemiology of LDL-C, C.3.1.Diabetes Mellitus as a Potential Side Effect of 
Statins, and D.Health Outcomes Associated with Elevated LDL-C Levels). Thus, although RCTs offer 
excellent control of confounding, they may have limited external validity, motivating the need to examine 
associations between statin use and T2D in populations more generalizable to real-world settings. 
Evidence from Observational Studies 
 In addition to RCT evidence, observational studies, generally characterized by larger sample sizes 
and longer duration of follow-up time compared to RCTs, have also supported an association between 
T2D and statins. For example, Culver et al. examined the Women’s Health Initiative (WHI) study, which 
recruited postmenopausal women aged 50-79 years at 40 clinical centers across the U.S. and enrolled 
women into either a clinical trial or prospective observational study.175 After three years of follow-up 
among 120,173 women without ASCVD in either the clinical trial or observational study, Culver et al. 
found statin users (defined using medication inventory data) had a higher risk of incident T2D (defined by 
questionnaire and self-report of a new physician diagnosis of treated T2D) (HR =1.48 [95% CI: 1.46-
1.62]) compared to statin nonusers.164 Similar results were found among enrollees in the San Antonio 
Military Area as Tricare Prime/Plus. After six years of follow-up among 25,970 patients aged 30-85 years 
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without ASCVD, Mansi et al. found the risk of T2D (defined using ICD-9-CM codes) to be higher among 
statin users (defined as patients who filled a statin for at least 90 days) compared to statin nonusers (OR 
=1.87 [95% CI: 1.67-2.01]). As more observational studies became available, Casula et al. conducted a 
meta-analysis and included observational studies examining statin use versus non-use, studies with 
≥1,000 participants, and follow-up ≥ one year.176 Casula et al. identified 20 studies for inclusion in the 
analysis, with follow-up time ranging from 2-20 years (median 7.2 years) and mean age ranging from 
40.0-65.4 years. Compared to statin non-users, statin users experienced a greater risk of incident T2D (RR 
=1.44 [95% CI: 1.31-1.58]), with geographic area, but not follow-up length of time or propensity score 
matching, to be a source for heterogeneity (p-value < 0.001). Publication bias was also assessed, and was 
found for a specific type of statin (atorvastatin [p-value = 0.03], but not for other statins or for use of any 
statin.  
 Although meta-analyses of observational studies demonstrated an estimated 30% increased risk 
of incident T2D compared to previous meta-analyses conducted in RCTs (RR =1.05-1.18 vs RR =1.44), 
differences may be attributed to characteristics of each study design. RCTs have several limitations that 
might reduce the strength of the increased risk of incident T2D attributed to statins. Past RCTs, similar to 
some observational studies, used intention to treat analyses, which compares the groups initially assigned 
by randomization, despite non-negligible proportions of dropout or non-adherence (12-33%).12 Non-
adherence and dropout result in underestimation of any treatment effect, particularly limiting in trials 
aimed at uncovering adverse effects of a treatment.165, 177 In addition, several RCTs, similar to 
observational studies, relied on physician reports of T2D rather than measuring glucose, potentially 
underestimating T2D incidence. 
 While observational studies may be larger and have longer duration of follow-up time, 
observational studies have limitations of their own. The inability to randomize participants questions 
exchangeability between comparison groups (i.e. confounding by indication), especially as statin users 
may be at higher risk of MI/CHD than non-statin users and may be more likely to develop T2D with 
higher frequency independent of statin use.178 Several individual observational studies have tried to obtain 
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comparable groups by adjusting for confounders and propensity score matching, although the number and 
type of confounders investigated have varied. Multiple observational studies included in the meta-analysis 
conducted by Casula et al. adjusted for demographic information (i.e. sex and age), however, there was a 
range with observational studies also including baseline ASCVD risk factors (i.e. BMI and hypertension), 
medication use, and comorbidities (i.e. prevalence of ASCVD) and one observational study that failed to 
adjust for any confounders. In addition to the variety of confounders examined, the observational studies, 
similarly to RCTs, used a variety of methods, ranging in sensitivity, to assess T2D. Several observational 
studies used multiple criteria to define incident T2D (T2D drugs and/or biochemical measurements), 
while others relied solely on physician-diagnoses. Furthermore, detection bias may arise in observational 
studies as participants prescribed statins may be more likely to make and attend appointments with 
primary care physicians, increasing their chances of being clinically evaluated and obtaining a T2D 
diagnosis.179 Currie et al., however, in the first study to the best of my knowledge to use active 
comparators to evaluate the statin-associated risk of T2D, compared new statin users to new diclofenac 
users (used to treat pain or symptoms of osteoarthritis or rheumatoid arthritis) and found statin users had a 
higher risk of T2D (HR =3.31 [2.56-4.30]), even when both groups had similar chances of being 
evaluated.180 
 Meta-analyses maximizing the internal validity of RCTs and external validity of observational 
studies and therefore incorporating the totality of the evidence may best quantify the association between 
statins and incident T2D among populations generalizable to those in the real-world (i.e. with respect to 
age, sex., and race).17 Examining both RCTs and observational studies could allow a balance between 
internal validity of RCTs including the benefits of randomization and external validity of observational 
studies including generalizability of findings to broader populations. In addition, incorporating additional 
observational studies would increase power and provide an opportunity to evaluate important sources of 
heterogeneity between studies as well as sensitivity analyses. For example, past RCT meta analyses did 
not find baseline BMI as a source of heterogeneity, but observational studies suggested that women with 
BMI <25 were at greater risk for T2D than those with BMI ≥30, surprising results as BMI is a strong risk 
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factor for T2D. In addition, Sattar et al. examined percent change in LDL-C as a source of heterogeneity. 
However, conducting sensitivity analyses examining baseline LDL-C levels may be more informative to 
better understand the relationship between statins and T2D, as LDL-C levels have been found to have 
protective effects with incident T2D (see section C.3.1.3.Potential Mechanisms). Furthermore, year of 
paper publication or year at study baseline have not been examined in a meta-analysis, however, both may 
reflect possible period effects, as the prevalence of statin use and statin recommendations have changed 
over time; additionally, early users of statins may have risk factor distributions that differ for populations 
using statins years (or decades) after their introduction in the late 1980s. Lastly, demographic 
characteristics such as age are important risk factors when calculating ASCVD risk (see section 
E.4.ACC/AHA Recommendations); thus conducting further sensitivity analyses may help to determine if 
T2D risk varies by age. While evidence from RCTs and observational studies examining statins and 
incident T2D have been evaluated, integrating both study designs may best help quantify the effect of 
statins on primary prevention populations. Previous published work has shown that combining 
observational studies and RCTs may increase precision and produce equally or more relevant and valid 
results compared to results based solely on RCTs.17, 18, 181 While heterogeneity between study designs may 
prevent combination, adding to this rich meta-analysis literature will allow us to incorporate large, 
recently released observational and RCT evidence, examine the effect of additional sources of 
heterogeneity, and estimate statin effects in primary prevention/population-based settings. This will 
provide an opportunity to quantify statin-associated T2D risks generalizable to real-world populations, 
estimates necessary to better understand the side effects of statins and inform our sensitivity analyses. 
Subclinical Effects of Statins on Glucose 
 In addition to meta-analyses examining incident T2D as an outcome, studies have evaluated 
effects on fasting glucose as well. Sukhija et al. examined the effect of statins on fasting blood sugar 
(FBS) among 345,417 patients from the Veterans Affairs VISN 16 database (mean age =61 years, 94% 
men).182 After two years of follow-up, among patients without T2D (N =324,692), FBS increased by 7 
mg/dl in statin users compared to 5 mg/dl in non-statin users, (p <0.01), and for patients with T2D (N = 
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20,725), FBS increased 39 mg/dl in statin users compared to 32 mg/dl in non-statin users, (p <0.01). 
Results suggested statin use increased FBS in patients with and without T2D; however, study limitations 
exist including the lack of information on medications that may have also affected FPG levels (i.e. T2D 
medications or diuretics). 
 To study the association between statins and glucose traits, Swerdlow et al. examined the 
association between a SNP in the HMG-CoA reductase gene (targeted by statins) and bodyweight, waist 
circumference, plasma insulin, and glucose.183 The investigators found the SNP, which served as a proxy 
for LDL-C lowering, to be associated with higher plasma insulin concentration (1.62% [95% CI: 0.53-
2.72]), plasma glucose concentration (0.23% [95% CI: 0.02-0.44]), bodyweight (0.30 kg [95% CI: 0.18-
0.43]), and waist circumference (0.32 cm [95% CI: 0.16-0.47]); further suggesting that lowering LDL-C 
through statins affects glycemic traits.183 Additional work, examining the association between glucose 
traits and statins, however, is suggested as further evidence of the impact of statins on glucose.  
 The body of evidence linking statins and T2D generated by previous work prompted the FDA in 
2012 to decide there was sufficient evidence to add warnings on statin labels, indicating that increases in 
fasting glucose levels and incident T2D have been reported with statins.184 However, comparing the trade-
offs between the cardioprotective benefits of statins versus the potentially increased risk in T2D becomes 
necessary as statins continue to be prescribed to larger and larger proportions of the population,  
particularly in the context of primary prevention.  
C.3.1.3. Potential Mechanisms 
 While the relationship between statins and incident T2D has been examined, the potential 
mechanisms remain unclear. Below we describe four potential mechanisms currently under investigation. 
Pancreatic β-Cells and Insulin Secretion: Pancreatic β-cells secrete insulin in response to 
elevated glucose to maintain blood glucose homeostasis, 140 which is initiated by an increase in 
Ca2+controlled by the opening of Ca2+ channels.185 Studies have shown that changes in Ca2+ concentration 
may affect insulin secretion and the ability to maintain glucose homeostasis. Xia et al. showed that 
chronic depletion of  cholesterol impaired insulin secretion and inhibited Ca2+ channel currents in mouse 
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pancreatic β-Cells,  suggesting that long-term use of statins  to reduce LDL-C may similarly impact 
insulin secretion.186 Research examining statin therapy and insulin secretion regulation, however, found 
that statins increased insulin secretion at low glucose levels, but did not increase insulin secretion when 
high glucose levels were introduced, suggesting possible loss of insulin secretion regulation.187 More 
research on the mechanism underlying the relationship between inhibited lipoprotein synthesis, Ca2+ 
channel function, and insulin secretion is needed. 
GLUT 4: Glucose uptake in adipocytes is mediated through glucose transporter 4 (GLUT4) upon 
activation by insulin.188 Research has reported a decrease in GLUT4 expression and consequent decreases 
in glucose uptake in adipocytes after statin use.189 Chabmerlain et al. examined the impact statins had on 
the expression of GLUT4 and found statins down-regulated GLUT4 and reduced glucose uptake in cells 
in response to insulin, suggesting that adipocytes become insulin resistant when GLUT4 expression is 
decreased.190 
Modifying LDL-C Levels: While the mechanism between statins and T2D remain unclear, results 
from multiple Mendelian randomization studies have found that SNPs associated with increasing LDL-C 
were associated with reduced T2D incidence, suggesting the relationship is related to the change in LDL-
C levels.191-193 For instance, White et al. found a 1-standard deviation genetically instrumented increase in 
LDL-C levels (equivalent to 38mg/dl increase) was associated with an increase in MI/CHD (OR =1.68 
[95% CI: 1.51-1.87]), but showed a decrease in T2D (OR =0.79 [95% CI: 0.71-0.88]). Furthermore, 
Schmidt et al. found 38.7 mg/dl reductions in LDL-C (identified using PCSK9 SNP-LDL-C effects) were 
associated with an increase in bodyweight of 1.03 kg (95% CI: 0.24-1.82) and 3.5 mg/dl (95% CI: 0.8-
5.8) higher fasting plasma glucose.193 Evidence suggests that LDL-C may be protective against T2D and 
reducing it may increases the risk of T2D; however, more research is still needed to better understand the 
relationship and the pathogenesis of T2D.192 
Health behaviors and lifestyle: Research has suggested that statins impact health behaviors and 
healthy lifestyle choices, although evidence on the relationship is still scarce. Statin-associated muscle 
symptoms have been previously reported in several RCTs, with myopathy, being reported in 1% to 5% of 
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patients.194 As mentioned previously, however, evidence suggests the incidence of myopathy is much 
larger in real-world practice than when measured in a clinical trial setting and investigators have 
hypothesized that myopathy could contribute to an inactive lifestyle and T2D. For instance, the Effect of 
Statins on Skeletal Muscle Performance (STOPM) study, examined the effects of statins on skeletal 
muscle in a young (mean age of 44 years) population treated with statins for up to six months (N =420). 
Thompson et al. found 9.4% of patients treated with statins developed myopathy compared to 4.8% of 
patients in the placebo group; however, the association between statins and T2D with myopathy as a 
potential mediator has yet to be examined. Research has also suggested statin use is associated with diet. 
For example, among statin users in NHANES, caloric intake in 2009-2010 was 9.6% greater (95% CI: 
1.8-18.1) than that among statin users in 1999-2000, and fat intake was 14.4% greater (95% CI: 3.8-26.1) 
in 2009-2010 than that among statin users in 1999-2000.195 The study, however, had several limitations 
including the use of cross sectional studies preventing temporality to be assessed and comparing 
inherently different groups (statin users versus statin nonusers) through different time periods (statin users 
in one wave may be different from statin users in subsequent waves). Investigators have hypothesized 
myopathy and unhealthy lifestyles to be potential mediators in the statin and T2D association as they can 
hinder active lifestyles; however, research examining the associations are still needed.  
C.4. Lifestyle Modification 
 Clinical trials have shown the effectiveness of reducing LDL-C levels and MI/CHD risk through 
medication and diet; however, recent lifestyle interventions have also reduced MI/CHD without affecting 
LDL-C levels, demonstrating the impact of diet on MI/CHD risk may not be mediated by diet’s effect on 
LDL-C. For example, the Lyon Diet Heart study, a randomized controlled trial, tested the effectiveness of 
a Mediterranean diet that emphasized fruits, vegetables, breads and cereals, and fish.196 After 46 months 
of follow-up, compared to the control group that consisted of less stringent diet requirements, the 
experimental group had reduced rates of MI/CHD recurrence and MI/CHD mortality; however, there was 
no effect of the diet on lipoproteins (LDL-C, HDL-C). Consistent results were recently found among the 
Prevención con Dieta mediterránia (PREDIMED) study conducted in Spain to compare two 
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Mediterranean diets to a low-fat diet.197 Compared with the low-fat diet, the Mediterranean diets had 
lower risks of MI/CHD (HR = 0.70 [95% CI: 0.53-0.91]) after five years;  however, there were minimal 
changes in LDL-C levels.198 
 In contrast to recent literature showing reduction in MI/CHD risk may occur in the absence of 
reduction in LDL-C levels, previous work has also examined the benefits of maintaining low levels of TC 
and LDL-C in early life on MI/CHD risk (i.e. primordial prevention). 199-201 For example, the Special 
Turku Coronary Risk Factor Intervention Project (STRIP) initiated low saturated fat diets to infants and 
parental counseling from when infants were 7 months old and until the age of 19 years. When children 
reached 19 years of age, investigators found that LDL-C values were lower in the intervention than 
control group for boys and girls: -6.96 mg/dl (95% CI: -10.05, -3.87) in boys; and -3.87 mg/dl (95% CI: -
7.35,-0.387) in girls. The results are relevant given exposure to even suboptimal LDL-C levels increases 
MI/CHD risk.199, 200, 202, 203 Taken together, evidence has shown that various lifestyle modifications, 
similar to various pharmacologic agents204 (see section C.2. Pharmacologic Treatments), have 
demonstrated the ability to reduce MI/CHD without affecting LDL-C or reduce LDL-C levels and 
subsequent MI/CHD risk; and both have generated evidence that shaped cholesterol treatment 
recommendations.  
D. Health Outcomes Associated with Elevated LDL-C Levels 
 As mentioned previously, elevated LDL-C levels is an established risk factor for atherosclerosis 
and downstream MI/CHD. This section reports the epidemiology and public health burden of MI/CHD as 




D.1. Myocardial Infarction/Coronary Heart Disease  
 Coronary heart disease (CHD) is the clinical manifestation of the blockage of the epicardial 
coronary arteries supplying blood to the myocardium. The definition of MI/CHD, typically in 
observational studies, depends on symptoms, signs, biomarkers (i.e. cardiac troponins, creatine kinase), 
electrocardiogram (ECG) and/or autopsy findings  to classify nonfatal (definite MI/CHD, probable 
MI/CHD, possible MI/CHD, unrecognized MI/CHD, medical procedure-related event, unstable angina 
pectoris, and stable angina pectoris) and fatal events (definite fatal MI/CHD, probable fatal MI/CHD, and 
possible fatal MI/CHD) 
(Table 5).205 In several 
observational studies, 
MI/CHD ascertainment is 
reviewed independently by 
multiple experts, with 
adjudicator agreement target 
goals of approximately 80%.  
Disagreements are resolved by consensus by committee and if individual adjudicator agreements with the 
final outcome falls below 80%, retraining can be undertaken.206, 207  
MI/CHD imparts a significant public health burden domestically and worldwide. In the U.S. 
MI/CHD is a leading cause of mortality, accounting for approximately 370,000 deaths annually. In 2013, 
approximately 660,000 Americans experienced an incident MI.208 The burden of prevalent CHD is also 
high—15.4 million in 2013—thereby imparting significant (and rising) health care costs in addition to 
putting large segments of the population at increased risk for heart failure, cardiac arrhythmias, and 
sudden death.40, 142 Even as age-adjusted rates of MI/CHD mortality have continued to decline since the 
mid-1960s40, deceleration of the MI/CHD mortality rate has been observed over the past decade, 
particularly in younger populations.209 In addition, the estimated medical costs between 2013 and 2030 
are projected to double210, exacerbating already high health care costs: MI ($11.5 billion) and CHD ($10.4 
Table 5. Classification of MI/CHD 
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billion) were two of the 10 most expensive hospital principal discharge diagnoses in 2011.211 
Furthermore, MI/CHD disproportionately affects men compared to women and African Americans 
compared to Caucasians. For instance, the Atherosclerosis Risk in Communities Surveillance Study 
(ARIC) examined 35-84 year old African American and Caucasian men and women from Washington 
County, Maryland; Forsyth County, North Carolina; Jackson, Mississippi; and Minneapolis, Minnesota 
and found  that the highest overall MI/CHD attack rates per 1,000 population from 2005-2012 were: 
African American men, 6.2; African American women, 4.1; Caucasian men, 3.7; and Caucasian women, 
2.1.40, 212, 213  
 In addition to major MI/CHD risk factors such as blood pressure, body mass index (BMI), 
cigarette smoking, and age, the importance of LDL-C as a major risk factor has been well documented, as 
described above. To estimate the impact LDL-C level reduction can have on the risk of MI/CHD, Law et 
al. analyzed data from 10 prospective observational cohorts with an average follow-up time of 14.5 years 
(period of recruitment ranged from 1950-1980).214Although the analysis excluded women (studies 
included did not evaluate women), Law et al. found a 23 mg/dl (approximate mean reduction in LDL-C 
attained in cohort studies) reduction in LDL-C from medication use was associated with a one-time 
decrease in incidence of MI/CHD by 54% at age 40 years, 39% at 50, 27% at 60, 20% at 70, and 19% at 
80. A recent meta-analysis among 27 RCTs showed LDL-C lowering through statins reduced the risk of 
MI/CHD by 24% per 38 mg/dl reduction in LDL-C.3 The strength of evidence regarding the contribution 
of LDL-C to MI/CHD risk highlights an important opportunity for populations to reduce LDL-C levels 
for improved MI/CHD prevention efforts and minimization of future health care costs attributed to 
MI/CHD.215  
D.2. Stroke 
 Stroke is a cardiovascular event caused by the acute interruption of blood flow to one or more 
sections of the brain. There are two main types of stroke: ischemic (87% of stroke cases) caused by the 
formation of a blood clot and hemorrhagic caused when a weakened blood vessel ruptures; and each type 
of stroke consists of a number of subtypes.40, 142 For instance, the two most common subtypes of ischemic 
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strokes are those due to large-artery atherosclerosis (~30%) and strokes of unknown origin classified as 
cryptogenic (~30%).216 Several observational studies, including the Reasons for Geographic and Racial 
Differences in Stroke (REGARDS), have classified stroke events following similar definitions to the 
World Health Organization outline (Table 6).217 Similar to physician adjudicated MI/CHD events 
conducted in observational studies, physician adjudicators assessing stroke are assessed in an ongoing 
fashion for agreement >80%.218  
Table 6. Stroke classification 
Stroke classification Definition 
Stroke Rapidly developing clinical signs of focal, at times 
global, disturbance of cerebral function, lasting more 
than 24 hours or leading to death with no apparent 
cause other than that of vascular origin 
Clinical stroke Characterized by symptoms lasting <24 hours, with 
neuroimaging consistent with acute ischemia or 
hemorrhage 
Probable stroke Adjudicators agreed that the event was likely a stroke 
or death related to stroke, but information was 
incomplete for clinical classification. 
 
 An estimated 795,000 adults in the US experience a stroke annually and of those, 185,000 are 
recurrent strokes.142 Carandang et al. found the incidence of all stroke was declining over the past 50 
years (1950-2000) from 7.6 to 5.3 per 1000 person-years and from 6.2 to 5.1 per 1000 person-years in 
men and women, respectively in FHS.219 Fang et al. found stroke incidence decreased as well among a US 
Medicare population from an age-adjusted rate of 1039 per 100,000 (95% CI: 1032-1045) in 1988 to 639 
per 100,000 (95% CI: 634-644) in 2008 with 30-day mortality from stroke also declining from 16.2% in 
1988 to 15.2% in 2008 (p <0.1).220 The burden of prevalent stroke, however, is already high—affecting 
6.6 million American adults in 2012 —estimated to increase by 20.5% by 2030, exacerbating already high 
health care costs (estimated $34 billion currently spent annually).  
 Evidence has shown the burden of stroke to vary by sex, age, and race/ethnicity 
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disproportionately placing large segments of the population at risk for lifelong disability and 
complications including immobility, formation of blood clots, visual impairment, and weakness in 
limbs.221, 222 For instance, stroke incidence rates are lower in women than men in younger and middle-age 
groups (ages 45-75 years); however, in the oldest age groups, the incidence rates are approximately equal 
or even higher among women (ages ≥75 years).223, 224 In addition to sex disparities, overall stroke 
mortality rates among African-Americans are about 50% higher than Caucasians with the largest disparity 
at younger ages.218, 225 For instance, Howard et al. used data from the National Longitudinal Mortality 
Study to examine the burden of stroke mortality among African Americans relative to Caucasians across 
age. After five years, the risk of stroke mortality for both African American men and women was 4.5 
times that of Caucasians at age 45, but decreased with age (p ≤0.05).225 To examine racial/ethnic 
disparities in stroke incidence and recent trends, Kleindorfer et al. used medical records from the Greater 
Cincinnati/Northern Kentucky Stroke Study from 1993 to 2005. The investigators found decreases in 
stroke incidence from 1993 to 2005 for Caucasian men (178 cases per 100,000 [169-188] to 154 [146-
162]), but increases (or no change) among African American men (271 [239-303] to 275 [246-305]).226-228  
While each stroke type has its own set of distinct risk factors, both ischemic and hemorrhagic 
stroke also share common risk factors including hypertension, sex, race/ethnicity, and cigarette 
smoking.229 In addition, research has found that TC and LDL-C levels can impact stroke. For instance, Iso 
et al. examined six years of follow-up in the MRFIT, which included >350,000 men, and found that 
compared to TC levels <160 mg/dl, relative risk of death from ischemic stroke increased for each level of 
TC (200-239 mg/dl, RR =1.21; 240-279 mg/dl, RR =1.81; >280 mg/dl, RR =2.57; p-value =0.06 
[corresponding to a test of homogeneity of adjusted RR estimates]).230 RCTs have also focused on the 
reduction of stroke associated with lowering LDL-C levels through statins (see section E.4. ACC/AHA 
Recommendations).231, 232 While statins have been shown to reduce MI/CHD events in past RCTs, the 
CARE study (see section C.3. Statin Therapy) was one of the first major RCTs to show a reduction in 
incident stroke (all types) among participants randomized to statins compared to those randomized to 
placebo (RR =0.69 [0.48-0.97]).127 To further evaluate the impact of statins on incident stroke, Amarenco 
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et al. conducted a meta-analysis among primary and secondary prevention trials.233 Among 26 RCTs 
totaling >90,000 participants and with mean follow-up times ranging from 0.5-6.1 years, Amarenco et al. 
found the relative odds reduction in incident stroke (all types) among participants randomized to statins 
compared to those randomized to placebo was 21% (OR: 0.79 [95% CI: 0.73-0.85]). Interests in 
estimating the impact of statins on stroke among populations free of clinically diagnosed MI/CHD or 
stroke prompted efforts to quantify the association between statins and incident stroke among primary 
prevention RCTs. For example, Taylor et al. identified 18 RCTs totaling >56,000 participants (60% men 
and 86% Caucasian) and found a 38.7 mg/dl reduction in LDL-C levels through statins was associated 
with a reduction in incident stroke (all types) (RR =0.78 [95% CI: 0.69-0.89]), results similar to those 
found among meta-analysis evidence of primary and secondary prevention RCTs.234 Results from the past 
RCTs and observational studies have strengthened the evidence of the importance of LDL-C on stroke, 
further highlighting the need to reduce population levels of LDL-C.234 
D.3. Atherosclerotic Cardiovascular Disease (ASCVD) 
 As knowledge of the benefits of statins on stroke has accumulated, risk prediction for statin 
recommendation has begun to emphasize both MI/CHD and stroke (all types). Risk estimators such as the 
Framingham risk scores determined 10-year MI/CHD risk to help identify populations that would benefit 
from statins (see section E.3. NCEP-ATP III); however, this method excluded stroke.235 To better capture 
the scope of disease impacted by statins, risk prediction has begun focusing on atherosclerotic 
cardiovascular disease (ASCVD) which includes MI/CHD and fatal or nonfatal stroke (all types) among 
both Caucasians and African Americans, consistent with past international cholesterol recommendations. 
For instance, the United Kingdom National Institute for Health and Care Excellence recommends statins 
to populations ≥40 years with a 10-year ASCVD risk ≥10% (estimated by the QRISK assessment tool236, 
a multifactor ASCVD risk prediction algorithm).237 Similarly, the European Society of 
Cardiology/European Atherosclerosis Society’s latest recommendations for the management of 
dyslipidemia recommends medication for populations with 10-year fatal ASCVD risk ≥5% (estimated by 
the Systemic Coronary Risk Estimation).238 Research has shown that previous risk assessments based on 
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Framingham data that focused only on MI/CHD events undervalued the risk and potential benefits of 
statins in women and African Americans.239 Because stroke accounts for a higher proportion of ASCVD 
events than MI/CHD in women and 55,000 more women die of stroke than men before the age of 75 
years, the inclusion of the stroke end point can identify at-risk women at younger ages that may have been 
missed by previous risk estimators levels.240  In addition, the incident risk for MI/CHD and stroke (all 
types) is higher among African Americans compared to Caucasians, specifically among populations <65 
years of age. The inclusion of race-specific coefficients and stroke endpoint helps identify and quantify 
different risk profiles in African Americans compared to Caucasians, particularly at younger ages.226, 239  
 Consistent with past research demonstrating an association between statins and MI/CHD and 
stroke, research has shown an association between LDL-C level reduction through statins and reduction in 
ASCVD mortality (Table 7). For instance, a recent meta-analysis of 27 primary and secondary prevention 
RCTs found that for each 1 mmol/L (38.7 mg/dl) reduction in LDL-C, statins reduced ASCVD events by 
about one-fifth.3 Additionally, comparing participants randomized to statins to participants randomized to 
placebo, protective effects of statins on ASCVD mortality were found among men (RR =0.87 [95% CI: 
0.82-0.92] and women (RR =0.92 [95% CI: 0.82-1.03]), with no evidence of heterogeneity by sex.3  
Table 7. Review of meta-analyses of TC and LDL-C and ASCVD mortality risk 
Author Year N of RCTs RR (95% CI) 
CTT Collaborators241 2005 14 0.83 (0.79-0.87) 
CTT Collaborators194 2010 26 0.86 (0.82-0.90) 
CTT Collaborators3 2015 27 0.88 (0.84-0.91) 
RCT: Randomized Controlled Trials 
RR: Relative Risk 
CI: Confidence Intervals 
CTT: Cholesterol Treatment Trialists’ Collaborators 
ASCVD: MI/CHD and stroke 
E. Development of Cholesterol Recommendations 
 The knowledge based management and therapy of LDL-C is reflected in the evolution of 
cholesterol recommendations in the past 30 years. The following section describes the development of 
cholesterol recommendations from the National Cholesterol Education Program’s (NCEP) inception to 
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the most current American College of Cardiology/American Heart Association (ACC/AHA) 
recommendations.  
E.1. NCEP-ATP I 
 After taking into account the large body of evidence that linked elevated LDL-C levels to 
MI/CHD, the National Institutes of Health (NIH) created the first Consensus Development Conference on 
Lowering Blood Cholesterol to Prevent Heart Disease in 1984 to resolve remaining questions regarding 
the steps that should be taken to diagnose and treat elevated LDL-C levels.242 The consensus panel 
provided recommendations for health professionals on which populations to treat, how to treat them, and 
goals for treatment. The panel also provided recommendations to the public on the importance of 
maintaining a diet that is low in total fat, saturated fat, and cholesterol to reduce TC and LDL-C levels. To 
help reduce the prevalence of elevated TC and LDL-C, the panel created the National Cholesterol 
Education Program (NCEP).243 Below several NCEP-initiated programs are described. 
 To develop 
recommendations and 
recommendations, the NCEP 
created the Adult Treatment 
Panel (ATP) in 1987 to inform 
the detection, evaluation, and 
treatment of high blood TC 
and LDL-C in adults. In 
addition to clinical management of high TC and LDL-C levels, the ATP defined TC and LDL-C cut-
points and provided recommendations on how to detect and monitor high-risk patients over time. The 
ATP recommendations defined populations with LDL-C levels ≥160 mg/dl as high-risk and those with 
LDL-C levels ≥130 mg/dl as borderline-high risk and recommended dietary changes (i.e. reducing 
saturated fatty acids, cholesterol) as initial treatment (Figure 5). However, because the relationship 
between LDL-C and MI/CHD was found to be continuous, the ATP cut-points were (recognized as) 
Figure 5. NCEP-ATP I cholesterol treatment recommendations 
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somewhat arbitrary, similar to classifications made for other risk factors (i.e. blood pressure).244 The ATP 
further recommended drug therapy for populations with LDL-C levels ≥190 mg/dl or ≥160 mg/dl if 
MI/CHD or two other MI/CHD risk factors (i.e., hypertension, smoking, male sex, family history of 
MI/CHD or stroke, T2D, and BMI >30) were present (Figure 5). The ATP suggested BAS and nicotinic 
acid as the primary options for drug therapy, as research demonstrated their ability to lower MI/CHD risk 
without long-term adverse events (see section C.2. Pharmacologic Treatments).245  
 In addition to the ATP recommendations, the NCEP also created panels focused on measuring TC 
and LDL-C levels and preventing high concentrations of TC and LDL-C at the population level, 
specifically during childhood. In 1991, the NCEP created the Population Panel to make recommendations 
focused on the population level to lower TC and LDL-C levels.246 While the ATP included 
recommendations suggesting dietary therapy as initial forms of treatment and that drug therapy should be 
considered only after dietary therapy failed to reduce LDL-C levels, the Population Panel exclusively 
intended to promote the adoption of healthy eating and lifestyle patterns. The panel envisioned healthy 
diets would lower TC and LDL-C levels in the majority of the population and concluded that excessive 
intakes of saturated fatty acids, total fat, and dietary cholesterol, together with excessive body weight, all 
contributed to elevated levels of TC and LDL-C. The panel emphasized expansion of awareness of TC 
and LDL-C as a critical risk factor for MI/CHD through mass media and highlighted interventions at the 
population level to include diet, exercise, and weight control. Combined with the ATP recommendations, 
the NCEP estimated the Population Panel would help prevent large proportions of the population from 
developing elevated TC and LDL-C levels and result in smaller proportions of the population that would 
require drug therapy and be at-risk of MI/CHD morbidity and mortality.  
E.2. NCEP-ATP II 
 In 1993, the NCEP updated its ATP recommendations from the first report and released the 
second report of the Expert Panel in Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (ATP II); however, the NCEP did not update the additional NCEP-initiated panels including the 
Population Panel.247 Similar to the ATP I, ATP II emphasized dietary treatment as the initial treatment 
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with drug therapy reserved for populations at high risk of MI/CHD (Figure 6). Since ATP I was released, 
however, several topics that were not included in ATP I emerged that deserved mention and 
considerations in ATP II. For example, in addition to MI/CHD risk factors mentioned in ATP I, ATP II 
added age as a risk factor, specifically older ages in men (≥45 years) and women (≥55 years). 
Furthermore, for 
patients with established 
MI/CHD, the panel 
reduced the LDL-C 
level recommended drug 
therapy from 160 mg/dl 
to 130 mg/dl (Figure 6).  
 Angiographic 
studies suggested that 
net regression of atherosclerosis was proportional to the decrease in LDL-C levels among populations 
with MI/CHD and prompted recommendations to lower the LDL-C level threshold among populations 
with MI/CHD from 160 mg/dl to 130 mg/dl.88, 248Among a U.S. population of 146 men (≤62 years of age), 
with family history of MI/CHD, and established atherosclerosis (measured using an arteriogram), Brown 
et al. used arteriography to examine average percentage change in stenosis (measured as an 
atherosclerotic lesion occluding the diameter of the artery) after randomizing the population to receive 
either niacin, statin, or a placebo. After 2.5 years of treatment, stenosis increased by 2.1% among the 
placebo group, but decreased by 0.7% among the group randomized to statins and 0.9% among the group 
randomized to niacin (P for trend <0.01). Furthermore, results showed that lipid lowering therapy (both 
statin and niacin groups compared to placebo) reduced the incidence of MI/CHD by 73% (RR =0.27 
[95% CI: 0.10-0.77]), providing further evidence that LDL-C lowering medication helped decrease 
progression of atherosclerosis, increase regression, and reduce MI/CHD events. As angiographic studies 
Figure 6. NCEP-ATP II cholesterol treatment recommendations 
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and clinical trials continued to accumulate data on the benefits of pharmacotherapy, cardioprotective 
evidence among larger populations spanning multiple years were still needed.  
E.3. NCEP-ATP III 
 In 2001 the NCEP updated its 
second report and released the third 
report of the Expert Panel in 
Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults 
(ATP III), modifying cholesterol 
treatment recommendations. Similar 
to the ATP I and ATP II 
recommendations, ATP III 
emphasized diet and lifestyle changes 
as initial treatment to lower LDL-C levels and continued to consider high LDL-C levels (≥190 mg/dl) and 
LDL-C levels ≥160 mg/dl among populations with at least one MI/CHD risk factor as targets for LDL-C 
lowering drug therapy (Figure 7). However, as mentioned previously (see section C.3. Statin Therapy), 
from 1993 to 2000, major clinical trials examined statins and MI/CHD risk, finding that statins 
consistently reduced MI/CHD incidence by an estimated 30% (Table 2).10 The RCTs provided evidence 
to modify criteria for the NCEP-ATP II Recommendations and in response, ATP III added new features. 
ATP III updated treatment recommendation categories to highlight the presence of MI/CHD and MI/CHD 
risk equivalents (i.e. peripheral arterial disease, carotid artery disease, or abdominal aortic aneurysm), 
T2D, and multiple MI/CHD risk factors (i.e. cigarette smoking, hypertension, low HDL-C [<40 mg/dl] 
(Figure 7).  
 ATP III focused on persons with multiple risk factors and used Framingham Heart Study (FHS) 
projections of 10-year absolute MI/CHD risk to identify populations for more intensive treatment, (Figure 
7). The FHS provided an algorithm including age, sex, TC, HDL-C, systolic blood pressure, diastolic 




blood pressure, hypertension medication use, T2D, and cigarette smoking status for estimating risk for 
MI/CHD in the short term (≤10 years).212 Previously, ATP II counted risk factors, however, this method 
did not quantify an estimate of absolute risk, did not account for variability in risk factor level or 
intensity, and may have underestimated the progressive impact of aging on absolute risk. Instead, ATP III 
used risk estimation methods, such as the Framingham risk scores, in addition to risk factor counting in 
order to better quantify absolute risk prediction of hard MI/CHD events (MI and CHD mortality). 
Additionally, ATP III counted T2D as a MI/CHD risk equivalent rather than part of the list of risk factors 
that modify LDL-C as evidence showed that patients with T2D had a high risk for developing MI/CHD 
(see section C.3.1.Diabetes Mellitus as a Potential Side Effect of Statins). 
 As research continued to examine statins and MI/CHD among populations with various baseline 
MI/CHD risks, questions remained regarding when to initiate statins, optimal LDL-C target levels, and if 
the cardioprotective benefits of statin were generalizable to populations excluded from past RCT trials.  
E.4. ACC/AHA Recommendations 
 After the publication of ATP III, major clinical trials assessing statins and clinical endpoints 
(MI/CHD, with extensions to include stroke) were published to further examine the treatment categories 
created by ATP III.249 For example, RCTs examined the effects of reducing LDL-C levels below 100 
mg/dl (ATP III recommendation treatment threshold) among high-risk patients to examine if the risk for 
MI/CHD continued to decrease or if there were no added benefits. The Heart Protection Study (HPS) 
randomly assigned men and women aged 40-80 years with MI/CHD (N =14,573) or T2D (5,963) from 
the U.K. to either statins or placebo.150 After approximately five years of follow-up, results found that 
participants randomized to statins had a reduced risk of MI/CHD (RR =0.73 [95% CI: 0.67-0.79]) and 
stroke (RR = 0.75 [95% CI: 0.66-0.85]) compared to participants randomized to placebo, supporting ATP 
III recommendation recommendations for treating populations deemed at high-risk (≥100 mg/dl with 
CHD or T2D). Furthermore, HPS investigators reported that the reduction in MI/CHD continued even 
when LDL-C levels were reduced to 77 mg/dl (levels below LDL-C treatment thresholds for populations 
with T2D or MI/CHD), suggesting the greatest reduction in absolute LDL-C levels from statins had the 
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greatest reduction in MI/CHD risk, although albeit in a racially homogenous population with T2D or 
prevalent MI/CHD.150 
In addition to examining benefits of treatment at LDL-C levels below NCEP III recommendation-
recommended thresholds among high-risk populations, RCTs also examined statin benefits among 
moderately high-risk (those with ≥2 risk factors and 10%-20% MI/CHD risk) and low-risk (10-year 
MI/CHD risk <10%) populations. The ASCOT-LLA trial (see section C.3.1.2.Incidence of T2D among 
Statin Users) examined populations with ≥3 MI/CHD risk factors over approximately three years and 
found participants randomized to statins not only reduced LDL-C levels by 35% (relative reduction), but 
had a lower risk of incident MI/CHD (HR =0.64 [95% CI: 0.50-0.83]) compared to those randomized to 
placebo.148 Sever et al. also found that benefits of statins were maintained when LDL-C levels were 
reduced to 88 mg/dl, further suggesting the use of statins to lower LDL-C levels below ATP III treatment 
thresholds; however, the generalizability of findings was again potentially limited (conducted in a 
European population of whom 81% were men). Furthermore, interests in estimating the benefits of statins 
among populations at low risk of MI/CHD prompted efforts to quantify the association between statins 
and incident MI/CHD among evidence from available RCTs. The Cholesterol Treatment Trialists’ (CTT) 
Collaboration examined the association between statins and incident MI/CHD among populations with 5-
year MI/CHD risk <10% and conducted a meta-analysis in 27 RCTs with median follow-up time of 
approximately five years, mean age of 63, and 23% women. The CTT found that compared to placebo, 
statins reduced the risk of incident MI/CHD events by 21% per 38 mg/dl reduction in LDL-C level (RR 
=0.79 [95% CI 0.77-0.81])4, suggesting the cardioprotective benefits from statins existed among low-risk 
populations, populations not recommended statins in past ATP recommendations.   
 In addition to RCT evidence supporting ATP III treatment categories and suggesting more 
aggressive treatment goals, researchers identified additional recommendations for subsequent 
recommendations. Researchers argued the Framingham risk scores were too limited in the inputs and 
were not able to take into account risk factors measured by laboratory testing.235 For example, the 
Reynolds Risk Score used hs-CRP, an inflammatory marker used to predict coronary events (see section 
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C.2.1.Statin Pleiotropic Effects),250 in addition to Framingham risk score variables when calculating risk. 
Alternatively, including additional measures such as imaging techniques could better assess risk in 
intermediate-risk patients through quantifying coronary artery calcium (CAC) and carotid intima-media 
(CIMT) thickening (precursors to atherosclerosis). Quantifying CAC and CIMT can further capture 
subclinical indicators of atherosclerosis. Researchers also have criticized the Framingham risk scores for 
being limited in their outputs (MI/CHD), as evidence had been generated revealing the benefits statins 
have beyond MI/CHD (see section D.3. Atherosclerotic Cardiovascular Disease). Results suggested future 
recommendations incorporating stroke as an endpoint along with MI/CHD would more comprehensibly 
identify populations who would benefit the most from statins. 
In reviewing the previous evidence, in 2013 the American College of Cardiology/American Heart 
Association (ACC/AHA) Recommendations were formed.22 Instead of focusing on a comprehensive 
approach to the detection, evaluation, and treatment of high LDL-C in adults, as previous ATP 
recommendations did, the ACC/AHA Recommendations focused on the development of evidence-based 
recommendations for the reduction of ASCVD risk. For example, in contrast to previous ATP 
recommendations, which outlined diet recommendations, the ACC/AHA recommendations acknowledged 
the importance of lifestyle factors in reducing ASCVD risk by highlighting the 2013 AHA/ACC 
Recommendations on Lifestyle Management to Reduce Cardiovascular Risk251; however, the cholesterol 
treatment recommendation primarily focused on statins as treatment. In addition to the change in focus, 
the ACC/AHA recommendations also discontinued using the Framingham risk score due to the derivation 
in a Caucasian population (although the risk score has been recalibrated for use in other populations)252 
and limited scope in assessing outcomes (MI/CHD). Instead the ACC/AHA developed the Pooled Cohort 
risk equations to estimate 10-year risk of developing ASCVD using traditional risk factors including age, 
sex, race/ethnicity, TC, HDL-C, systolic blood pressure, diastolic blood pressure, hypertension 
medication use, T2D, and smoking status (see Appendix figures 1 and 2). To increase generalizability, the 
recommendations used data from community-based cohorts of adults from the ARIC Study253, the 
Cardiovascular Health Study254, the Coronary Artery Risk Development in Young Adults (CARDIA) 
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study255, and both Framingham Original and Offspring Study256, 257 to develop the algorithm. Cohorts 
included African American or Caucasian participants free of clinically diagnosed ASCVD with at least 12 
years of follow-up.  The focus on ASCVD rather than MI/CHD alone was also consistent with the AHA 
and American Stroke Association (ASA) call to include stroke events in the outcome of interest for risk 
assessment, as described previously.258  
The ACC/AHA aimed to reduce ASCVD by creating four statin benefit groups, which were 
identified from RCT 
evidence (Figure 8). 
Similar to previous 
recommendations, 
populations with LDL-
C levels ≥190 mg/dl 
were recommended to statins; however, the ACC/AHA also recommended statins to populations with 
ASCVD and populations between the ages of 40 and 75 years with 10-year risk of ASCVD ≥ 7.5%. In 
addition, the ACC/AHA recommendations also lowered the threshold to recommend statins among 
populations with T2D from 100 mg/dl (ATP III) to 70 mg/dl. Furthermore, instead of treatment goals 
used to define when LDL-C levels were controlled and if modification of treatment regimen was 
warranted, the ACC/AHA recommendations assumed long-term treatment (i.e. for life) with statin dose 
appropriate for risk (low dose vs high dose).  
 Over the past 30 years, efforts to reduce ASCVD morbidity and mortality have evolved from 
detecting, evaluating, and treating high levels of LDL-C to focusing on the management of ASCVD risk 
as assessed by the Pooled Cohort risk equation. As definitions for what constitutes as being “at-risk” 
continue to modify and increase the statin eligible population, research on understanding and weighing 
the potential consequences of various ASCVD risk reduction thresholds must be conducted.  
Figure 8. ACC/AHA cholesterol treatment recommendations 
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F. Public Health Significance and Gaps 
F.1. Recent Guideline Recommendations 
 Ideally, public health recommendations would aim to focus on segments of the population that 
will subsequently develop an incident or recurrent ASCVD event (high sensitivity) while avoiding 
unnecessary treatment among those in the population who will not develop an ASCVD event (high 
specificity).259 Current recommendations prioritize sensitivity but not specificity by recommending statin 
therapy to populations at lower ASCVD risk.6 Because the benefits and risks of statin treatment at lower 
risk thresholds are unknown, the net gain in disease burden is unclear.  
Uncertainty in the net benefit of statin treatment for primary prevention prompted changes to 
treatment recommendations in 2016. In the United States, the USPSTF makes recommendations about the 
effectiveness of specific preventive care services for patients. In 2016, the USPSTF recommended statins 
for primary prevention among adults with 10-year ASCVD risk ≥10%, similar to the NCEP-ATP III 
recommendations. This recommendation contrasts with more recent recommendations for cholesterol 
treatment issued by the ACC/AHA, which recommended treatment for primary prevention among adults 
with 10-year ASCVD risk ≥ 7.5%. The USPSTF concluded with moderate certainty that the net benefit is 
small when initiating statins among populations with 10-year risk of ASCVD 7.5% to 10%. Because the 
underlying 10-year ASCVD risk is low, a smaller proportion of this population will benefit from 
treatment because a majority of the population would not develop incident ASCVD.  
The proposed recommendations by the USPSTF, although similar to NCEP-ATP III 
recommendations, still result in substantial proportions of the U.S. population who are newly eligible for 
statin treatment. If all adults were treated according to USPSTF recommendations, statin therapy 
initiation would be recommended for an additional 15.8% of adults compared with an additional 24.3% of 
adults who would be recommended for statin therapy by ACC/AHA recommendations. The result is an 
excess of 8.9% of adults who would no longer be recommended for statins according to the latest 
ACC/AHA recommendations compared to the USPSTF recommendations.21 Projecting estimates to the 
US population, there could be an estimated 17.1 million versus 26.4 million adults with a new 
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recommendation for statin initiation, a difference of 9.3 million people. Recent projections have also been 
estimated comparing the ATP III to ACC/AHA recommendations, which found the change in treatment 
recommendations would impact 14.4 million adults who would be newly eligible for statins as a result of 
the ACC/AHA recommendations, with 8.2 million newly eligible for primary prevention.5 
F.2. Future Cholesterol Treatment Recommendations 
 Following publication of the ACC/AHA recommendations and despite USPSTF 
recommendations, researchers have suggested initiating statins at even younger ages.20, 260, 261 Age is a 
dominant factor in the pooled cohorts risk calculator, leading to recommended initiation of treatment for 
the majority of adults in older age. For example, nearly all men exceed the 7.5% risk threshold in their 
mid to late 60s and nearly all women in their 70s, despite an otherwise optimal risk factor profile.20 The 
emphasis of chronological age when calculating ASCVD favors treatment later in life, but treatment may 
not reverse damage from the accumulation of atherosclerosis throughout life and some RCT evidence has 
suggested modest to no effect of statin benefits in older populations.260, 262 Thus, recommended updates to 
cholesterol recommendations were prompted by the benefits associated with achieving low levels of 
LDL-C early in life. For example, a series of Mendelian randomization studies estimated the effect of 
long-term exposure to lower LDL-C levels on the risk of MI/CHD mediated by SNPs.261 The studies were 
combined in a meta-analysis and compared to LDL-C level reductions found from statins among adults. 
Long-term exposure to lower LDL-C was associated with a 55% (95% CI:48.8%-59.5%) reduction in the 
risk of MI/CHD for each 38.7 mg/dl lower LDL-C compared to LDL-C reductions from statins started 
later in life, highlighting the potential benefits of maintaining low levels of LDL-C early in life compared 
to reducing LDL-C levels later in life. 261 
 In addition to proponents of initiating statins at younger ages, researchers have argued for statins 
among populations at low-ASCVD risk. As described above, RCTs have shown that statin therapy 
reduces ASCVD events in healthy participants at lower risk than recommended by ACC/AHA treatment 
recommendations.4, 14 For instance, Boekholdt et al. conducted a meta-analysis among eight RCTs with a 
mean follow-up of approximately six years and mean LDL-C levels of 132 mg/dl to examine the 
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association between very low levels of LDL-C (<50 mg/dl) and incident ASCVD. Among 38,153 
participants, the risk of incident ASCVD decreased as the level of LDL-C level attained decreased.263 For 
example, compared to participants that attained LDL-C levels between 50-75 mg/dl (N =10,395), the risk 
of incident ASCVD was lower among participants that attained LDL-C levels <50 mg/dl (N =4,375) (RD 
=0.07 [95% CI: 0.06-0.07]) with the number of participants who would need to be treated to prevent one 
additional ASCVD event 14.3. Along with the motivation to recommend statins to larger proportions of 
the population, some researchers have suggested using statins for primary prevention of diseases beyond 
ASCVD, such as breast cancer, potentially increasing the statin-eligible segment of the population even 
further.264 
F.3. Gaps in Statin Associated Outcome Evidence 
 Our understanding of the relationship between statins and treatment-associated outcome remains 
incomplete. This section describes gaps in our understanding of these relationships.  
F.3.1. Statin-associated Benefits and Harms 
 Statin-associated benefits and harms remain inadequately quantified. For example, Robinson et 
al. contrasted statin benefits versus harms by summarizing results from recent RCT meta-analyses and 
estimated the number needed to treat (NNT) with statins to cause one excess case of T2D. The authors 
reported that the number needed to harm (NNH) over five-years ranged from 66 to 200 depending on the 
strength of statin, while the NNT to prevent one ASCVD event over five-years ranged from 40 to 60.4, 12, 
23 However, relying on past meta-analyses to calculate benefits and harms has several limitations. First, 
the definition of T2D varied by study, potentially underestimating T2D incidence, particularly when 
studies relied solely on physician self-report.265 Secondly, non-adherence and withdrawal from RCTs 
ranged from 11%155 to 29%125 among participants randomized to statins, again potentially 
underestimating T2D incidence. Thirdly, among the primary prevention trials included in the meta-
analyses, few were conducted among the elderly and the trials that did include elderly populations 
selected participants enriched for ASCVD risk factors.150, 153, 154, 163 These distinctions are important, as 
according to recent projections, of the 10.4 million adults projected to be eligible for statins for primary 
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prevention based on the ACC/AHA recommendations compared to the ATP III, 80% are between the 
ages of 60-75.5 Past studies of the benefits of statins among older adults with ASCVD risk factors have 
shown mixed findings, suggesting that there may be insufficient evidence to determine if statin use is 
beneficial among otherwise healthy older adults.20 For example, the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) was a trial conducted among people with 
hypertension and at least one ASCVD risk factor.156 Han et al. conducted a post hoc analysis of a 
subgroup of participants (n =2,867) free of clinically diagnosed ASCVD at baseline and found there was 
no benefit for ASCVD events among participants aged 65-75 years (HR =0.85 [95% CI:0.62-1.15]) or 
among participants ≥75 years of age (HR =1.34 [95% CI: 0.98-1.84]) when randomized to statins 
compared to placebo.262 Thus, when attempting to quantify the relationship between statins, T2D and 
ASCVD, it is important to ensure the benefits of statins outweigh potential risks, especially among 
populations potentially at low risk of ASCVD who are most affected by current recommendations. 
 Further, to assess adverse outcomes associated with long-term statin use based on 10-year 
ASCVD risk thresholds, Robinson et al. included 10-year extrapolations conducted by the ACC/AHA 
cholesterol recommendations. Using meta-analyses results that were used to calculate the five-year NNT 
and NNH estimates above, 10-year projections of incident T2D and ASCVD were calculated from annual 
relative risk reductions (NNH =100 [did not specify ASCVD risk threshold] and NNT =67, 44, and 33 for 
10-year ASCVD risks of 5%, 7.5%, and 10%).23 Because of concerns of safety, the ACC/AHA 
cholesterol recommendations recommended use of statins in participants with characteristics similar to 
those participating in RCTs; however, few RCTs have conducted follow-up beyond six years or assessed 
outcomes after the studies have ended to evaluate the long-term efficacy of statins. Ford et al. evaluated 
the long-term impact of statin therapy on MI/CHD mortality using electronic health records of former 
participants of the WOSCOPS study and after 20-years of follow-up, MI/CHD mortality was reduced 
among the participants randomized to statins compared to those randomized to placebo ([HR = 0.79 [95% 
CI: 0.69-0.90]).266 Similar results were found among 11.3 years of follow-up (8.6 years of follow-up post-
trial) in the PROSPER primary prevention trial (HR =0.81 [95% CI: 0.69-0.95]).267 In contrast, the 
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ASCOT-LLA trial found a significant reduction in MI/CHD mortality associated with statins 
approximately two years post follow-up (HR =0.64 [95% CI: 0.53-0.78]), but not 11 years post follow up 
(HR =0.89 [95% CI: 0.72-1.11]).268, 269 The benefits of statins observed in long-term follow up may 
suggest a legacy benefit of LDL-C lowering by statin use. However, treatment information post-trial was 
not always known (last 10-years of WOSCOPS and last 8.6 years of PROSPER). These results suggest 
that three to 10-year treatment periods may be sufficient to produce a benefit while limiting lifetime 
exposure to statins. However, the association between long-term, persistent use of statins and adverse 
events such as T2D remains poorly quantified. 
F.3.2. Critical Research Barriers to Effective Cholesterol Treatment Recommendations 
 Despite the vast resources dedicated to developing cholesterol recommendations and criteria, 
there still remain evidence gaps in the literature informing policymakers’ ability to select ASCVD risk 
reduction thresholds that deliver the most benefit and least harm.270, 271 Although RCTs have examined the 
association between statin therapy and T2D12, these studies were limited by highly selective inclusion 
criteria that limited generalizability and short duration, which constrained the examination of long-term 
adverse events. These limitations have left several questions unanswered, including the long-term effects 
of statin use on T2D incidence among populations with contemporary ASCVD risk factor distributions. 
Thus, studies to address these gaps are needed. Yet, such studies must (1) be contemporary, (2) span ages 
specified by current recommendations, (3) include high quality statin measures, and (4) precisely and 
validly measure ASCVD and T2D incidence (5) within generalizable male and female (6) multi-ethnic 
populations (7) with adequate follow-up time. Very few individual studies can meet all of these criteria.  
F.3.3. The Research-practice Gap: an Opportunity for Simulation Tools 
 As an alternative, simulation tools can help extend the reach of epidemiological studies and RCTs 
by synthesizing high quality observational and experimental findings. Pencina et al. used data from the 
National Health and Nutrition Examination Surveys (NHANES) to estimate the number of people in the 
U.S. who would become eligible for statins under the ACC/AHA recommendations compared with the 
ATP III recommendations5; however, no study to the best of our knowledge has extended these efforts to 
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look at intended benefits and side effects of statins. Such a simulation that examines both the intended 
benefits and adverse effects of statins (1) requires primary data inputs from RCTs and population-based 
studies, (2) includes adverse event data, and (3) includes health-related outcomes, which as we describe 
below are available. Therefore the objective of this proposal is to synthesize data from RCT and 
observational studies using meta-analytic methods and simulation tools to examine the consequences of 
pre-specified ASCVD risk thresholds on the incidence and prevalence of T2D and ASCVD. Findings 
from this work can inform how new statin treatment ASCVD risk thresholds may contribute to ASCVD 
benefits and T2D burdens. 
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CHAPTER 4. RESEARCH PLAN 
A. Overview 
 This work will be conducted in two parts. In Aim 1, a meta-analysis will be conducted to 
determine the effects of statins on T2D incidence among populations free of clinically diagnosed 
ASCVD. We propose conducting this meta-analyses using all available published data from large primary 
prevention statin RCTs and observational studies. Results from Aim 1 will then be used to inform 
projections estimated in Aim 2, which will use a Markov model to project changes in T2D and ASCVD 
incidence and prevalence from changes in ASCVD risk thresholds recommended from various cholesterol 
treatment recommendations.6, 21 Aim 2 will be conducted by assembling and integrating contemporary 
and validated data from NHANES, REGARDS, RCT meta-analyses, and results from Aim 1 into a 
Markov model using decision analyses software TreeAge Pro. 
B. Specific Aim 1 
 In Aim 1, a meta-analysis will be conducted using both RCT and observational studies. Upon 
completion, Aim 1 will yield statin-T2D RRs to be used for Aim 2. As described above, previous 
published work has suggested that combining observational studies and RCTs may increase precision and 
produce equally or more relevant and valid results compared to results based solely on RCTs.17, 18, 181 
While the importance of using both study designs have been proposed, statistical methods combining 
RCT and observational studies in a meta-analysis setting are still being developed. In the end, the 
literature may in fact not be comparable, but obtaining estimates from both study designs would still 
provide valuable information to inform the sensitivity analyses for Aim 2. 
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B.1 Data Sources and Search Strategies 
B.1.1. Literature Search 
 Studies will be identified by searching electronic databases and scanning reference lists of 
articles, particularly published RCT and observational study meta-analyses. This search will be applied to 
Pubmed (1994-Present) and Embase (1994-Present). We will use the following free text and MeSH terms 
to search all databases with the following terms consistent with previous systematic reviews and meta-
analyses of RCT and observational studies: (Statin OR Statins OR Anticholesteremic Agents OR 
Anticholesteremic OR Hydroxymethylglutaryl-CoA Reductase Inhibitors) AND (Diabetes OR Diabetes 
Mellitus II OR Diabetes Mellitus Type II OR Diabetes Mellitus Type 2) AND adverse effects OR adverse 
events AND cohort study OR case-control study OR trial.  
B.1.2. Eligibility Criteria 
 From the articles resulting from the search terms above, we will examine abstracts (if available) 
to identify articles that meet all of the following criteria: 1) the study has follow-up >one year; 2) majority 
of participants are asymptomatic adults without prior ASCVD events (i.e. MI/CHD, stroke) at baseline; 3) 
the risk estimate is reported as an OR, HR, or RR; and 4) the 95% CI for the risk estimate or information 
to enable its estimation is included. 
B.2. Data Items 
B.2.1. Data Extraction  
 For each study population in each article, we will extract incident T2D estimates and study 
factors of interest, which include methodological factors and study population characteristics (Table 8). If 
information on study factors of interest are not available from the articles, we will contact corresponding 
authors via email with follow-up emails sent two weeks after the initial inquiry as needed.   
 
58 
Table 8. Study factors of interest 
Methodological factors 
Study design (RCT, Observational study) 
Mean length of follow-up time 
Study sample size 
Year of publication data 
Year of study baseline 
Method to control confounding (propensity score, adjusted in the model, randomization, did not adjust) 
Types of confounders included 
Methods to measure and define T2D status (physician diagnosis, medication data, laboratory data) 
Type of effect estimate metric (OR, RR, HR) 




% prescribed statins 
Type of statins included  
Mean BMI 
Mean LDL-C levels 
Mean fasting plasma glucose levels 
Mean systolic blood pressure levels 
% hypertensive 
% current smokers 




B.2.2. Validation of Data Abstraction and Data Entry 
 Two reviewers will independently scan all potential titles and abstracts. The reviewers will assess 
full-text versions of potentially relevant articles and abstract all relevant data into tables. The tables will 
be compared and disagreements will be resolved by consulting with the initial articles.  
B.3. Planned Methods of Analysis 
B.3.1. Assessment of Risk of Bias 
 PRISMA criteria will be used to describe the quality of RCTs272 and assess potential for bias. 
Specifically, the following dimensions (agree or disagree) will be evaluated: 1) adequate use of measures 
to conceal allocation (adequate through the use of randomization); 2) application of blinding (whether to 
the participant, care provider or outcome assessors); 3) proportion of participants lost to follow-up 
reported; and 4) whether the analysis followed the intention-to-treat principle.273 
 To assess quality of OBSs, articles will be assigned scores using criteria consistent with past 
meta-analysis of cohort studies274 (agree or disagree): 1) Was a well-defined sample of participants 
identified?; 2) Were there clear definitions of statin use and 3) T2D?; 4) Was there information on 
baseline LDL-C levels and 5) fasting plasma glucose levels by treatment status?; and 6) Were differences 
in baseline factors accounted for?275 
B.3.2. Assessment of Publication Bias 
 Publication bias can result when studies with statistically significant, clinically favorable, or 
novel results or are more likely to be published than studies with non-significant, unfavorable, or 
“uninteresting” results.276 We will assess the possibility of publication bias using both qualitative and 
quantitative methods overall and by study type (RCT vs observational study). First, we will evaluate a 
funnel plot displaying each study’s effect estimates against each study’s precision (i.e. standard error).277 
In the absence of bias, the effect estimates from smaller studies should scatter more widely at the bottom, 
with the spread narrowing among larger studies.278 Second, we will calculate a p-value for Begg and 
Mazumdar’s log rank test and Egger’s regression test to provide quantitative assessments of the symmetry 
of the funnel plot.279, 280 It is important to note that both Begg’s and Egger’s tests have low statistical 
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power to detect evidence of asymmetry of funnel plots in the literature; as a result, we will use a high 
alpha-value, such as 0.1. Third, we will use Duval and Tweedie’s trim and fill imputation procedure as an 
additional analysis to evaluate bias in funnel plots.281 The trim and fill method imputes effect estimates in 
three steps: 1) removes estimates that make the funnel asymmetric, forming a trimmed dataset and leaving 
a symmetric remainder from which the true center of the funnel can be estimated; 2) uses the trimmed 
dataset to compute a presumptively less biased summary effect and standard error; and 3) the trimmed 
trials are then replaced and their missing counterparts imputed or filled around the adjusted summary 
estimate.  
B.3.3. Pooled Estimates 
 Incident T2D RRs and 95% CIs from the available studies will be obtained. Study-specific RRs 
will be pooled using a random-effects model meta-analysis rather than a fixed-effects model because of 
the model assumption that the true effect estimate is normally distributed with a different mean and 
variance in each given study. The random-effects model will account for between-study and between-
study type heterogeneity that may have been introduced by the various methods for diagnosing T2D and 
different study populations included in each study.282  
B.3.4. Assessment of Overall Heterogeneity and By Study Type 
 We will assess heterogeneity of effect estimates among published studies to assure observed 
study-specific estimates are not too inconsistent or heterogeneous to be over-simplified as one summary 
estimate. Heterogeneity assessment will be implemented by computing a p-value of Cochran’s Q statistic 
in a homogeneity test283 (alpha value of 0.1 will be applied to assess homogeneity) and using the 𝐼𝐼2 
statistic, which is derived from Cochran’s Q statistic (𝐼𝐼2 = 100𝑥𝑥(𝑄𝑄 − 𝑑𝑑𝑑𝑑)/𝑄𝑄) and provides a measure of 
the proportion of the overall variation attributable to between-study heterogeneity.284 Negative values of 
𝐼𝐼2 are set to zero so that 𝐼𝐼2 lies between 0% and 100%. A value of 0% indicates no observed 




 Meta-regression analyses will be performed in order to explore potential sources of 
heterogeneous estimates between studies and by study type (RCT vs observational). Meta-regression 
analyses examines the associations between study-level characteristics and treatment effects, with the 
outcome as the magnitude of the effect estimate in each study and the independent variables as the study 
factors of interest (continuous or categorical), providing information regarding the strength of each study 
factor for explaining potential sources of heterogeneity among studies.285 A random-effects model will be 
used to take into account the variability in between-study differences with study weights incorporating 
both between and within study variance. Meta-regressions will be performed on all methodological 
factors and baseline study population characteristics (Table 8).  
Conclusions 
 Completion of Aim 1 will yield statin-T2D associated RRs to be used in Markov models for Aim 
2. 
C. Specific Aim 2 
 We will leverage multi-ethnic 
(African American and Caucasian) and 
sex-specific data from NHANES and 
REGARDS studies as well as meta-
analyses of RCT reported statin associated 
RRs and results from Aim 1 to assess 
changes in the number of ASCVD events 
prevented and cases of T2D incurred 
associated with changes in cholesterol 
treatment recommendations (Figure 9).  
Figure 9. Conceptual diagram of association of statins and 
ASCVD and DM 
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C.1.Data Sources and Inputs 
 Specific aim 2 will be conducted by assembling and integrating contemporary and validated data 
from NHANES, REGARDS, past meta-analyses, and results from Aim 1 into a Markov model (Table 9).  
REGARDS is the only data source that requires a manuscript proposal to obtain data and our REGARDS 
manuscript proposal (2017-P409) was recently approved (Appendix Figure 1). 




 Data from NHANES will be used to construct the initial statin-eligible population (population 
size and baseline characteristics) and to estimate the prevalence of current statin users required for the 
statin parameters. NHANES is a series of cross-sectional surveys and physical examinations conducted 
biennially to assess the health and nutritional status of the U.S. population.286 NHANES collects 
demographic, nutritional, and health status information on a nationally representative probability sample 
of the U.S. civilian population (aged 0-80+ years) instituted by the National Center for Health Statistics 
(NCHS). Participants are randomly selected through a complex, multistage cluster sampling probability 
design. Young children, older adults, African Americans, and Mexican Americans are oversampled at 
each survey to provide sufficient numbers to support analysis in these underrepresented populations. All 
analyses will use sample weights to produce estimates generalizable to the original sampling frame288 For 
this study, we will use data from the three most-recent NHANES population cross-sections, conducted in 
2011-2016.   
Study ~N† Design Scope Race/ethnicity‡  Age  Time 





National AA, EA, MA 0-80+ 2005-16‡ 
Reasons for Geographic and 






AA, EA 45+* 2003-date 





 NHANES participants self-reporting congestive heart failure, MI/CHD, angina, stroke (all types), 
participants classified as having T2D, participants with triglyceride levels >400 mg/dl, participants with 
LDL-C levels ≥190 mg/dl, and participants with ASCVD risk scores unable to be calculated (i.e. missing 
data) will be excluded from the study. Additionally, only African American and Caucasian populations 
between the ages of 40-75 years will be considered in the analysis to overlap with ages eligible for statin 
treatment under the ACC/AHA treatment recommendations.  
C.1.2. REGARDS 
 Data from REGARDS will be used to estimate ASCVD and T2D incidence and statin 
discontinuation. REGARDS is a national, population-based, longitudinal study designed to evaluate 
factors underlying the excess stroke burden in the southeastern US and among African Americans.218 
Potentially eligible REGARDS participants were identified from commercially available nationwide lists 
of U.S. residents with a recruitment goal of including 30% of participants from the “Stroke Belt” (North 
Carolina, South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas). Eligible 
participants were sent an initial mailing, followed by a telephone call and a subsequent in-home visit.  
Between January 2003 and October 2007, REGARDS enrolled 30,239 non-institutionalized African-
American and Caucasian adults aged ≥45 years. The second in-home visit took place from May 2013 to 
Dec 2016. 
Exclusion criteria 
 REGARDS participants self-reporting congestive heart failure, MI/CHD, angina, or stroke (all 
types), participants classified as having T2D, participants with triglycerides >400 mg/dl, or participants 
with LDL-C ≥190 mg/dl will be excluded from the analyses. Only participants between the ages 45-75 
years will be considered in the analysis to overlap with ages eligible for statin treatment under the 
ACC/AHA treatment recommendations (minimum age for REGARDS is 45 years). Since ASCVD 
incidence is low in populations <45 years of age, we will assign the ASCVD incidence from the 45-50 
year old age-group and assess different specifications via meta-analyses. 
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C.1.3. Data inputs 
C.1.3.1. Data from NHANES 
 Data from NHANES were used to obtain baseline characteristics of the study population, 
prevalence and 10-year risk of ASCVD, prevalence of T2D, and prevalence of current use of statins. 
Questionnaires were used to assess prevalence of ASCVD, demographic information, smoking status, and 
blood pressure treatment; mean of final two of three blood pressure measurements from the medical 
examination were used to assess systolic blood pressure; fasting blood samples were used for lipid 
analyses to measure total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and 
triglycerides; and low-density lipoprotein cholesterol (LDL-C) levels were calculated using the 
Friedewald equation.289 The prevalence of T2D was assessed by participant-report of a doctor or health 
professional diagnosis of T2D (yes/no) or report of T2D medication use. The prevalence of current use of 
statins was defined by self-report of ever taking cholesterol medications.  
C.1.3.2. Data from REGARDS 
 Incident and prevalent ASCVD and T2D will be estimated to inform ASCVD and T2D 
parameters and will be ascertained from the REGARDS study by participant report and adjudicated by 
physicians.  
MI/CHD 
 Self-reported MI/CHD prevalence will be ascertained using the following questions: (1) “Has a 
doctor or any other health professional ever told you that you had a myocardial infarction or heart 
attack?” (2) “Have you ever had a coronary artery bypass surgery, such as a graft, CABG, or a bypass 
procedure on the arteries of your heart?” and (3) “Have you ever had an angioplasty or stenting of a 
coronary artery with or without placing a coil in the artery to keep it open?” All questions were scored 
“yes”, “no”, “don’t know”, and “refused”.218 MI/CHD was defined as a yes response to any one of those 
three questions. 
 Incident MI/CHD events will be ascertained during follow-up. Participants were contacted by 
telephone every six months to assess hospitalizations, emergency department visits, overnight stays in 
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nursing homes or rehabilitation centers, or death. If suspected heart event was reported, medical records 
were pursued. MI/CHD were adjudicated based on the presence of signs or symptoms suggestive of 
ischemic; diagnostic cardiac enzymes (rising or falling pattern in cardiac troponin or creatinine 
phosphokinase-MB isoenzyme concentrations over ≥ six hours with a peak concentration greater than 
twice the upper limit of normal); and ECG changes consistent with ischemia or MI/CHD (see section D.1. 
Myocardial Infarction/Coronary Heart Disease).287 In the case where a participant died outside the 
hospital, interviews with family members or other proxies, proximal hospitalizations, baseline medical 
history, death certificates, and the National Death Index were used to identify MI/CHD as the underlying 
cause of death. 
Stroke 
 Prevalent stroke will be defined as a positive response to either “Were you ever told by a 
physician that you had a stroke?” or “Were you ever told by a physician you had a mini-stroke or TIA, 
also known as a transient ischemic attack?”.218  
 Similar to the ascertainment of incident MI/CHD, incident stroke will be determined during 
follow-up. Participants were contacted by telephone every six months to assess vital status, identify 
hospitalizations, emergency department visits, overnight stays in nursing homes or rehabilitation centers, 
or death during the previous six months. Reasons for medical encounters were asked and medical records 
were sought for stroke, TIA, death, unknown reason for hospitalization, or if reason was brain aneurysm, 
brain hemorrhage, sudden weakness, numbness, trouble speaking, sudden loss of vision, headache, other 
stroke symptoms.218 Reports of possible incident stroke events were reviewed by a stroke nurse and then 
reviewed by at least two physician members of a panel of stroke experts in accordance with the World 
Health Organization definition (see section D.2. Stroke).226 For proxy reported deaths, interview was 





 T2D will be ascertained during the first in-home visit (to ascertain prevalent T2D) and second in-
home visit (to ascertain incident T2D) using REGARDS investigator defined outcomes (T2D if fasting 
glucose ≥126 mg/dl, non-fasting glucose >200 mg/dl or taking T2D medication).218 
Statin discontinuation 
 Statin discontinuation will be defined using statin discontinuation estimates obtained from 
preliminary data provided by an ongoing study conducted in REGARDS and past studies.132 
C.1.3.3. Additional Data Inputs 
Statin associated RRs 
 Statin-associated RRs will be estimated to inform ASCVD, T2D, and mortality parameters. The 
statin-T2D RRs will be obtained from our meta analysis from Aim 1. The statin-ASCVD and statin-
mortality RRs will be obtained from the Cholesterol Treatment Trialists’ meta-analysis comparing the 
effectiveness of statin therapy for the primary prevention of ASCVD events from 22 trials (statin therapy 
versus control).3  
Non-ASCVD Mortality 
 Non-ASCVD mortality rates were obtained from the National Center for Health Statistics 
(NCHS) and were calculated based on population estimates for July 1, 2014.290 Available data 
were collected by the NCHS from death certificates filed in all 50 states and the District of 
Columbia and were compiled into a national database. Non-ASCVD deaths/year were defined 
excluding cardiovascular and cerebrovascular deaths. 
C.2. Markov Models 
 The simulation tool is constructed as a series of Markov models. Markov models are frequently 
used to simulate the progression of populations through mutually exclusive health states. Instead of 
possible outcomes over time being modelled as a large number of possible pathways, Markov models 
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provide a more complex framework that is reflected as a set of possible transitions (operationalized as 
user-defined probabilities) between health states over a series of discrete time periods.291  
 The Markov model assumes that a population is always in one of a finite number of states of 
health (“Markov states”) and the population 
may transition from one state to another. The 
time horizon of the analysis is divided into 
equal increments of time, referred to as 
Markov cycles and can represent any user-
defined increment, e.g. days, weeks, years, 
decades etc. During each cycle, all individuals in the populations can transition from one state to another. 
Figure 10 shows an example of a Markov model modelling populations transitioning from a healthy state 
(well) to a sick state. The initial population is healthy (“well”) and can transition into one of two states 
(“stay well” or “sick”) after one cycle. The proportion of the populations that “stays well” after a cycle is 
determined by the user-defined transition probability; here 25% of the participants stay well after one 
cycle and 75% of the participants transition into “sick”. The example in Figure 10 only describes one 
cycle, however subsequent cycles can be performed. Further, for studies of incidence, the “sick” state can 
be defined as an “absorbing state”, i.e. once populations enter the “sick” state they cannot be reclassified 
as “well”. Therefore, in the above example, defining an “absorbing state” will result in observing the 
healthy populations after each cycle transitioning to either “sick” or remaining “well” (with transition 
probabilities remaining constant [i.e. 0.25 and 0.75]); the Markov model could then be repeated until all 
populations are classified as “sick”.  
 Similar to the example in Figure 10, in Aim 2 we will use a Markov model to simulate the 
progression of statin-eligible populations to downstream consequences (ASCVD, T2D, mortality) through 
the use of transition probabilities (Figure 9).   
Figure 10. Markov model example 
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Statin eligibility using ACC/AHA recommendations 
 To identify statin-eligible populations from NHANES, 10-year ASCVD risk scores will be 
estimated among a primary prevention population with triglycerides levels ≤400 mg/dl and LDL-C levels 
<190 mg/dl to focus on participants that will only become statin-eligible through their ASCVD risk 
scores. The ASCVD risk scores will determine which participants will become statin-eligible based on 
ASCVD risk thresholds (i.e. 10-year ASCVD risk of 10% vs. 10-year ASCVD risk of 7.5%). 
 Using NHANES data, the predicted 10-year risk for ASCVD will be calculated using the Pooled 
Cohort risk equations, developed by the ACC/AHA Task Force on Practice Recommendations.292 
Separate equations were developed for African American and Caucasian men and women, which included 
the following variables in the equations: age (years), concentration of TC (mg/dl) and HDL-C (mg/dl), 
treated or untreated systolic blood pressure (mmHg), T2D status (yes/no), and self-reported current 
smoking status (yes/no).  
 Calculation of the 10-year ASCVD risk will be done in a series of steps (Appendix 1). First, the 
natural log of age, TC, HDL-C, and systolic blood pressure will be calculated with systolic blood pressure 
being either a treated or untreated value. Next, we will multiply these values by the coefficients from the 
estimated equation parameters of the Pooled Cohort Equations for the specific race-sex group of the 
population. The sum of the products of the previous calculations are then calculated for the population. 
Finally, we estimate the 10-year risk of ASCVD event as 
𝑃𝑃𝑃𝑃𝑃𝑃𝑑𝑑𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑑𝑑 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑅𝑅𝑃𝑃𝑅𝑅𝑅𝑅 =  1 − 𝐴𝐴0(𝑃𝑃)𝑒𝑒
𝐼𝐼𝐼𝐼𝐼𝐼 𝑋𝑋′𝐵𝐵−𝑀𝑀𝑀𝑀𝑀𝑀𝐼𝐼 𝑋𝑋′𝐵𝐵  
 The ASCVD risk will be calculated as 1 minus the survival rate at 10 years (Appendix 1), raised 
to the power of the exponent of the coefficient*value sum minus the race and sex specific overall mean 
coefficient*value sum.293 Each participant is assigned a probability of statin treatment, which is used to 
determine which participant is statin-eligible according to one of the three 10-year ASCVD risk 
thresholds we will be testing (10%, 7.5%, and 5%). 
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 Once the statin-eligible population is determined, the Markov model will project the initial 
population (“healthy”) transitioning to one of three states (ASCVD, T2D, or mortality) or remaining in 
the “healthy” state after one cycle (one cycle = 1 years). The proportion of the population that transitions 
into one of the three states will be determined by transition probabilities estimated from parameters 
estimated using data from REGARDS, published statin-ASCVD meta-analyses, and results from Aim 1 
(Table 10). For example, to calculate transition probability or ASCVD, we will first estimate the 
probability of ASCVD for non-statin users, stratifying by age, sex, race/ethnicity, and five-year age 
groups, according to the formula: 
 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝑛𝑛𝑛𝑛−𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑠𝑠𝑛𝑛𝑖𝑖𝑠𝑠𝑖𝑖𝑒𝑒𝑛𝑛𝑖𝑖𝑒𝑒 𝑛𝑛𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑜𝑜𝑜𝑜/((1−
𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠) + 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 ∗ 𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠) 
Where 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑠𝑠𝑛𝑛𝑖𝑖𝑠𝑠𝑖𝑖𝑒𝑒𝑛𝑛𝑖𝑖𝑒𝑒 𝑛𝑛𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑜𝑜𝑜𝑜 is ASCVD incidence, 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 is the prevalence of current statin users, 
and 𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 is the RR of ASCVD among statin users compared to non-statin users. Combining 
estimates of the probability of ASCVD among non-statin users with the previously estimated 
𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 allows estimation of the probability to calculate the proportion of the initial population that 
will transition into the ASCVD state (i.e. transition probability): 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝑛𝑛𝑛𝑛−𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 ∗ 𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 
Transition probabilities will be similarly calculated for the proportion of the initial population to 
transition into the T2D and mortality states.  
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Table 10. Markov model parameters 
Age (5-year) sex-specific 
parameters 
Sources of data Metric estimated 
ASCVD parameters   
ASCVD incidence 
overall 
REGARDS Annual incidence 
rate 
Statin-ASCVD RR Cholesterol Treatment Trialists’ Collaboration4 RR 
T2D parameters   
T2D incidence 
overall 
REGARDS Annual incidence 
rate 
















**Will vary in sensitivity analyses 
 
C.3. TreeAge Pro Software 
 The series of Markov models used in these analyses will be implemented through the TreeAge 
Pro software. TreeAge Pro executes the techniques of decision analysis by organizing and analyzing the 
decision making process in a use-friendly integrated graphical user interface.294 Users can create model 
structures to represent problems being studied, including decision points and all of the events that can 
occur. Once models are created, TreeAge Pro can automatically generate the algorithms required to 
evaluate the model and help choose the optimal strategy. One type of model supported by TreeAge Pro, is 
the healthcare model, which allows users to create decision trees that are evaluated on the basis of cost or 
effectiveness. Healthcare models generally begin with a decision node including a branch for each 
treatment option for a specific health condition, with each treatment option branch including any number 
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of possible outcomes including incidence, prevalence, quality adjusted life years, and cost. If healthcare 
models need to follow a disease process into the future, a Markov model can be implemented through the 
decision tree structure supported by TreeAge Pro.294  
 The design of a basic Markov model in TreeAge requires consideration of a number of 
components (Table 11). Once the Markov model is built, a cohort analysis can be conducted to generate 
output by cycle and cumulative cycles to identify incident cases (i.e. T2D and ASCVD).  
Table 11. Components of Markov models in TreeAge 
Component Definition Proposal definition/operationalized 
States The set of distinct health states 
under consideration in the model 




The length of time represented by 







Set of probabilities used only at 
the outset of the process, 
describing the initial distribution 
of the cohort among the states 
 





Probabilities of moving between 
health states from one cycle to the 
next 
 










A logical test evaluated at the 
beginning of each new cycle  to 
determine if the process should 
continue or stop 
 




 TreeAge Pro provides users with tools to validate models by checking the most common flaws 
identified in models. The specific validation checks include missing probabilities, missing states, and 
unused variables.  
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C.4. Overview of Interventions 
 Each scenario will be operationalized by a Markov model stratified by 5-year age groups, sex, 
and race/ethnicity (African American and Caucasian).  
Base-case scenario  
 ACC/AHA recommendations with the ASCVD risk threshold set to 10% as recommended by the 
USPSTF. Using the Pooled Cohort risk equations, we will classify populations with 10-year ASCVD risk 
scores ≥10% as predicted statin users.  
Intervention scenarios 
 We will compare our base case scenario to three different intervention scenarios: 
• ACC/AHA recommendations with the ASCVD risk threshold set to 7.5%. Using the Pooled Cohort 
risk equations, we will classify populations with 10-year ASCVD risk scores ≥7.5% as predicted 
statin users. 
• ACC/AHA recommendations with the ASCVD risk threshold set to 5%. Using the Pooled Cohort 
risk equations, we will classify populations with ASCVD risk scores ≥5% as predicted statin 
users.  
• ACC/AHA recommendations with the ASCVD risk threshold set to 7.5%, but also including all 
populations ≥55 years of age. Using the Pooled Cohort risk equations, we will classify 
populations with ASCVD risk scores ≥7.5% as well as populations ≥55 years of age as predicted 
statin users. 
C.5. Sensitivity Analyses 
 To evaluate heterogeneity in statin-associated ASCVD and T2D risk20, 240, we assessed 
the number of ASCVD events prevented and number of excess T2D events incurred by sex and 
age. In addition, to examine the influences of our assumptions of statin discontinuation, we   
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projected the number of ASCVD events prevented and number of excess T2D events incurred 
under three different statin discontinuation scenarios and assumed annual relative decrease in 
statin use of 25% and 50%, as well as full adherence across 10 years.132 
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CHAPTER 5. EVIDENCE OF HETEROGENEITY IN STATIN-ASSOCIATED TYPE 2 
DIABETES MELLITUS RISK: A META-ANALYSIS OF RANDOMIZED 
CONTROLLED TRIALS AND OBSERVATIONAL STUDIES 
A. Introduction 
 Hmg CoA reductase inhibitors, commonly known as statins, are the most widely prescribed class 
of medication used to reduce cardiovascular disease CVD risk and to treat elevated low density 
lipoprotein cholesterol (LDL-C).2, 295, 296 Changes in cholesterol treatment recommendations from the 
Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program recommendations 
to the American College of Cardiology/American Heart Association (ACC/AHA) 2013 recommendations 
increased the number of adults newly eligible for statin therapy for primary prevention by an estimated 
10.4 million, with 80% of the increase attributable to individuals between the ages of 60-75.22  
While the cardioprotective effect of statins are undeniable3, 4, experimental and observational 
research has also suggested that statins may lead to harm in lower risk individuals by increasing the risk 
of type 2 diabetes mellitus (T2D).11-15, 176 Yet, most meta-analyses have combined primary and secondary 
prevention populations to examine statin associated T2D risk. Secondary prevention populations, 
however, include survivors of ASCVD whose mortality risk has been estimated to be five to six times 
higher than that of people of the same age who did not experience an ASCVD.170 Further, the risk of T2D 
may differ when used for primary vs. secondary prevention,19 complicating  efforts to quantify statin-
associated T2D risk in primary prevention populations. As primary prevention populations are most 
impacted by the statin-eligibility recommendations, additional research quantifying statin-associated T2D 
risk is needed.  
In addition to combining primary and secondary populations, published meta-analyses of statin-
associated T2D risk have also been restricted to either randomized controlled trials (RCTs) or 
observational studies (OBSs). Yet, meta-analyses that incorporate summary data from both study designs 
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may take advantage of the internal validity of RCTs and the external validity of OBSs. This approach 
better reflects the existing evidence base, and may increase statistical power to investigate heterogeneity 
and expand upon past meta-analyses’ limited heterogeneity assessments.17, 18 Therefore, to estimate the 
effect of statins on T2D among populations most affected by changes to statin use recommendations and 
examine potential sources of heterogeneity, we performed a systematic review and meta-analysis of 
statin-associated T2D risk by synthesizing published data from RCTs and OBSs, excluding secondary 
prevention populations. 
B. Materials and Methods 
 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) recommendations throughout the design, implementation, analysis, and reporting of this meta-
analysis.272 
B.1. Data Sources 
 In consultations with a reference librarian (MW), studies of statin-associated T2D risk were 
identified by searching PubMed (1994-present) and EMBASE (1994-present) on 25 January 2018. 
Reference lists of articles were scanned, which included published RCT and OBS meta-analyses12-15, 176 
and all document types, languages, and publication dates.  Consistent with previous systematic reviews 
and meta-analyses of RCT and OBSs examining statin-associated T2D risk12-15, 176, the following free text 
and Medical Subject Headings terms were used: (Statin OR Statins OR Anticholesteremic Agents OR 
Anticholesteremic OR Hydroxymethylglutaryl-CoA Reductase Inhibitors) AND (Diabetes OR Diabetes 
Mellitus II OR Diabetes Mellitus Type II OR Diabetes Mellitus Type 2) AND (adverse effects OR 
adverse events) AND (cohort study OR case-control study OR trial).  
B.2. Study Selection 
 Articles selected for the meta-analysis had to meet all of the following criteria: 1) follow-up >one 
year; 2) >50% of participants free of clinically diagnosed ASCVD; 3) adult participants ≥30 years old; 4) 
reported statin-associated T2D effect estimates using the odds ratio (OR), hazard ratio (HR), or risk ratio; 
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and 5) quantified precision using the 95% confidence interval (CI) or included information to enable 
estimation. 
B.3. Data Extraction and Evaluation 
 Citations were downloaded to an electronic reference manager (EndNote X7, Thomson 
Reuters297) and duplicates were removed. Two reviewers (JCE and AS) independently reviewed all titles 
and abstracts and extracted relevant information into tables. The tables were compared and disagreements 
were resolved by consulting the initial articles. For each study population in each article, the reviewers 
extracted statin-associated T2D relative risks (RR; primary endpoint), study design, mean length of 
follow-up time, sample size, year of publication, year of baseline, methods used to address for 
confounders (in OBSs only), type of effect estimate, methods used to measure and define T2D, residence 
of participants, proportion of population that is Caucasian, proportion of population taking statins, mean 
baseline characteristics (age, body mass index [BMI], low-density lipoprotein cholesterol [LDL-C] levels, 
glucose levels, systolic blood pressure [SBP] levels), baseline characteristics proportions (hypertensive, 
current smokers, ASCVD) and methodological qualities of each study (Table 14). If information on study 
and participant characteristics of interest were not available, corresponding authors were contacted via 
email with one follow-up email sent two weeks after the initial inquiry and a final follow-up email sent 
two weeks thereafter. 
B.4. Quality Assessment  
 PRISMA criteria were used to describe the quality of RCTs272 and assess potential for bias. 
Specifically, the following dimensions (agree or disagree) were evaluated: 1) adequate use of measures to 
conceal allocation (adequate through the use of randomization); 2) application of blinding (whether to the 
participant, care provider or outcome assessors); 3) proportion of participants lost to follow-up reported; 
and 4) whether the analysis followed the intention-to-treat principle.273 
 To assess quality of OBSs, articles were assigned scores using criteria consistent with past meta-
analysis of cohort studies274 (agree or disagree): 1) Was a well-defined sample of participants identified?; 
2) Were there clear definitions of statin use and 3) T2D?; 4) Was there information on baseline LDL-C 
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levels and 5) fasting plasma glucose levels by treatment status?; and 6) Were differences in baseline 
factors accounted for?275 
B.5. Data Synthesis 
 Publication bias was assessed using both qualitative and quantitative methods overall and by 
study design (OBS; RCT). First, funnel plot asymmetry was evaluated using a plot of each study-specific 
RR versus its precision.277 Second, p-values (α=0.1) for Begg and Mazumdar’s log rank test and Egger’s 
regression test were calculated to provide quantitative assessments of funnel plot assymetry.279, 280 Third, 
Duval and Tweedie’s non-parametric trim and fill imputation procedure was conducted to impute 
hypothetically missing results due to publication bias.281 
 Inter-study heterogeneity was assessed by Cochran’s Q test283 (α=0.1298) and the 𝐼𝐼2 statistic, 
which is derived from Cochran’s Q test (𝐼𝐼2 = 100𝑥𝑥(𝑄𝑄 − 𝑑𝑑𝑑𝑑)/𝑄𝑄).284 To further assess the extent of 
heterogeneity between studies, Galbraith plots were constructed displaying each study’s effect size 
divided by each study’s standard error (𝑍𝑍 score) versus the inverse of each study’s standard error.299 
 Variation in the strength and precision of estimated RRs by study design (OBS; RCT) and across 
levels of the study and participant characteristics was assessed by estimating a summary random-effects 
RR within each study and participant characteristic using univariable random-effects meta-regression.282 
We considered the following study and participant characteristics for interrogation via meta-regression: 
mean length of follow-up time, sample size, year of publication, year of baseline, methods used to address 
for confounders, type of effect estimate, methods used to measure and define T2D, residence of 
participants, proportion of population that is Caucasian, proportion of population taking statins, mean 
baseline characteristics (age, BMI, LDL-C, glucose levels, SBP levels), and baseline characteristics 
proportions (hypertensive, current smokers, ASCVD). All analyses were performed using STATA 





 The systematic review identified a total of 459 candidate studies for screening (Figure 11). Of 
these studies, 23 (5%; eight RCTs and 15 OBSs) met the eligibility criteria for inclusion in the meta-
analyses (see Supplement for article references). Eligible studies were conducted between 1998 and 2016, 
with OBSs on average being published more recently (mean publication date = 2012 vs 2005) and using 
more recent data (mean baseline study year = 2000 vs 1998) compared to RCTs (Tables 12 and 13). In 
contrast to RCTs, the mean length of follow-up time was longer (6.9 years vs 4.3 years), participants were 
more likely to be women (mean proportion of women = 51.5% vs 36%), more likely to be Caucasian 
(mean proportion Caucasian = 71.2% vs 63.6%), and less likely to be current smokers (mean proportion 
current smoker = 18% vs 24.5%) among OBSs.  
Participant characteristics also differed by study design. Participants in OBSs were on average 
younger (mean age = 57.4 years vs 63.6 years), had lower mean LDL-C levels at study baseline (124.4 
mg/dL vs 145 mg/dL) and mean fasting plasma glucose levels (96.4 mg/dL vs 101.6 mg/dL) compared to 
participants enrolled in the RCTs (Tables 12,13,15, and 16). In addition, 50% of RCTs used a 
combination of physician diagnosis, T2D medication, and lab results to define T2D (compared to 13% of 
OBSs); while 53% of OBSs used physician diagnosis and T2D medication. 
 Quality assessment of RCTs showed >87% (7/8) of RCTs fulfilled the intention-to-treat, loss to 
follow-up, and randomization criteria; while two studies (25%) failed to adequately blind participants 
(Figure 14). The quality evaluation among OBSs found >93% (14/15) of studies accounted for differences 
in baseline factors and clearly defined the sample, T2D, and statins use. However, >66% (10/15) of 
studies lacked information on baseline fasting glucose levels and >46% (7/15) of studies lacked 
information on LDL-C levels at baseline by treatment status (Figure 15). 
 Among RCTs and OBSs, statin users had higher risk of incident T2D compared to non-statin 
users, although the magnitude of effect was larger in OBSs (RR = 1.55 [95% CI: 1.39-1.74]) compared 
with RCTs (RR = 1.11 [95% CI: 1.00-1.22]) (Figure 12). Given the differences in the magnitude of 
effects, a summary effect is not reported. Funnel plots both overall and by study design suggested little 
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evidence of publication bias (Figures 16 and 17). This evidence is consistent with results from Begg’s and 
Egger’s tests ([RCTs: p-values =0.23 and 0.54] and [OBSs: p-values = 0.91 and 0.32]), but the “trim and 
fill” method imputed one hypothetically missing RCT (RR = 1.64) and three hypothetically missing OBSs 
with RRs <1.0. In contrast to RCTs where two studies reported effect estimates below the null (ie. RR < 
1.0), all of the OBSs reported effect estimates above the null. 
Evidence of heterogeneity varied by study design. Galbraith plots for RCTs indicated that one 
(Figures 18 and 19) 𝑍𝑍 score fell outside the 95% confidence bounds, evidence of heterogeneity that was 
consistent with the Cochran’s Q and 𝐼𝐼2 tests (𝐼𝐼2= 27% [p-value = 0.21] and PCochrane = 0.04). Similarly, 
among OBSs, 47% of 𝑍𝑍 scores (7/15) fell outside the 95% confidence bounds, providing strong evidence 
of heterogeneity that was consistent with Cochran’s Q and 𝐼𝐼2 (𝐼𝐼2 = 97.6% [p-value <0.01] and PCochrane 
<0.01).  
 Analyses examining sources of heterogeneity overall and by study design demonstrated variations 
in effect estimates by study and participant characteristics (Figure 13 and Tables 17-19). Overall, the 
association between statin use and T2D risk was stronger in OBSs compared to RCTs (RR = 1.45 [95% 
CI: 1.11-1.88]) and in studies published more recently (RR = 1.03 [1.00-1.06]).  Comparing participant 
characteristics across study design, there was a decreased risk for T2D among, participants who were 
older (RR = 0.79 [95% CI: 0.63-0.98] per 10 year increase); smokers (RR = 0.27 [95% CI: 0.11-0.68] per 
1% increase in the proportion of smokers); and had lower LDL-C levels (RR = 0.92 [95% CI: 0.87-0.97] 
per10mg/dL increase) (Figure 13 and Table 17). Among OBSs, the association between statin use and 
risk of incident T2D was stronger among study populations from non-European countries and study 
populations that were younger, had fewer smokers, and lower LDL-C levels (Table 18). No significant 





 Results of this meta-analysis, which are consistent with earlier studies synthesizing estimates of 
statin-associated T2D risk in primary and secondary prevention populations12, 176, suggest that statins have 
a moderate effect on T2D risk, increasing risk 11-55%. Yet, strong evidence of heterogeneity was 
observed, particularly with regard to participant age and baseline LDL-C level. Potential evidence of 
heterogeneity was not fully examined in earlier meta-analyses and merits further investigation in light of 
statin recommendations that target growing proportions of primary prevention populations, particularly 
populations with lower ASCVD risk profiles (e.g. individuals with ASCVD 10-year risk estimates 
<10%). 
 The current RCT meta-analysis findings are consistent with results from past meta-analyses 
conducted among primary and secondary prevention populations that reported T2D risks that were 9%-
13% higher in participants randomized to statins compared to placebo.11, 12, 14, 15 Interestingly, a prior US 
Preventive Services Task Force (USPSTF) meta-analysis among six primary prevention RCTs suggested 
an attenuated association (RR = 1.05 [95% CI: 0.91-1.20]). The USPSTF estimated effect is slightly 
smaller in size and less precise than our estimate of RR=1.11 (95% CI: 1.00-1.22), which included newly 
available data from the Heart Outcomes Prevention Evaluation (HOPE-3) trial (N= 12,705). Overall, the 
body of literature examining statin-associated T2D risk in RCTs suggests a modest relative effect that was 
consistent across primary and secondary populations.   
 Meta-analyses of OBSs indicated a similarly elevated statin-associated T2D risk, although the 
magnitude of effect was considerably higher (RR = 1.55 [95% CI: 1.39-1.74]), possibly reflecting 
differences in source population, outcome measurement error, or confounding. For example, RCTs often 
exclude participants that demonstrate signs of drug intolerance before randomization, participants who 
may be more susceptible to developing T2D, and participants with relevant comorbidities.301, 302 Such 
exclusions may yield selected populations that are less prone to adverse drug events, including T2D, than 
community-based populations.303 Regarding outcome measurement error, in contrast to RCTs, for which a 
majority included biomarkers (i.e. fasting plasma glucose) when measuring T2D, only four of fifteen 
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OBS studies included biomarkers to measure T2D. Assessing biomarkers of T2D is important given the 
large burden of undiagnosed T2D in U.S. populations, as  contemporary national estimates suggest that 
one in three adults with T2D are undiagnosed.304 Studies also suggest the potential for outcome 
measurement error to bias results towards the null305, which, if the case, would suggest that both RCT and 
OBSs underestimate T2D risk.  Yet, use of fasting plasma glucose to define T2D was not a significant 
predictor of variation in statin-associated T2D risk although the small number of studies that measure 
fasting plasma glucose may have decreased our ability to detect an association. Finally, the potential for 
confounding may exist if factors associated with T2D diagnosis also were associated with statin 
prescription.306 For example, OBS participants prescribed statins may have been more likely to make and 
attend appointments with primary care physicians, increasing their chances of being clinically evaluated 
and obtaining a T2D diagnosis.179 However, studies using active comparators to evaluate statin-associated 
T2D risk reported that statin users had an even higher risk of T2D (RR =3.31 [95% CI: 2.56-4.30]) 
compared to new diclofenac users, even when both groups had similar chances of being evaluated.180 
Overall, the magnitude of statin-associated T2D risk remains difficult to quantify, with the potential that 
existing studies in aggregate underestimate statin-associated T2D risk.  
 We also detected evidence of heterogeneity, particularly among OBSs, which may indicate 
specific subpopulations particularly vulnerable to statin-associated T2D risk. For example, our 
observation of increased statin-associated T2D risk among studies with lower baseline mean LDL-C 
levels is consistent with evidence of an inverse association between LDL-C and T2D.192 Further, a recent 
meta-analysis among 34 RCTs found more intensive compared with less intensive LDL-C lowering 
therapy was associated with a greater reduction in risk of ASCVD mortality in populations with baseline 
LDL-C levels ≥ 100mg/dL, but not among populations with LDL-C levels < 100 mg/dL.307 Together, 
these results suggest that populations with the lowest estimated benefits of pharmacologically lowered 
LDL-C may also have the highest risk of T2D. However, our results remain somewhat tentative as 47% 
of OBSs included in the present meta-analysis either did not collect or report baseline LDL-C levels. In 
addition to missing baseline LDL-C levels, the majority of OBSs lacked baseline glucose levels. OBS 
 
82 
populations that did not include fasting plasma glucose levels may have had elevated levels at baseline, 
potentially biasing the risk estimate for OBS towards a higher risk. However, a major risk factor for 
elevated fasting plasma glucose levels is BMI, and mean BMI estimates were similar between RCT and 
OBS (Tables 12 and 13). Meta-regression results examining heterogeneity by fasting plasma glucose 
levels also were not significant predictors of T2D risk.     
 The association between statins and T2D also varied by mean participant age. However, we had 
limited ability to fully interrogate the role of age, as the OBSs on average consisted of younger 
populations compared to RCTs and evidence of heterogeneity precluded pooling across study designs. 
Understanding the role age may play in the association between statins and T2D is important because age 
is a dominant factor when determining ASCVD risk and thus statin initiation. For example, in the U.S. 
nearly all men exceed the 7.5% ASCVD risk threshold for statin initiation in their mid to late 60s and 
nearly all women in their 70s, despite an otherwise optimal risk factor profile.20  
Given the public health and clinical relevance of enumerating statin-associated risks and benefits, 
future studies specifically designed to accurately estimate statin-associated risk overall and in strata 
defined by baseline LDL-C and age, and possibly other plausible effect measure modifiers, are needed. 
Yet, such studies require careful consideration of design features. For example, five of fifteen OBSs were 
conducted using insurance claims databases, which may not capture participant baseline characteristics, 
including LDL-C. Contemporary, population-based cohort studies can provide validated baseline 
measurements on participant characteristics such as LDL-C or information on glucose levels and collect 
data on T2D incidence and medications. Yet, multi-year gaps between visits complicate the ability to 
precisely identify statin initiation and T2D diagnosis, although novel approaches that enable linkage with 
EMRs and claims data may offer opportunities to address some limitations.308  Other potential avenues 
include large biobanks linked to EMR (e.g. the UK Biobank), although low response rates may introduce 
additional sources of bias, the effect of which may be difficult to predict.309 In sum, these considerations 
suggest that comprehensively examining statin-associated T2D risk will continue to require multiple 
study designs, as the optimal design may not be feasible. 
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 Despite many strengths, there are limitations that merit consideration. First, there were several 
studies that did not respond to repeated requests for additional study or participant characteristics. 
Obtaining missing estimates may have increased statistical power for heterogeneity investigations and 
allowed us to further examine potentially important characteristics such as age, LDL-C, fasting plasma 
glucose levels, or BMI. However, this study provides some of the first evidence of heterogeneity in statin-
associated T2D risk, which may motivate future studies that address these limitations. Second, our 
investigation of heterogeneity leveraged aggregate rather than individual-participant data (IPD). Reliance 
on aggregate data reflected challenges associated with accessing, understanding, and analyzing separate 
datasets.310 Importantly, it has been suggested that an aggregate data meta-analysis is one of the first steps 
in conducting an IPD meta-analysis and can inform future IPD meta-analyses studies about the potential 
sources of heterogeneity that warrant examination.311 Third, our investigation of heterogeneity was 
limited by study and participant characteristics reported at large enough numbers to enable well-powered 
investigations. For instance, we were not able to obtain enough information to assess statin dose or type 
as a source of heterogeneity, although some degree of effect modification by dose on statin-associated 
T2D has been reported.282 However, we were able to assess statin use in multiple settings and compare 
populations under strict observation (i.e. RCT) with populations under conditions more generalizable to 
broader populations.171 Fourth, we were unable to investigate the role of statin adherence, although 
several studies attempted to exclude participants at risk of non-adherence.312 The effects of statin 
adherence are difficult to quantify, although failure to address medication non-adherence are long-
described.313 Finally, our meta-analysis was limited to examining T2D, given the unavailability of studies 
examining statin-associated elevations in prediabetes risk or interval measures of glucose homeostasis. 
Future studies on these topics are warranted, given the association of fasting plasma glucose with elevated 
risk of cardiovascular disease.314  
 In conclusion, this meta-analysis adds to a growing body of literature addressing statin-associated 
T2D risk. Findings highlight potentially increased statin-associated T2D risk in younger populations, and   
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populations with lower LDL-C concentrations at study baseline. Taken together, these results help to 
inform risks of statin use across CVD risk profiles and underscore the need for more research on statin-





E. Tables and Figures 
Table 12. Selected characteristics of interest among eight randomized controlled trials examining statin-associated type 2 diabetes risk 





























Downs (1998)  5.2 6605 1993 T2D diagnosis, 
T2D 
medication 
use, and FPG 
>126mg/dL 
15.1 89 58 26.7 150 R 




0.0 100 55 25.9 193.3 86.5 
Furberg (2002)  4.8 10355 1994 FPG 
>126mg/dL 
49 41 66.4 29.9 146 122.1 




51.7 100 75.3 26.8 146.9 92.5 
Sever (2003)  3.3 10341 1999 FPG 
>126mg/dL 
18.8 94 63.2 28.7 131.5 111.7 
Nakamura (2006)  5.3 7832 1999 T2D diagnosis, 
T2D 
medication 
use, and FPG 
>126mg/dL 




Ridker (2008)  1.9 17802 2007 T2D diagnosis, 
T2D 
medication 
use, and FPG 
>126mg/dL 
38.2 71.3 66 28.4 108 94 
Yusuf (2016)  5.6* 12705 2010 T2D diagnosis, 
T2D 
medication 
use, and FPG 
>126mg/dL 
46.7 20 65.8 27.1 128.6 95.4* 
8 studies (1998-
2016) 
4.3 9754.9 1998  35.9 64.4 63.6 27.2 145.0 101.6 
BMI = Body mass index 
LDL-C = Low-density lipoprotein 
FPG = Fasting plasma glucose 
R = Data requested, but not available 







Table 13. Selected characteristics of interest among 15 observational studies examining statin-associated type 2 diabetes risk 
  Study characteristics Participant characteristics 







































49.1 100 59.2 27.6 NA NA 




100 83.7 63.2 27.8 120.4 94 
Wang (2012)  Insurance 
claims 





50 0 63 NA NA NA 
Danaei (2012)  Insurance 
claims 





55.5 100 63.2 27.7 135.9 NA 











Chen (2013)  Insurance 
claims 
2 11715 2004 T2D 
diagnosis 
100 0 61.3 NA NA NA 





47 69.5 49.9 R R R 
Zaharan (2013)  Insurance 
claims 





64 100 R R R R 
Macedo (2014)  Cohort 20 2016094 1989 T2D 
diagnosis 
47 100 62.3 NA NA NA 
Bhattacharya 
(2014)  
Cohort 2 44047 2004 T2D 
diagnosis 
55 73 R NA NA NA 
Cederberg 
(2014)  







0 100 57.1 26.8 130.2 103 
Mansi (2015)  Cohort 10 6702 2004 T2D 
diagnosis 
38.8 NA 53 NA 117 NA 
Radford (2015)  Cohort 3 8853 1998 T2D 
medication 






Olotu (2016)  Insurance 
claims 





48.9 NA 46.3 NA NA NA 
Rha (2016)  Insurance 
claims 




48 0 60.3 24.5 114 94 
15 studies 
(2004-2016) 
 6.9 257098 2000  51.5 71.2 57.4 26.9 124.4 96.4 
OBS = Observational study 
BMI = Body mass index 
LDL-C = Low-density lipoprotein 
FPG = Fasting plasma glucose 




Figure 11. Flow diagram of literature search to identify randomized controlled trials and 
observational studies for inclusion in meta-analysis examining statin-associated type 2 diabetes risk 
 
T2D = Type 2 diabetes 








Figure 13. Results from meta-regression analyses examining significant study and baseline 
participant characteristics among randomized controlled trials and observational studies 
 
A = Mean low-density lipoprotein cholesterol levels by statin associated type 2 diabetes risk 
B = Mean age by statin associated type 2 diabetes risk 
C = Year of publication by statin associated type 2 diabetes risk 






F. Supplemental Material 
F.1. Risk of Bias Among Observational Studies 
 To further assess the risk of bias among observational studies (OBSs), we used the average 
standardized absolute mean difference (ASAMD) to assess balance between statin-treated and 
comparison groups, with lower ASAMD indicating better balance.275 Balance was assessed across 
covariates selected based on past evidence and theory. ASAMD was calculated by subtracting each of the 
comparison group means from the corresponding statin-treated group mean, taking the absolute value of 
each difference, dividing each absolute difference by the pooled standard deviation of the covariate (if 
continuous), and then computing the mean of the standardized absolute differences.275 
F.2. Supplemental Figures 
Figure 14. Summary of quality assessment for included eight randomized controlled trials 

















Figure 15. Summary of quality assessment for included 15 observational studies examining statin-
associated type 2 diabetes risk 
 
FPG = Fasting plasma glucose 
LDL-C = Low-density lipoprotein 
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Figure 16. Funnel plot displaying reported and imputed relative risks examining statin-associated 





Figure 17. Funnel plots displaying reported and imputed relative risks examining statin-associated 





Figure 18. Galbraith plot displaying relative risks examining statin-associated type 2 diabetes risk 








Figure 19. Galbraith plot displaying relative risks examining statin-associated type 2 diabetes risk 






F.3. Supplemental Tables 
Table 14. Study and baseline participant characteristics abstracted from 23 studies examining 
statin-associated type 2 diabetes risk 
Study characteristics 
Study design (randomized controlled trials cohort, case-control, cross sectional) 
Mean length of follow-up time 
Study sample size 
Year of publication data 
Year of study baseline 
Method to control confounding (propensity score, adjusted in the model, randomization, did not adjust) 
Methods to measure and define type 2 diabetes status (physician diagnosis, medication data, laboratory 
data) 




Mean Age (10-year age groups) 
% Caucasian 
Residence of participant  
% prescribed statins 
Type of statins included  
Mean BMI 
Mean LDL-C levels 
Mean fasting plasma glucose levels 
Mean systolic blood pressure levels 
% hypertensive 
% current smokers 






Table 15. Additional characteristics of interest among eight randomized controlled trials examining statin-associated type 2 diabetes risk 
 Study 
characteristics 
  Participant characteristics 


























RR  North 
America 
Lovastatin 49.8 138 22 12.5 0 
Freeman 
(2001)149 
HR  Europe Pravastatin 50 135 16 43 0 
Furberg 
(2002)302  
RR  North 
America 
Pravastatin 49.6 145 100 23.2 14 
Shepherd 
(2002)154 
HR  Europe Pravastatin 50 154.6 61.9 26.8 44.2 
Sever 
(2003)148 
HR  Europe Atorvastatin 50 164.2 100 32.7 11 
Nakamura 
(2006)155 
HR  Asia Pravastatin 49.5 132.25 40.9 15.4 0 
Ridker 
(2008)315 
HR  Multiple Rosuvastatin 50 134 NA 15.8 0 
Yusuf 
(2016)163 
HR  Multiple Rosuvastatin 50 137.9 37.8 26.8 0 
8 studies 
(1998-2016) 
    50 142.6 54.1 24.5 8.7 






Table 16. Additional characteristics of interest among 15 observational studies examining statin-associated type 2 diabetes risk 
 Study 
characteristics 
  Participant characteristics 

























Jick (2004)312 OR Controlled  Europe 22.0 NA 40.23 22.2 0.0 
Culver 
(2012)164 
HR Controlled  North 
America 
7.0 NA NA 7.0 15.9 
Wang 
(2012)316 
HR Unadjusted  Asia 20.0 NA NA NA 47.0 
Danaei 
(2012)317 
HR Controlled  Europe 4.9 NA 51.3 42.1 0.0 
Izzo (2013)318 HR Controlled  Europe 14.0 141.8 NA NA 0.0 
Chen 
(2013)319  
OR Controlled  Asia 3.8 NA 4.0 NA 4.0 
Currie 
(2013)180 
HR Controlled  Oceania 39.3 NA NA NA NA 
Zaharan 
(2013)320 





 Europe 21.4 NA 26.2 17.7 36.0 
Bhattacharya 
(2014)321 
OR Controlled  North 
America 
50.0 NA NA 18.5 10.0 
Cederberg 
(2014)166 







50.0 NA 35.4 6.2 0.0 
Radford 
(2015)322 
OR Controlled  North 
America 











50.0 NA 17.3 NA NA 
Rha (2016)324 OR Propensity 
scores 
 Asia 21.0 NA 53.0 NA 13.0 
15 studies 
(2004-2016) 
    23.7 141.8 30.0 18.0 11.0 
*All OBSs included multiple statins 




Table 17. Results from meta-regression models among 23 randomized controlled trials and 
observational studies examining statin-associated type 2 diabetes risk 
Characteristics N Relative risk (95% CI) P-value 
Study  characteristics    
Study design 23   
Randomized 
controlled trials 
8 Ref  
Observational studies 15 1.45 (1.11-1.88) 0.01* 
Mean length of follow-
up 
23 0.99 (0.96-1.03) 0.71 
Sample size 23 1 (0.99,1.00) 0.92 
Year of publication 23 1.03 (1.00-1.06) 0.01* 
Year of baseline 23 1.02(0.99-1.05) 0.10 
Methods address 
confounders 
23   
Randomization 8 Ref  
Controlled 10 1.40 (1.05-1.85) 0.03* 
Propensity or 
unadjusted 
5 1.53 (1.01-2.15) 0.02* 
Type of effect estimate 
metric 
23   
Hazard ratio 16 Ref  
Relative risk or odds 
ratio 
7 1.12 (0.81-1.56) 0.48 
Methods to measure 
and define T2D 
23   
Physician report, 
medication use, lab 
results 
6 Ref  
2 out of 3 methods 9 1.25 (0.88-1.79) 0.20 
1 out of 3 methods or 
self-report 
8 1.40 (0.97-2.01) 0.07 





   
Residence of 
participants 
23   
Europe 9 Ref  
North America 7 1.30 (0.93-1.82) 0.12 
Other 7 1.30 (0.92-1.83) 0.13 
% Women 23 1.49 (0.81-2.76) 0.19 
Mean age (10-year 
increase) 
21 0.79 (0.63-0.98) 0.04* 
% Caucasian 21 0.88 (0.59-1.32) 0.52 
Proportion taking 
statins 
22   
>30% 12 Ref  
<30% 10 1.03 (0.76-1.39) 0.85 
Mean BMI (kg/m2) 15 0.98 (0.90-1.07) 0.69 
Mean LDL-C levels 
(10-mg/dl increase) 
15 0.92 (0.87-0.97) <0.01* 
Mean plasma glucose 
levels (10-mg/dl 
increase) 
12 0.98 (0.83-1.16) 0.80 
Mean systolic blood 
pressure levels (10-
mmHG increase) 
9 1.00 (0.99-1.02) 0.37 
% Hypertensive 15 0.68 (0.34-1.33) 0.23 
% Current smokers 15 0.27 (0.11-0.68) 0.01* 
% ASCVD  21 1.23 (0.54-2.78) 0.61 
*P-value <0.05 
FPG = Fasting plasma glucose 
BMI = Body mass index 
LDL-C = Low-density lipoprotein cholesterol 





Table 18. Results from meta-regression models among 15 observational studies examining statin-
associated type 2 diabetes risk 
Characteristics N Relative risk (95% CI) P-value 
Study characteristics    
Mean length of follow-
up 
15 0.98 (0.94, 1.02) 0.24 
Sample size 15 0.99 (0.99-1) 0.56 
Year of publication 15 1.05 (0.99-1.12) 0.12 
Year of baseline 15 1.02 (0.99-1.06) 0.20 
Type of effect estimate 
metric 
15   
Hazard ratio 10 Ref  
Odds ratio 5 1.16 (0.76-1.76) 0.47 
Methods to measure 
and define T2D 
15   
Used 1 method 
(physician report, lab 
results, medication 
use) 
6 Ref  
Used > 1 method 9 0.96 (0.64-1.43) 0.83 
Use of FPG to define 
T2D 
15   
Not used 11 Ref  
Used 4 0.95 (0.60-1.51) 0.83 
    
Participant 
characteristics 
   
Residence of 
participants 
15   
Europe 6 Ref  
Other 9 1.50 (1.11-2.04) 0.01* 
% Women 15 1.12 (0.48-2.59) 0.78 
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Mean age (10-year 
increase) 
13 0.71 (0.52-0.96) 0.03* 
% Caucasian 13 0.75 (0.43-1.28) 0.26 
Proportion taking 
statins 
15   
>30% 5 Ref  
<30% 10 0.71 (0.50-1.10) 0.06 
Mean BMI (kg/m2) 7 0.84 (0.70-1.01) 0.06 
Mean LDL-C levels 
(10-mg/dl increase) 
7 0.78 (0.67-0.92) 0.01* 
Mean glucose levels 
(10-mg/dl increase) 
5 0.89 (0.27-2.95) 0.78 
% Hypertensive 8 0.28 (0.07-1.04) 0.06 
% Current smokers 7 0.31 (0.11-0.87) 0.03* 
% ASCVD  13 0.85 (0.28-2.61) 0.76 
Type of statin user    
Prevalent User 12 Ref  
New User 3 1.14 (0.70-1.82) 0.56 
*P-value <0.05 
BMI = Body mass index 
LDL-C = Low-density lipoprotein cholesterol 
FPG = Fasting plasma glucose 





Table 19. Results from meta-regression models among eight randomized controlled trials 
examining statin-associated type 2 diabetes risk 
Characteristics N Relative risk (95% CI) P-value 
Study characteristics    
Mean length of follow-
up 
8 0.94 (0.87-1.00) 0.08 
Sample size 8 1(0.99-1.00) 0.41 
Year of publication 8 1(0.98-1.03) 0.91 
Year of baseline 8 1(0.99-1.03) 0.43 
    
Participant 
characteristics 
   
% Women 8 1.39 (0.74-2.61) 0.24 
Mean age (10-year 
increase) 
8 1.21 (0.99-1.48) 0.06 
% Caucasian 8 1.05 (0.73-1.51) 0.76 
Mean BMI (kg/m2) 8 1.03 (0.96-1.10) 0.34 
Mean LDL-C levels 
(10-mg/dl increase) 
8 0.96 (0.92-1.00) 0.10 
Mean glucose levels 
(10-mg/dl increase) 
7 1.02 (0.90-1.16) 0.70 
Mean systolic blood 
pressure levels (10-
mmHG increase) 
8 1.00 (0.99-1.02) 0.39 
% Hypertensive 7 1.30 (0.89-1.89) 0.14 
% Current smokers 8 0.48 (0.12-2.03) 0.26 
% ASCVD  8 1.66 (0.75-3.65) 0.17 
BMI = Body mass index 
LDL-C = Low-density lipoprotein cholesterol 
ASCVD = Atherosclerotic cardiovascular disease 
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CHAPTER 6. PROJECTIONS OF ATHEROSCLEROTIC CARDIOVASCULAR 
DISEASE AND TYPE 2 DIABETES ACROSS STATIN TREATMENT 
RECOMMENDATIONS 
A. Introduction 
 Methyl-glutaryl-Coenzyme A reductase inhibitors, commonly known as statins, are the most 
widely prescribed class of medication used to prevent atherosclerotic cardiovascular disease (ASCVD).1, 2 
Numerous meta-analyses have demonstrated that statins decrease ASCVD incidence by approximately 
20% for every 38 mg/dL reduction low-density lipoprotein cholesterol (LDL-C) and this protective effect 
extends to populations at low ASCVD risk.3, 4 In 2013, the American College of Cardiology/American 
Heart Association (ACC/AHA) cholesterol treatment recommendations were changed from a 10% 10-
year coronary heart disease (CHD) risk to a 7.5% 10-year ASCVD (CHD and stroke) risk. As a result, an 
estimated 10.4 million adults were newly eligible for statin treatment, with females5 and adults 60-75 
years of age6 experiencing the greatest increases. Other recommendations proposed even more aggressive 
treatment thresholds, for example a 5% 10-year ASCVD risk threshold or initiating statin treatment in 
populations ≥55 years of age regardless of risk factor profile,7 whereas others proposed increasing the 10-
year ASCVD risk threshold to 10%.6, 8, 9  
While the cardioprotective effect of statins are well-established,4, 10experimental and 
observational research has suggested the potential for adverse drug effects, including type 2 diabetes 
(T2D), a side effect of particular interest because of its associated adverse health outcomes and impact on 
patient quality of life.11-15 Accumulating evidence has suggested that statins increase the relative risk (RR) 
of T2D by 5-55%12-17, with potentially elevated risks in younger populations compared to older 
populations and populations with lower LDL-C compared to populations with higher LDL-C. Such 
findings merit further investigation in light of evolving statin recommendations that target growing 
proportions of primary prevention populations, for whom the risk-benefit profile of statins remains 
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incompletely quantified.18 Specifically, few studies have directly compared the number of statin-
associated ASCVD events prevented alongside the number of T2D events incurred across proposed statin 
recommendations. Therefore, this study projected the number of expected ASCVD events prevented and 
incident cases of T2D incurred in primary prevention populations across four proposed 10-year ASCVD 
risk statin treatment recommendations.5, 6, 8, 19 
B. Methods 
B.1. Motivation for Simulation Model 
 This study employed a simulation model to examine intended and unintended consequences of 
statin treatment through synthesis of high quality observational and experimental data. A simulation 
model was needed because few available studies (1) were contemporary, (2) spanned ages specified by 
current recommendations, (3) included high quality statin adherence measures, and (4) precisely and 
validly measured ASCVD and T2D incidence within generalizable male and female multi-ethnic 
populations with adequate follow-up.20  
B.2. Data Sources and Inputs 
The first step in constructing a simulation model is to collect and estimate data inputs. In an 
attempt to maximize generalizability, we prioritized studies that included multi-ethnic (non-Hispanic 
African American and non-Hispanic Caucasian; capturing 85% of the U.S. population21), male and female 
statin-eligible adults aged 40-75 years, reflecting the ages specified by primary prevention 
recommendations.5  
Demographic characteristics, 10-year ASCVD risk, and population eligibility were estimated 
using the National Health and Nutrition Examination Survey (NHANES, waves 2007-2014), pooling four 
waves to ensure sufficient precision of data inputs. NHANES conducts biennial cross-sectional surveys 
and physical examinations that measures demographic, nutritional, and health status information on 
nationally representative, independent probability samples of the non-institutionalized US civilian 
population22 (see Supplement). We defined the primary prevention population as 40-75 year old males 
and females of self-reported non-Hispanic African American or Caucasian race/ethnicity who did not 
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report a doctor or health professional diagnosis of ASCVD, T2D, or type 1 diabetes, who reported never 
taking cholesterol medications (measured by self-report and medication inventory), and who had 
measured fasting LDL-C levels ≤ 190mg/dl. Race/ethnic-, sex-, -and anti-hypertensive therapy- specific 
predicted 10-year ASCVD risk for each participant of the primary prevention population were then 
calculated using the Pooled Cohort Equation (Supplement, Supplemental Table 23).23   
ASCVD and T2D incidence rates were estimated using the Reasons for Geographic and Racial 
Differences in Stroke (REGARDS) study (2003-2015), a national, population-based, longitudinal cohort 
study designed to evaluate factors underlying the excess stroke burden in the southeastern US and among 
African Americans versus Caucasians (see Supplement).24 Incident CHD was defined based on medical 
records, signs and symptoms, diagnostic cardiac enzymes, or ECG changes consistent with ischemia 
CHD (Table 20). Incident stroke was centrally adjudicated by physicians using the World Health 
Organization definition or by review of final reports from all available neuroimaging studies consistent 
with acute ischemia.25, 26 T2D incidence was ascertained at visit 2 and classified using investigator-
defined criteria (T2D if fasting glucose ≥126 mg/dl, non-fasting glucose >200 mg/dl or use of T2D 
medication) (Table 20).  
Non-ASCVD mortality was obtained data from the National Center for Health Statistics 
(NCHS),27 which compiles death certificates filed in all 50 states and the District of Columbia. Non-
ASCVD deaths/year were defined excluding cardiovascular (International Statistical classification of 
Disease, 10th Edition codes [ICD-10]: I00-I09, I11, I13, I20-I51) and cerebrovascular deaths (ICD-10: 
I60-I69). 
Statin-associated ASCVD RRs were obtained from the Cholesterol Treatment Trialists’ meta-
analysis of  22 trials (statin treatment versus control), from which we abstracted separate RRs for males 
(0.64) and females (0.84) given statistically significant evidence of heterogeneity by sex.4 Statin-T2D 
RRs were obtained from a recent meta-analysis of randomized controlled trials and observational studies: 
1.11 (randomized controlled trials [RCTs]), 1.32 (RCT and observational study pooled), and 1.55 
(observational studies).17 Because of evidence of heterogeneity found by study design, we included all 
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three statin-T2D RRs. In the absence of consistent meta-analysis evidence for the association between 
statins  and non-ASCVD mortality28, the RR was set to 1.0. 
B.3. Model Overview 
 We contrasted statin-associated ASCVD and T2D incidence associated with four statin treatment 
recommendations  (see below) using state-transition Markov simulation models.29 For each one-year 
model cycle, statin-eligible population could either remain alive and non-diseased or transition to having 
T2D, an ASCVD event, or a non-ASCVD death. The disease and non-ASCVD mortality states were 
absorbing, i.e. the part of the cohort entering these states was no longer simulated (see example in Figure 
20).29  The one-year cycle was repeated 10 times for each age- (one-year) and sex-specific group and for 
each intervention scenario assessed to project statin-associated 10-year ASCVD and T2D incidence. 
Assignment of statin treatment was made at study baseline (i.e. before initiating the first cycle) 
using predicted 10-year ASCVD risks estimated by the Pooled Cohort Equation. We assigned statin 
treatment if the predicted 10-year ASCVD risk equaled or exceeded the following four previously 
proposed treatment recommendations: 
• ≥ 10%19  
• ≥ 7.5%5  
• ≥  5%6  
• ≥ 7.5% or ≥55 years of age8  
Statin adherence among statin-eligible adults was informed by past studies.30 Briefly, full 
implementation of statin treatment recommendations and 100% statin adherence were assumed at year 0, 
after which we assumed a 20% absolute annual decrease through year four (Supplemental Figure 24). At 
year four, we assumed 20% of adults would continue taking statins through year 10.   
We then examined a fifth scenario whereby no participants received statin treatment, which 
served as our reference group (Supplement).  
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Using these scenarios, we calculated the absolute benefit of statin treatment as the number needed 
to treat (NNT) to prevent one ASCVD event (1/ [statin-associated ASCVD risk difference]), with smaller 
values indicating a more favorable outcome; hereafter NNT will be referred to as number needed to 
benefit (NNB). Absolute harm of statin treatment was calculated as the number needed to harm (NNH/ 
1/statin-association T2D risk difference) to cause one excess incident case of T2D, with larger values 
indicating a more favorable outcome.31 In addition, we estimated the likelihood to be helped or harmed 
(LHH), defined as the ratio of the NNH to NNB, with larger values indicating a more favorable outcome 
and values < 1 indicating when the number of incident cases of T2D incurred exceeds the number of 
ASCVD events prevented.32 Statistical analyses were performed using STATA (College Station, TX), 
TreeAge Healthcare Pro Suite 2018 (TreeAge Software, Williamstown, MA), and SAS (Cary, NC).33 
B.4. Sensitivity Analyses 
 To evaluate possible sources of heterogeneity, we assessed the expected benefits and harms 
incurred by sex and age.19, 34 We also projected the expected number of ASCVD events prevented and 
expected number of excess incident case of T2D incurred under three annual relative decrease in statin 
use of 25% and 50%, as well as full adherence (i.e. 0% decrease) across 10 years.30 
C. Results 
 When weighted to the 2014 U.S. population, a total of 61,125,042 adults without evidence of 
prior statin treatment, ASCVD, or T2D composed our primary prevention population. Among the initial 
population, a majority were female (58.5%) and Caucasian (89.4%) (Table 21). The proportion of the 
population eligible for statin treatment ranged from 21.8% (≥10% ASCVD risk threshold) to 53.2% 
(≥7.5% ASCVD risk threshold or 55 years of age), representing a difference of 19,218,259 adults (31.4% 
absolute increase). Adults eligible for statin treatment based on the ≥10% ASCVD risk threshold 
recommendation had the highest mean age (mean=65.4 years) and lowest levels of total cholesterol 
(mean=204 mg/dL) when compared to the other three statin treatment recommendations. In contrast, 
adults with a 10-year ASCVD risk ≥7.5 or who were ≥ 55 years of age were on average younger 
(mean=62.1 years) and had higher levels of total cholesterol (mean=207 mg/dL); this treatment 
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recommendation also was the only recommendation for which a majority of the eligible population was 
female (55%).  
 Direct associations between the proportion of adults eligible for statin therapy and the number of 
ASCVD events prevented were observed (Figure 21). For example, the ≥10% ASCVD risk threshold 
recommendation (21.8% of adults eligible for therapy) was projected to prevent the fewest number of 
ASCVD events (N=103,009) over 10 years (Figure 21, panel A). In contrast, the ≥7.5% ASCVD risk 
threshold or 55 years of age recommendation (53.2% of adults eligible for therapy) was projected to 
prevent the largest number of ASCVD events over 10 years (N=181,039; N=78,030 additional ASCVD 
events prevented when compared to the ≥10% ASCVD risk threshold recommendation). These 
projections corresponded to 10-year NNBs of 155 and 216, respectively (Figure 25, panel A) and did not 
differ by statin-associated T2D risk (Figure 21, panels A-C).  
The ≥10% ASCVD risk threshold and the ≥7.5% ASCVD risk threshold or 55 years of age 
recommendations also were associated with the fewest (N=35,990) and greatest (N=86,090) number of 
incident cases of T2D incurred over 10 years, respectively, when assuming a statin-associated T2D risk of 
1.11 (Figure 21, panel A). These projections corresponded to 10-year NNHs of 453 (LHH=2.90) and 444 
(LHH = 2.10), respectively, indicating that for all statin treatment recommendations, the number of 
ASCVD events prevented was at least twice as large as the number of incident cases of T2D incurred 
(Figure 21, panel D, Supplemental Figure 2, panel A). However, variability in the assigned statin-
associated T2D RR changed this observation. As an example, when the statin-associated T2D RR was 
increased to 1.32, NNHs strengthened to 199-202 (LLH range: 0.95-1.30) across the four statin treatment 
recommendations (Figure 21, panel E). When the statin-associated T2D RR was increased to 1.55, the 
number of incident cases of T2D incurred exceeded the number of ASCVD events prevented across all 
four recommendations (LLH range: 0.66-0.94; Figure 21, panel F), indicating that for every 100 
ASCVD events prevented, 106-152 incident cases of T2D were incurred. Sensitivity analyses that varied 
adherence of statin treatment over 10 years from 25% to 100% resulted in proportional decreases in the 
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number of ASCVD events prevented and incident cases of T2D incurred (Figure 27), although the LLH 
remained relatively unchanged.   
We also observed evidence of heterogeneity in the number of ASCVD events prevented and 
incident cases of T2D incurred for the four statin treatment recommendations by sex. Specifically, when 
assuming a statin-associated T2D RR of 1.11, females received lower absolute benefits of statin treatment 
and incurred a higher relative burden of adverse events across the four treatment recommendations (NNB 
range: 196-281; LHH range: 1.50-2.40) when compared to males (NNB range: 110-131; LHH range: 
2.50-3.00) (Figure 22, panels A and D). The higher relative burden of adverse events among females 
became even more pronounced when assuming higher statin-associated T2D RRs. For example, among 
females, when the statin-associated T2D RR was increased to 1.32, the number of incident cases of T2D 
incurred exceeded the number of ASCVD events (NNB range: 190-272) prevented for three of the four 
statin treatment recommendations (LHH range: 0.7-1.11).  However, for males, the number of ASCVD 
events prevented (NNB range: 107-128) always exceeded the number of incident cases of T2D incurred 
(LHH range: 1.2-1.4) when assuming a statin-associated T2D RR of 1.32 (Figure 22, panels B and E).  
The absolute and relative benefits of statin treatment also differed age. For instance, when 
assuming a statin-associated T2D RR of 1.11, adults aged 40-50 received the lowest absolute benefits of 
statin treatment (NNB range across statin treatment recommendations: 322-378) and incurred the highest 
relative burden of adverse events. Specifically, for every incident cases of T2D incurred, 1-1.14 ASCVD 
events were prevented (Figure 23, panel A). However, the relative benefit of statin treatment was 
reversed when higher statin-associated T2D RRs were assumed. For example, when assuming a statin-
associated T2D RR of 1.32, every one ASCVD event prevented also incurred 2.04-2.32 incident cases of 
T2D (Figure 23, panel E). In contrast, statin treatment in adults aged 70-75 years was projected to confer 
absolute benefits (NNB range: 106-107) that were approximately three times as high as the absolute 
benefits conferred in adults aged 40-50 years. Adults aged 70-75 also incurred the lowest relative burden 
of adverse events (LHH range: 3.95-3.96) that differed little across statin treatment recommendations 
(Figure 23, panel D). Further, the number of ASCVD events prevented always exceeded the number of 
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incident cases of T2D incurred among adults aged 70-75 years, regardless of assumed statin associated 
T2D RR (Figure 23, panels D, H, L).  
D. Discussion  
 In this simulation study, we compared the number of ASCVD events prevented and incident 
cases of T2D incurred across four recently proposed statin treatment recommendations in a contemporary, 
biracial adult primary prevention population. Overall, we projected that between 13 and 32 million adults 
would be newly eligible for statin treatment, among whom one ASCVD event would be prevented for 
every 155-216 adults treated. Projecting the absolute harm of statin treatment was more complex; 
considerable variability in statin-associated T2D risk was identified, with the highest relative burden of 
T2D occurring in female and younger adult populations. Further efforts quantifying statin-associated 
benefits and harms is needed to more precisely characterize populations for whom expansion of statin 
treatment is warranted, as well as populations for whom statin treatment may introduce a large burden of 
adverse events.  
One major challenge for research comparing harms and benefits of interventions is comparing 
intended and unintended events that may not be equivalent. We realize the broad clinical spectrum of an 
ASCVD event (small myocardial infarction diagnosed by biomarker to sudden death) and a new diagnosis 
of T2D (slightly elevated hemoglobin A1c managed by lifestyle change to diabetes requiring multiple 
medications, including injectables, and blood frequent blood glucose monitoring) would have different 
implications for patients. That said, as the goal of statin therapy is to prevent ASCVD events, and T2D is 
a common, persistent, and clinically important harm associated with statin therapy, this contrast remains a 
relevant comparison. Particularly of interest are scenarios where the number of incident cases of T2D 
incurred were greater than, sometimes by five to ten orders of magnitude, the number of ASCVD events 
prevented.18 Thus the implications of elevated statin-associated T2D risk remains a critically important, 
yet unanswered question. One way forward may be to incorporate patient preferences when comparing 
statin-associated benefits and harms.35 For example, patients from Ethiopia and Switzerland weighted 
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ASCVD events as most important outcomes associated with statins;36 however, quantifying patient 
preferences, especially among populations that may be at high risk for adverse effects is still warranted as 
more information on the statin-associated harms become available. 
Statin-associated T2D risk was the most influential model input when projecting statin-associated 
harm as well as the model input with the least consistent evidence base. Inconsistency in the underlying 
evidence base stems from our decision to include estimates of statin-associated T2D risk from both RCTs 
and observational studies. Although the majority of published studies examining statin harms and benefits 
have leveraged statin-associated T2D RRs from RCTs,18 RCTs may underestimate adverse drug effects 
through under-reporting of harms and limited follow-up time.37 Selective RCT inclusion criteria also may 
make RCT populations less prone to developing adverse drug effects, including T2D, than community-
based populations.38 On the other hand, observational studies may be more prone to confounding.39 These 
two sources of data provided a wide-range of statin-associated T2D RRs (1.11-1.55), changing 
projections of relative benefit by as much as two fold. One way forward may be to prioritize future 
research in populations for which estimates of statin-associated T2D RR were most influential, e.g. 
females and younger adult populations.  
Our projections also suggested that females and younger adults incurred lower relative benefits 
compared to males and older adults. Understanding the risk-benefit profile of statin treatment in younger 
and female populations is important, given that the majority of the statin-eligible primary prevention 
population was female and 26% were younger than 50 years of age. Heterogeneity by sex may reflect 
several factors, including the assigned statin-associated ASCVD RR, which assumes a more protective 
effect in males (RR=0.64) than females (RR=0.84). The statin-associated RRs, combined with absolute 
risks of T2D and statin-associated T2D risk that did not differ by sex, contributed to a higher relative 
burden of T2D in females. Yet, existing evidence suggests that we may be underestimating disparities in 
statin-associated benefits and harms by sex. For instance, an increased statin-associated T2D risk in 
females has been found among observational studies and emerging results from past meta-analysis.17, 40 
However, females have been historically underrepresented in RCTs and past studies did not consistently 
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report results by sex.4, 41 Quantifying statin-associated T2D RR among meta-analyses including 
individual-patient data merit further investigation to better characterize statin-associated harms. 
In addition, the youngest age groups, who on average had the lowest ASCVD risk42, did not 
experience the same statin-associated benefits as the oldest age groups. Examining when statin benefits 
may outweigh potential harms becomes important, as statin initiation in younger ages may be associated 
with potentially decades of statin treatment despite mixed evidence of long-term effectiveness. For 
example, the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm found a significant 
reduction in ASCVD associated with statins approximately two years post follow-up (HR =0.64 [95% CI: 
0.53-0.78]), but not 11 years post follow up (HR =0.89 [95% CI: 0.72-1.11]).43, 44 In addition, information 
on post-trial statin use among those initially randomized to statins or placebo was not always known, 
further suggesting the association between long-term, persistent use of statins and adverse events remains 
poorly quantified.43, 45  
Despite many strengths, there are limitations that merit consideration. First, we were unable to 
examine additional statin associated adverse events, including rhabdomyolysis (breakdown of muscle 
tissue).46-48 Although rare, the annual incidence of statin-associated rhabdomyolysis is approximately 
0.0042% (potentially impacting 546-1,344 adults who were newly-eligible for treatment in our study),46 
thereby resulting in a very modest underestimate of statin-associated harm. Similarly, we did not consider 
additional potential benefits of statin treatment, including studies reporting a decreased risk of breast 
cancer recurrence among females treated with statins. This decision reflected our prioritization of 
ASCVD for which the evidence base was the strongest, although future simulations may consider breast 
cancer recurrent and other potential benefits as evidence accumulates.49-51 Third, our assumptions about 
statin users may have overestimated the number of statin-associated events. We assumed that adults who 
would become statin-eligible would initiate statin use; however, current statin recommendations 
recommend an informed risk-benefit discussion between the patient and physician before the initiation of 
statin therapy.5 Fourth, we limited our study to as the age range specified by statin recommendations 
(~40% of the U.S. population), although the Pooled Cohort Equations has been used among adults >75 
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years of age to guide statin recommendation; however, that segment of the population is where statin-
associated benefits and harms are unclear.43, 52 Fifth, although we were not able to take into account drop 
out between REGARDS visits 1 and 2, if we assume that 24% of T2D cases are undiagnosed, then our 
incident rate would be comparable to our estimated incidence rate.53 In addition, due to insufficient 
sample sizes, we were not able to examine further stratification of statin benefits and harms by 
race/ethnicity. 
In conclusion, this simulation study adds to a growing body of literature of projected statin-
associated effects. Findings highlight the highest relative burden of T2D occurred among female and 
younger adult populations, with disparities continuing to widen as statin-associated T2D RR increased. 
Taken together, these results help to inform the absolute and relative benefits and harms associated with 
statins treatment recommendations and underscore the need for more research on quantifying statin-
associated harms.   
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E. Tables and Figures 
Table 20. Model input parameters stratified by 5-year age groups and sex 
Population Parameters Males (95% CI) Females (95% CI) 
ASCVD   
ASCVD annual incidence 
rate/10,000 person-years*  
  
40-45** 50 (30-70) 20 (10-30) 
46-50 50 (30-70) 20 (10-30) 
51-55 70 (50-90) 30 (20-40) 
56-60 60 (50-70) 40 (10-70) 
61-65 110 (90-130) 10 (50-80) 
66-70 150 (130-170) 100 (70-130) 
71-75 200 (160-240) 130 (110-150) 
Statin-ASCVD relative risk 0.650 0.740 
T2D   
T2D annual incidence rate/ 
10,000 person-years* 
  
40-45** 160 (120-220) 140 (100-180) 
46-50 150 (120-190) 180 (120-180) 
51-55 170 (140-190) 160 (100-180) 
56-60 160 (130-190) 140 (100-180) 
61-65 130 (100-150) 150 (120-180) 
66-70 140 (110-170) 130 (110-170) 
71-75 120 (90-150) 110 (80-140) 
Statin-T2D relative risk 1.11-1.55 1.11-1.55 




40-45 20 (16-24) 10 (8-12) 
46-50 30 (24-36) 20 (16-24) 
51-55 50 (40-60) 30 (24-36) 
56-60 60 (50-70) 40 (32-48) 
61-65 80 (70-90) 50 (40-60) 
66-70 100 (90-110) 70 (60-80) 




ASCVD = Atherosclerotic cardiovascular disease 
*Estimated from REGARDS218 
**45-50 year age group IRs were assigned given REGARDS participants ≥45 years in age. 
***Estimated from NCHS290  
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Table 21. Comparison of demographic and cardiovascular risk profiles for U.S. Caucasian and 
African American primary prevention populations aged 40-75 years overall and according to four 













risk ≥7.5% or ≥55 
years old 
N 61,125,042 13,325,617 18,613,696 27,850,426 32,543,876 
Female (%) 58.5% 35.0 37.2 41.4 55.0 
Caucasian (%) 89.4% 86.2 86.1 87.4 89.7 
Age (mean) 54.7 65.4 63.6 61.4 62.1 
Mean high-density lipoprotein 
(mg/dL) 
55 51 52 51 55 
Mean total cholesterol  (mg/dL) 204 204 205 207 207 
Mean systolic blood pressure 
(mmHg) 
122 134 133 129 127 
On hypertension treatment (%) 34.2 59.8 55.9 50.1 45.3 
Current smokers (%) 20.6 29.1 28.6 27.7 20.2 
ASCVD = Atherosclerotic cardiovascular disease 
*Weighted means and proportions 
**After excluding prevalent statin users and adults with self-reported ASCVD and T2D and upweighting to the 





Figure 20. Statin treatment recommendation model among females 40 years old through one-year. 
Rectangles correspond to disease states and arrows represent the allowed transitions. T2D: type 2 




Figure 21. Cumulative number of events of atherosclerotic cardiovascular disease (ASCVD) and 
type 2 diabetes (T2D) (Panels A-C) and likelihood to be helped or harmed (number needed to 





Figure 22. Likelihood to be helped or harmed (number needed to harm/number needed to treat; 
among females (Panels A-C) and males (Panels D-F) associated with four statin treatment 
recommendations among eligible African Americans and Caucasians in the US in 2014 from a 






Figure 23. Likelihood to be helped or harmed (number needed to harm/number needed to treat) associated with four statin treatment 
recommendations among 40-50 (Panels A, E, I) 51-60 (Panels B, F, J) 61-70 (Panels C,G, K) 71-75 (Panels D, H, L) baseline age groups 
associated with four statin treatment recommendations among eligible African Americans and Caucasians in the US in 2014. 
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F. Supplemental Material 
F.1. Supplemental Methods 
 We leveraged multi-ethnic (African American and Caucasian) and sex-specific data from the 
National Health and Nutrition Examination Survey (NHANES) and the Reasons for Geographic and 
Racial Differences in Stroke (REGARDS) study as well as statin associated relative risks (RRs) from past 
meta-analyses to assess changes in type 2 diabetes (T2D)  and atherosclerotic cardiovascular disease 
(ASCVD) incidence from changes in 10-year ASCVD risk thresholds. 
F.1.1. Data Sources and Inputs 
  The project was conducted by assembling and integrating contemporary and validated data from 
NHANES, REGARDS, and past meta-analyses into a Markov model. 
F.1.2. NHANES 
 Data from NHANES were used to construct the initial statin-eligible population (population size 
and baseline characteristics). NHANES is a series of cross-sectional surveys and physical examinations 
conducted biennially to assess the health and nutritional status of the U.S. population.286 NHANES 
collects demographic, nutritional, and health status information on a nationally representative probability 
sample of the U.S. civilian population (aged 0-80+ years) instituted by the National Center for Health 
Statistics (NCHS). Participants are randomly selected through a complex, multistage cluster sampling 
probability design. Young children, older adults, African Americans, and Mexican Americans are 
oversampled at each survey to provide sufficient numbers to support analysis in these underrepresented 
populations. All analyses used sample weights to produce estimates generalizable to the original sampling 
frame288 For this study, we used data from three recent NHANES population cross-sections, conducted in 
2007-2014.  
Exclusion criteria 
 NHANES participants self-reporting myocardial infarction/coronary heart disease (MI/CHD), 
angina, stroke (all types), participants classified as having T2D, participants with triglyceride levels >400 
mg/dl, participants with LDL-C levels ≥190 mg/dl, and participants with ASCVD risk scores unable to be 
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calculated (i.e. missing data) were excluded from the study. Additionally, only African American and 
Caucasian populations between the ages of 40-75 years were considered in the analysis to overlap with 
ages eligible for statin treatment under the ACC/AHA treatment recommendations.  
F.1.3. REGARDS 
 Data from REGARDS were used to estimate ASCVD and T2D incidence and statin 
discontinuation. REGARDS is a national, population-based, longitudinal study designed to evaluate 
factors underlying the excess stroke burden in the southeastern US and among African Americans.218 
Potentially eligible REGARDS participants were identified from commercially available nationwide lists 
of U.S. residents with a recruitment goal of including 30% of participants from the “Stroke Belt” (North 
Carolina, South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas). Eligible 
participants were sent an initial mailing, followed by a telephone call and a subsequent in-home visit.  
Between January 2003 and October 2007, REGARDS enrolled 30,239 non-institutionalized African-
American and Caucasian adults aged ≥45 years. The second in-home visit took place from May 2013 to 
Dec 2016. 
Exclusion criteria 
 REGARDS participants self-reporting MI/CHD, angina, or stroke (all types), participants 
classified as having T2D, participants with triglycerides >400 mg/dl, or participants with LDL-C ≥190 
mg/dl were excluded from the analyses. Only participants between the ages 45-75 years were considered 
in the analysis to overlap with ages eligible for statin treatment under the ACC/AHA treatment 
recommendations (minimum age for REGARDS is 45 years). Since ASCVD incidence is low in 
populations <45 years of age, we assigned the ASCVD incidence from the 45-50 year old age-group and 
assessed different specifications via meta-analyses. 
F.1.4. Data Inputs 
F.1.4.1. Data from NHANES  
 Data from NHANES were used to obtain baseline characteristics of the study population, 
prevalence and 10-year risk of ASCVD, prevalence of T2D, and prevalence of current use of statins. 
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Questionnaires were used to assess prevalence of ASCVD, demographic information, smoking status, and 
blood pressure treatment; mean of final two of three blood pressure measurements from the medical 
examination were used to assess systolic blood pressure; fasting blood samples were used for lipid 
analyses to measure total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and 
triglycerides; and low-density lipoprotein cholesterol (LDL-C) levels were calculated using the 
Friedewald equation.289 The prevalence of T2D was assessed by participant-report of a doctor or health 
professional diagnosis of T2D (yes/no) or report of T2D medication use. The prevalence of current use of 
statins was defined by self-report of ever taking cholesterol medications.  
F.1.4.2. Data from REGARDS 
 Incident and prevalent ASCVD and T2D were estimated to inform ASCVD and T2D parameters 
and were ascertained from the REGARDS study by participant report and adjudicated by physicians.  
MI/CHD 
 Self-reported MI/CHD prevalence was ascertained using the following questions: (1) “Has a 
doctor or any other health professional ever told you that you had a myocardial infarction or heart 
attack?” (2) “Have you ever had a coronary artery bypass surgery, such as a graft, CABG, or a bypass 
procedure on the arteries of your heart?” and (3) “Have you ever had an angioplasty or stenting of a 
coronary artery with or without placing a coil in the artery to keep it open?” All questions were scored 
“yes”, “no”, “don’t know”, and “refused”.218 MI/CHD was defined as a yes response to any one of those 
three questions. 
 Incident MI/CHD events were ascertained during follow-up. Participants were contacted by 
telephone every six months to assess hospitalizations, emergency department visits, overnight stays in 
nursing homes or rehabilitation centers, or death. If suspected heart event was reported, medical records 
were pursued. MI/CHD were adjudicated based on the presence of signs or symptoms suggestive of 
ischemic; diagnostic cardiac enzymes (rising or falling pattern in cardiac troponin or creatinine 
phosphokinase-MB isoenzyme concentrations over ≥ six hours with a peak concentration greater than 
twice the upper limit of normal); and ECG changes consistent with ischemia or MI/CHD.287 In the case 
 
128 
where a participant died outside the hospital, interviews with family members or other proxies, proximal 
hospitalizations, baseline medical history, death certificates, and the National Death Index were used to 
identify MI/CHD as the underlying cause of death. 
Stroke 
 Prevalent stroke was defined as a positive response to either “Were you ever told by a physician 
that you had a stroke?” or “Were you ever told by a physician you had a mini-stroke or TIA, also known 
as a transient ischemic attack?”.218  
 Similar to the ascertainment of incident MI/CHD, incident stroke was determined during follow-
up. Participants were contacted by telephone every six months to assess vital status, identify 
hospitalizations, emergency department visits, overnight stays in nursing homes or rehabilitation centers, 
or death during the previous six months. Reasons for medical encounters were asked and medical records 
were sought for stroke, TIA, death, unknown reason for hospitalization, or if reason was brain aneruysm, 
brain hemorrhage, sudden weakness, numbness, trouble speaking, sudden loss of vision, headache, other 
stroke symptoms.218 Reports of possible incident stroke events were reviewed by a stroke nurse and then 
reviewed by at least two physician members of a panel of stroke experts in accordance with the World 
Health Organization definition.226 For proxy reported deaths, interview was conducted with next of kin. 
T2D 
 T2D was ascertained during the first in-home visit (to ascertain prevalent T2D) and second in-
home visit (to ascertain incident T2D) using REGARDS investigator defined outcomes (T2D if fasting 
glucose ≥126 mg/dl, non-fasting glucose >200 mg/dl or taking T2D medication).218 
F.1.5. Statin Eligibility Using Pooled Cohort Risk Equations 
 To identify statin-eligible populations from NHANES, 10-year ASCVD risk scores were 
estimated among the primary prevention population to determine statin treatment assignment. 
 Using NHANES data, the predicted 10-year risk for ASCVD was calculated using the Pooled 
Cohort risk equations, developed by the ACC/AHA Task Force on Practice Recommendations.292 
Separate equations were developed for African American and Caucasian men and women, which included 
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the following variables in the equations: age (years), concentration of TC (mg/dl) and HDL-C (mg/dl), 
treated or untreated systolic blood pressure (mmHg), DM status (yes/no), and self-reported current 
smoking status (yes/no). First, the natural log of age, TC, HDL-C, and systolic blood pressure were 
calculated with systolic blood pressure being either a treated or untreated value. Next, we multiplied these 
values by the coefficients from the estimated equation parameters of the Pooled Cohort Equations for the 
specific race-sex group of the population. The sum of the products of the previous calculations were then 
calculated for the population. Finally, we estimated the 10-year risk of ASCVD event as 
𝑃𝑃𝑃𝑃𝑃𝑃𝑑𝑑𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑑𝑑 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑅𝑅𝑃𝑃𝑅𝑅𝑅𝑅 =  1 − 𝐴𝐴0(𝑃𝑃)𝑒𝑒
𝐼𝐼𝐼𝐼𝐼𝐼 𝑋𝑋′𝐵𝐵−𝑀𝑀𝑀𝑀𝑀𝑀𝐼𝐼 𝑋𝑋′𝐵𝐵  
 The ASCVD risk was then calculated as 1 minus the survival rate at 10 years (Appendix 1), 
raised to the power of the exponent of the coefficient*value sum minus the race and sex specific overall 
mean coefficient*value sum.293 Each participant was assigned a probability of statin treatment, which was 
used to determine which participant was statin-eligible according to one of the four 10-year ASCVD risk 
thresholds we evaluated. 
F.1.6. Projection of ASCVD and T2D Incidence and Non-ASCVD Mortality 
 Next, we calculated annual age- and sex-specific ASCVD, T2D, and non-ASCVD mortality 
transition probabilities by statin treatment. The transition probabilities were then used to project the 
expected number of incident ASCVD events, incident T2D, and number of non-ASCVD deaths annually 
in Markov models. As an example, calculation of the one-year transition probability for ASCVD stratified 
by statin use, sex and five-year age groups, was estimated as: 
𝑅𝑅𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑑𝑑 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑛𝑛𝑛𝑛 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 =
𝑅𝑅𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑜𝑜𝑜𝑜
((1 − 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠) + 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 ∗ 𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠))
 
and: 
𝑅𝑅𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 = 𝑅𝑅𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑛𝑛𝑛𝑛 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 ∗  𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 
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where 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑜𝑜𝑜𝑜 was the one-year incidence rate of ASCVD, 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 was the prevalence of 
statin users (to accommodate statin discontinuation), and 𝑅𝑅𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 was the RR of ASCVD among 
statin users compared to non-statin users.  
 We then converted the ASCVD rate to the ASCVD transition probability as: 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑑𝑑 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛 𝑢𝑢𝑠𝑠𝑒𝑒𝑢𝑢𝑠𝑠 = 1 − 𝑃𝑃−𝑅𝑅𝑠𝑠𝑠𝑠𝑒𝑒 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝑀𝑀𝑠𝑠𝑠𝑠𝐼𝐼 𝑢𝑢𝑠𝑠𝑀𝑀𝑢𝑢𝑠𝑠∗𝑇𝑇𝑠𝑠𝑇𝑇𝑒𝑒 
where Time corresponded to the number of years each cycle represented (1 cycle = 1 year). 
F.1.7. TreeAge Pro Software 
 The series of Markov models used in these analyses were implemented through the TreeAge Pro 
software.294 We used the healthcare model supported by TreeAge Pro to create decision trees for each 
intervention. Each decision node corresponded to a 5-year age group stratified by sex that included 
branches for each health state (T2D, ASCVD, mortality).294 Once the Markov model was built, a cohort 
analysis was conducted to generate output by one-year cycles to identify incident cases (i.e. T2D and 
ASCVD). In addition, the TreeAge Pro software allowed us to check missing probabilities, missing states, 





F.2. Supplemental Tables 
Table 22. Markov model parameters 
Age (5-year) sex-specific 
parameters 
Sources of data Metric estimated 
Statin Eligibility NHANES 10-year ASCVD 
risk 
ASCVD parameters   
ASCVD incidence 
overall 
REGARDS Annual incidence 
rate 
Statin-ASCVD RR Cholesterol Treatment Trialists’ Collaboration4 RR 
T2D parameters   
T2D incidence 
overall 
REGARDS Annual incidence 
rate 






















Table 23. Estimation of race- and sex-specific ASCVD risk using the ASCVD pooled cohort risk equations 
 
 
S0(t) at 5 
years 
S0(t) at 10 
Years 
Mean Individual Score 
Participants not taking antihypertensive medications 









27.82 × ln(SBP) - 6.087 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
= - 29.799 × ln(age) + 4.884 × ln(age)2 + 13.54 × ln(TC) - 3.114 × ln(age) × ln(TC) -13.578 × 
    ln(HDL-C) + 3.149 × ln(age) × ln(HDL-C) + 1.957 × ln(SBP) (+ 7.574 - 1.665 × ln(age) if 
    current smoker) (+ 0.661 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.809 × ln(SBP) (+ 0.549 if current 
    smoker) (+ 0.645 if diabetes) 
White men 0.96254 0.9144 61.18 = 12.344 × ln(age) + 11.853 × ln(TC) - 2.664 × ln(age) × ln(TC) - 7.99 × ln(HDL-C) + 1.769 × 
    ln(age) × ln(HDL-C) + 1.764 × ln(SBP) (+ 7.837 - 1.795 × ln(age) if current smoker) (+ 0.658 
    if diabetes) 
Participants taking antihypertensive medications 









29.291 × ln(SBP) - 6.432 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
= - 29.799 × ln(age) + 4.884 × ln(age)2 + 13.54 × ln(TC) - 3.114 × ln(age) × ln(TC) -13.578 × 
    ln(HDL-C) + 3.149 × ln(age) × ln(HDL-C) + 2.019 × ln(SBP) (+ 7.574 - 1.665 × ln(age) if 
    current smoker) (+ 0.661 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.916 × ln(SBP) (+ 0.549 if current 
    smoker) (+ 0.645 if diabetes) 
White men 0.96254 0.9144 61.18 = 12.344 × ln(age) + 11.853 × ln(TC) - 2.664 × ln(age) × ln(TC) - 7.99 × ln(HDL-C) + 1.769 × 
    ln(age) × ln(HDL-C) + 1.797 × ln(SBP) (+ 7.837 - 1.795 × ln(age) if current smoker) (+ 0.658 
    if diabetes) 
TC = total cholesterol 
HDL-C = high-density lipoprotein cholesterol 
SBP = Systolic blood pressure 




F.3. Supplemental Figures 
Figure 24. Proportion of adults adhering to statin treatment recommendations over 10 years among 




Figure 25. Number needed to treat or harm overall (Panels A-C), among females (Panels D-F), and 
males (Panels G-I) associated with four statin treatment recommendations among eligible African 




Figure 26. Cumulative number of events of atherosclerotic cardiovascular disease (ASCVD) and 
type 2 diabetes (T2D) among females (Panels A-C) and males (Panels D-F) associated with four 
statin treatment recommendations among eligible African Americans and Caucasians in the US in 





Figure 27. Likelihood to be helped or harmed (number needed to harm/number needed to treat) 
according to statin adherence assessed for four statin treatment recommendations among eligible 
African Americans and Caucasians in the US in 2014 from a sample of 61,125,042. Grey line 




CHAPTER 7. DISCUSSION AND CONCLUSION 
While the cardioprotective effect of statins are undeniable3, 4, experimental and observational 
research has also suggested that statins may lead to harm in lower risk individuals by increasing the risk 
of type 2 diabetes (T2D).11-15, 176 Few studies have been able to perform a direct comparison of the number 
of statin-associated ASCVD events prevented alongside the number of statin-associated T2D events 
incurred across various proposed statin recommendations; however, simulation tools can help extend the 
reach of traditional epidemiological studies examining intended and unintended consequences of statin 
treatment through synthesis of high quality observational and experimental data. 
 Therefore, to obtain the required data inputs to project harms of statin treatment, we performed a 
systematic review and meta-analysis of statin-associated T2D risk to estimate the effect of statin on T2D 
by synthesizing published data from RCTs and OBSs, excluding secondary prevention populations. 
Results of this meta-analysis, which are consistent with earlier studies synthesizing estimates of statin-
associated T2D risk in primary and secondary prevention populations12, 176, suggest that statins have a 
moderate effect on T2D risk, increasing risk 11-55%. Yet, strong evidence of heterogeneity was observed, 
particularly with regard to participant age and baseline LDL-C level. Potential evidence of heterogeneity 
was not fully examined in earlier meta-analyses and merits further investigation in light of statin 
recommendations that target growing proportions of primary prevention populations, particularly 
populations with lower ASCVD risk profiles (e.g. individuals with ASCVD 10-year risk estimates 
<10%). 
  Meta-analyses of OBSs indicated an elevated statin-associated T2D risk, although the magnitude 
of effect was considerably higher compared to RCT meta-analysis findings, possibly reflecting 
differences in source population, outcome measurement error, or confounding. For example, RCTs often 
exclude participants that demonstrate signs of drug intolerance before randomization, participants who 
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may be more susceptible to developing T2D, and participants with relevant comorbidities.301, 302 Such 
exclusions may yield selected populations that are less prone to adverse drug events, including T2D, than 
community-based populations.303 Regarding outcome measurement error, in contrast to RCTs, for which a 
majority included biomarkers (i.e. fasting plasma glucose) when measuring T2D, only four of fifteen 
OBS studies included biomarkers to measure T2D. Assessing biomarkers of T2D is important given the 
large burden of undiagnosed T2D in U.S. populations, as  contemporary national estimates suggest that 
one in three adults with T2D are undiagnosed.304 Studies also suggest the potential for outcome 
measurement error to bias results towards the null305, which, if the case, would suggest that both RCT and 
OBSs underestimate T2D risk.  Yet, use of fasting plasma glucose to define T2D was not a significant 
predictor of variation in statin-associated T2D risk  although the small number of studies that measure 
fasting plasma glucose may have decreased our ability to detect an association. Finally, the potential for 
confounding may exist if factors associated with T2D diagnosis also were associated with statin 
prescription.306 For example, OBS participants prescribed statins may have been more likely to make and 
attend appointments with primary care physicians, increasing their chances of being clinically evaluated 
and obtaining a T2D diagnosis.179 However, studies using active comparators to evaluate statin-associated 
T2D risk reported that statin users had an even higher risk of T2D (RR =3.31 [95% CI: 2.56-4.30]) 
compared to new diclofenac users, even when both groups had similar chances of being evaluated.180 
Overall, the magnitude of statin-associated T2D risk remains difficult to quantify, with the potential that 
existing studies in aggregate underestimate statin-associated T2D risk.  
 We also detected evidence of heterogeneity, particularly among OBSs, which may indicate 
specific subpopulations particularly vulnerable to statin-associated T2D risk. For example, our 
observation of increased statin-associated T2D risk among studies with lower baseline mean LDL-C 
levels is consistent with evidence of an inverse association between LDL-C and T2D.192 Further, a recent 
meta-analysis among 34 RCTs found more intensive compared with less intensive LDL-C lowering 
therapy was associated with a greater reduction in risk of ASCVD mortality in populations with baseline 
LDL-C levels ≥ 100mg/dL, but not among populations with LDL-C levels < 100 mg/dL.307 Together, 
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these results suggest that populations with the lowest estimated benefits of pharmacologically lowered 
LDL-C may also have the highest risk of T2D. However, our results remain somewhat tentative as 47% 
of OBSs included in the present meta-analysis either did not collect or report baseline LDL-C levels. In 
addition to missing baseline LDL-C levels, the majority of OBSs lacked baseline glucose levels. OBS 
populations that did not include fasting plasma glucose levels may have had elevated levels at baseline, 
potentially biasing the risk estimate for OBS towards a higher risk. However, a major risk factor for 
elevated fasting plasma glucose levels is BMI, and mean BMI estimates were similar between RCT and 
OBS (Tables 12 and 13). Meta-regression results examining heterogeneity by fasting plasma glucose 
levels also were not significant predictors of T2D risk.     
 Our meta-analysis adds to a growing body of literature on statin-associated T2D risk. As a result, 
the statin-associated T2D RRs obtained from our meta-analysis allowed us to project statin-associated 
harms. We used a simulation framework to combine evidence from meta-analyses, observational studies 
measuring ASCVD and T2D incidence, and population surveys informing ASCVD risk factor 
distributions and demographics to estimate the number of ASCVD events prevented and number of T2D 
events incurred in primary prevention populations across four proposed 10-year ASCVD risk statin 
treatment recommendations.5, 6, 8, 20 
 In our simulation study, we compared the number of ASCVD events prevented and T2D events 
incurred among four recently proposed statin treatment recommendations in a contemporary, biracial 
adult primary prevention population. We projected that between 13 and 32 million adults would be newly 
eligible for statin treatment, among whom one ASCVD event would be prevented for every 155-216 
adults treated. Projecting the absolute harm of statin treatment was more complex; considerable 
variability in statin-associated T2D risk was identified, with the highest relative burden of T2D occurring 
in female and younger adult populations. Further efforts quantifying statin-associated benefits and harms 
is needed to more precisely characterize populations for whom expansion of statin treatment is warranted, 
as well as populations for whom for statin treatment may introduce a large burden of adverse events.   
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 Statin-associated T2D risk was the model input that had the largest effect on projections of 
absolute and relative harm; statin-associated T2D risk also was the parameter for which the evidence base 
is most heterogeneous. To take into account the internal validity of RCTs and external validity of 
observational studies, we assessed a range of statin-associated T2D RRs from a recent meta-analysis325, 
with the lowest estimated from RCTs (RR=1.11) and highest estimated from observational studies (1.55), 
with potential underestimation in RCTs possibly reflecting differences in source populations. For 
example, RCTs often exclude participants that demonstrate signs of drug intolerance before 
randomization, participants who may be more susceptible to developing T2D, and participants with 
relevant comorbidities.149, 301-303 Such exclusions may yield selected populations that may be less prone to 
adverse drug events, including T2D, than community-based populations.303  Overall, the magnitude of 
statin-associated T2D risk remains difficult to quantify, warranting additional efforts to estimate the risk, 
as well as detect and characterize any sources of heterogeneity.  
 We also observed evidence of heterogeneity in the projected effects of the four statin treatment 
recommendations, with females and younger adults incurring lower relative benefits compared to males 
and older adults. Understanding the risk/benefit profile of statin treatment in younger and female 
populations is warranted, given that the majority of the statin-eligible primary prevention population was 
female and 26% were younger than 50 years of age. Heterogeneity by sex may reflect several factors, 
including the assigned statin-associated ASCVD RR, which assumes a more protective effect in males 
(RR=0.65) than females (RR=0.74). These estimates, combined with absolute risks of T2D and statin-
associated T2D risk that did not differ by sex, contributed to a higher relative burden of T2D in females. 
Yet, existing evidence suggests that we may be underestimating disparities in statin-associated benefits 
and harms by sex. For instance, among postmenopausal females in the Women’s Health Initiative, the 
statin-associated T2D RR was found to be higher (RR = 1.48 [95% CI: 1.38-1.59]) than the pooled statin-
associated T2D risk (RR=1.11) estimated by RCTs. An increased statin-associated T2D risk in females 
also is consistent with emerging results from past meta-analysis.164, 325 However, females have been 
historically underrepresented in RCTs and past studies did not consistently report results by sex.4, 333 
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Quantifying statin-associated T2D RR among meta-analyses including individual-patient data merit 
further investigation to better characterize statin-associated harms. 
 In addition, the youngest age groups, who on average had the lowest ASCVD risk334, did not 
experience the same statin-associated benefits as the oldest age groups. Examining when statin benefits 
may outweigh potential harms becomes important, as statin initiation in younger ages may be associated 
with potentially decades of statin treatment. Evidence of long-term effectiveness of statins is mixed. For 
example, follow-up among the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm found 
a significant reduction in ASCVD associated with statins approximately two years post follow-up (HR 
=0.64 [95% CI: 0.53-0.78]), but not 11 years post follow up (HR =0.89 [95% CI: 0.72-1.11]).268, 269 In 
addition, information on post-trial statin use among those initially randomized to statins or placebo was 
not always known, further suggesting the association between long-term, persistent use of statins and 
adverse events remains poorly quantified.267, 268  
 One challenge to research comparing harms and benefits of treatments or interventions is 
comparing intended and unintended events that may not be equivalent. In the U.S., ASCVD is the leading 
cause of mortality, which may be increasing335, accounting for approximately 837,000 deaths annually.142 
Between 2011 and 2014, 36.6% of adults (~92 million) had been diagnosed with prevalent ASCVD, with 
direct and indirect costs for ASCVD estimated to be $329.7 billion from 2013-2014.337 T2D, on the other 
hand, was estimated to impact 31 million adults (diagnosed and undiagnosed T2D) between 2011-2014, 
with medical costs estimated at $245 billion.142 Past work has emphasized the increase in T2D risk 
associated with statin treatment is outweighed by the benefits in ASCVD reduction. However, we 
identified several plausible scenarios where the number of T2D event incurred were greater than, 
sometimes by several orders of magnitude, the number of ASCVD events prevented.23 Research also has 
suggested T2D as an ASCVD risk equivalent338; however, a recent meta-analyses found that individuals 
with T2D had a 43% lower risk of developing ASCVD than those with prior ASCVD, but without 
T2D.339 While the topic of T2D as an ASCVD equivalent may still be controversial, questions on the 
elevated risk of T2D in association with ASCVD remain unanswered.  
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 Although powerful, we found statins alone may not be the most effective option for continued 
reduction in ASCVD burden due to gains potentially offset by more T2D, and primordial prevention of 
elevated lipids may still have to be the emphasis. The ACC/AHA recommended that risk reduction should 
begin as early as possible in order to effectively reduce lifetime risk of ASCVD, with dietary and lifestyle 
interventions key components of such primordial prevention initiatives. 
 In conclusion, this dissertation adds to a growing body of literature on projected statin-associated 
effects. Taken together, these results help to inform the absolute and relative benefits and harms 
associated with statins treatment recommendations and underscore the need for more research on 
quantifying statin-associated harms. 
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S0(t) at 5 
years 
S0(t) at 10 
Years 
Mean Individual Score 
Participants not taking antihypertensive medications 









27.82 × ln(SBP) - 6.087 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
= - 29.799 × ln(age) + 4.884 × ln(age)2 + 13.54 × ln(TC) - 3.114 × ln(age) × ln(TC) -13.578 × 
    ln(HDL-C) + 3.149 × ln(age) × ln(HDL-C) + 1.957 × ln(SBP) (+ 7.574 - 1.665 × ln(age) if 
    current smoker) (+ 0.661 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.809 × ln(SBP) (+ 0.549 if current 
    smoker) (+ 0.645 if diabetes) 
White men 0.96254 0.9144 61.18 = 12.344 × ln(age) + 11.853 × ln(TC) - 2.664 × ln(age) × ln(TC) - 7.99 × ln(HDL-C) + 1.769 × 
    ln(age) × ln(HDL-C) + 1.764 × ln(SBP) (+ 7.837 - 1.795 × ln(age) if current smoker) (+ 0.658 
    if diabetes) 
Participants taking antihypertensive medications 









29.291 × ln(SBP) - 6.432 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
= - 29.799 × ln(age) + 4.884 × ln(age)2 + 13.54 × ln(TC) - 3.114 × ln(age) × ln(TC) -13.578 × 
    ln(HDL-C) + 3.149 × ln(age) × ln(HDL-C) + 2.019 × ln(SBP) (+ 7.574 - 1.665 × ln(age) if 
    current smoker) (+ 0.661 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.916 × ln(SBP) (+ 0.549 if current 
    smoker) (+ 0.645 if diabetes) 
White men 0.96254 0.9144 61.18 = 12.344 × ln(age) + 11.853 × ln(TC) - 2.664 × ln(age) × ln(TC) - 7.99 × ln(HDL-C) + 1.769 × 
    ln(age) × ln(HDL-C) + 1.797 × ln(SBP) (+ 7.837 - 1.795 × ln(age) if current smoker) (+ 0.658 
    if diabetes) 
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